

# CITATION REPORT

List of articles citing

Sildenafil citrate therapy for pulmonary arterial hypertension

DOI: 10.1056/nejmoa050010

New England Journal of Medicine, 2005, 353, 2148-57.

**Source:** <https://exaly.com/paper-pdf/39152096/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2099	Sildenafil for pulmonary hypertension. <b>2004</b> , CD003562		12
2098	Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. <b>2005</b> , 96, 47M-51M		150
2097	An observational examination of the literature in diagnostic anatomic pathology. <b>2005</b> , 22, 126-38		6
2096	Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. <b>2006</b> , 15, 733-42		26
2095	Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. <b>2006</b> , 5, 271-82		8
2094	Pulmonary arterial hypertension : a comprehensive review of pharmacological treatment. <b>2006</b> , 5, 117-27		15
2093	Portopulmonary hypertension. <b>2006</b> , 10, 653-63, x		16
2092	[Porto-pulmonary hypertension]. <b>2006</b> , 23, 629-41		9
2091	Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. <b>2006</b> , 4, 293-300		41
2090	Recently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension. <b>2006</b> , 22, 11-15		
2089	Pulmonary arterial hypertension. <b>2006</b> , 114, 1417-31		538
2088	[Pulmonary arterial hypertension and systemic sclerosis]. <b>2006</b> , 35, 1929-37		18
2087	Hipertensi?n pulmonar. <b>2006</b> , 9, 4241-4247		
2086	Systemic sclerosis: hypothesis-driven treatment strategies. <b>2006</b> , 367, 1683-91		141
2085	Retrospective Evaluation of Sildenafil Citrate as a Therapy for Pulmonary Hypertension in Dogs. <b>2006</b> , 20, 1132-1135		77
2084	Sildenafil citrate for the treatment of pulmonary arterial hypertension. <b>2006</b> , 7, 825-8		7
2083	Hypertension artfielle pulmonaire associè aux connectivites. <b>2006</b> , 23, 61-72		13

2082	Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. <b>2006</b> , 48, 1433-7	101
2081	Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. <b>2006</b> , 48, 2546-52	393
2080	Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. <b>2006</b> , 114, 1482-9	489
2079	Exercise intolerance in adults with congenital heart disease. <b>2006</b> , 24, 641-60, vii	50
2078	Mediators and modulators of pulmonary arterial hypertension. <b>2006</b> , 291, L547-58	45
2077	Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. <b>2006</b> , 114, 1807-10	112
2076	Effect of regular phosphodiesterase type 5 inhibition in hypertension. <b>2006</b> , 48, 622-7	80
2075	Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. <b>2006</b> , 25, 1353-7	31
2074	Pulmonary hypertension in older children: new approaches and therapies. <b>2006</b> , 7 Suppl 1, S177-9	3
2073	[Pulmonary hypertension, the "bête noire" of systemic diseases: from systemic sclerosis to hereditary hemorrhagic telangiectasia]. <b>2006</b> , 27, 899-902	
2072	Treatments for pulmonary arterial hypertension. <b>2006</b> , 100, 765-74	11
2071	Renal hyporesponsiveness to brain natriuretic peptide: both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension. <b>2006</b> , 27, 2993-9	15
2070	Complications of Chronic Obstructive Pulmonary Disease. <b>2006</b> , 49, 321	
2069	A CASE OF PULMONARY VENOCCLUSIVE DISEASE TREATED WITH SILDENAFIL. <b>2006</b> , 130, 307S	
2068	Effects of sildenafil on hypoxic pulmonary vascular function in dogs. <b>2006</b> , 101, 1085-90	28
2067	The current treatment of pulmonary arterial hypertension: time to redefine success. <b>2006</b> , 130, 1198-202	69
2066	Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. <b>2006</b> , 145, 152-3	111
2065	Is PDE5 inhibition effective in pulmonary arterial hypertension?. <b>2006</b> , 3, 63-63	1

2064	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <b>2006</b> , 2006, 392-393	1
2063	Hypertension artfielle pulmonaire. <b>2006</b> , 3, 1-27	2
2062	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <b>2006</b> , 2006, 60-62	
2061	Hypoxemic fetoplacental vasoconstriction: a graduated response to reduced oxygen conditions in the human placenta. <b>2006</b> , 103, 439-42, table of contents	8
2060	Pulmonary arterial hypertension and women. <b>2006</b> , 14, 312-8	7
2059	Pharmacologic treatment for pulmonary arterial hypertension. <b>2006</b> , 21, 561-8	9
2058	An evidence-based approach to the management of pulmonary arterial hypertension. <b>2006</b> , 21, 385-92	27
2057	Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. <b>2006</b> , 15, 353-60	72
2056	Abnormal vascular tone in infants and children with lung hypoplasia: Findings from cardiac catheterization and the response to chronic therapy. <b>2006</b> , 7, 589-94	40
2055	Successful use of surfactant to treat severe intrapulmonary hemorrhage after iatrogenic lung injury--A case report. <b>2006</b> , 7, 583-5	10
2054	Endothelin receptor antagonists for pulmonary arterial hypertension. <b>2006</b> , CD004434	20
2053	Scleroderma: it has been a long hard journey. <b>2006</b> , 36, 519-23	11
2052	Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?. <b>2006</b> , 60, 1026-7	0
2051	First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. <b>2006</b> , 36 Suppl 3, 32-8	54
2050	Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. <b>2006</b> , 36 Suppl 3, 44-8	25
2049	The role of nitric oxide in tumour progression. <b>2006</b> , 6, 521-34	944
2048	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. <b>2006</b> , 5, 689-702	366
2047	Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness. <b>2006</b> , 18, 423-31	26

2046	[Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment]. <b>2006</b> , 65, 297-300, 302-5	2
2045	New insights in the treatment strategy for pulmonary arterial hypertension. <b>2006</b> , 20, 377-86	23
2044	[Pulmonary hypertension: the future has begun]. <b>2006</b> , 101, 328-33	1
2043	[Raynaud phenomenon in dermatology : Part 2: therapy]. <b>2006</b> , 57, 927-38; quiz 941	7
2042	How valid are animal models to evaluate treatments for pulmonary hypertension?. <b>2006</b> , 373, 391-400	58
2041	The emerging role for type 5 phosphodiesterase inhibition in heart failure. <b>2006</b> , 3, 123-8	12
2040	Adjunctive sildenafil for the treatment of pulmonary hypertension after mitral valve replacement. <b>2006</b> , 12, 347-8	3
2039	For the motion. <b>2006</b> , 49, 749-750	1
2038	Systemic sclerosis: clinical features and management. <b>2006</b> , 34, 480-488	3
2037	Respiratory medicine: anti-IgE therapy, lung cancer and pulmonary hypertension. <b>2006</b> , 34, 431-434	1
2036	Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery. <b>2006</b> , 132, 1420-5	31
2035	Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil. <b>2006</b> , 12, 690-1	11
2034	'Raising the bar' for the treatment of pulmonary arterial hypertension. <b>2006</b> , 27, 510-1	5
2033	Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. <b>2006</b> , 15, 327-30	2
2032	Update in pulmonary hypertension 2005. <b>2006</b> , 173, 499-505	32
2031	Targeting vascular disease in systemic sclerosis. <b>2006</b> , 6, 401-7	2
2030	Overview of lung transplantation and criteria for selection of candidates. <b>2006</b> , 27, 441-69	30
2029	[Diagnosis and treatment of pulmonary hypertension]. <b>2006</b> , 60, 428-40; quiz 441-2	2

2028	[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors]. <b>2006</b> , 131, S311-4	6
2027	Usual interstitial pneumonia. <b>2006</b> , 27, 634-51	37
2026	Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. <b>2006</b> , 174, 1257-63	465
2025	[Diagnosis and treatment of pulmonary hypertension]. <b>2006</b> , 131, 635-8	2
2024	[Diagnosis and therapy of chronic pulmonary hypertension]. <b>2006</b> , 60, 749-71	27
2023	Sildenafil for pulmonary arterial hypertension. <b>2006</b> , 2, 137-43	1
2022	Clinical year in review II: occupational lung disease, pulmonary vascular disease, bronchiectasis, and chronic obstructive pulmonary disease. <b>2006</b> , 3, 557-60	2
2021	Sildenafil citrate therapy for pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1091-3; author reply 1091-3	59.2 35
2020	Pulmonary hypertension. <b>2006</b> , 6, 17-22	1
2019	Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. <b>2006</b> , 28, 691-4	203
2018	Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. <b>2006</b> , 281, 21469-21479	114
2017	cGMP-Dependent Protein Kinase in Regulation of the Pulmonary Circulation. <b>2006</b> , 2, 373-381	3
2016	Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. <b>2006</b> , 45, 1455-7	18
2015	Enhanced alpha1-adrenergic trophic activity in pulmonary artery of hypoxic pulmonary hypertensive rats. <b>2006</b> , 291, H2272-81	21
2014	Hypoxia- and non-hypoxia-related pulmonary hypertension - established and new therapies. <b>2006</b> , 72, 30-40	36
2013	How should we treat portopulmonary hypertension?. <b>2006</b> , 28, 466-7	20
2012	Pulmonary arterial hypertension (PAH) in connective tissue diseases. <b>2006</b> , 45 Suppl 3, iii11-3	15
2011	Pulmonary arterial hypertension. <b>2006</b> , 3, 111-5	70

2010	A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. <b>2006</b> , 70, 1822-31	32
2009	Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. <b>2006</b> , 28, 1195-203	255
2008	Treatment of Advanced Heart Disease. <b>2006</b> ,	1
2007	Vasoactive therapies in systemic sclerosis. <b>2006</b> , 45 Suppl 3, iii49-51	6
2006	Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: Is more better?. <b>2006</b> , 28, 683-6	7
2005	Sildenafil treatment for portopulmonary hypertension. <b>2006</b> , 28, 563-7	168
2004	Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment. <b>2006</b> , 45 Suppl 4, iv22-5	24
2003	Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options. <b>2006</b> , 2, 431-438	3
2002	Connective tissue associated pulmonary arterial hypertension. <b>2006</b> , 15, 138-42	32
2001	Pathobiologic Mechanisms of Pulmonary Arterial Hypertension. <b>2006</b> , 33-49	
2000	Treatment for Pulmonary Arterial Hypertension. <b>2006</b> , 99-118	1
1999	Hemolytic Anemia Associated Pulmonary Hypertension. <b>2006</b> , 170-187	3
1998	Emerging treatments for pulmonary arterial hypertension. <b>2006</b> , 11, 609-19	5
1997	Sildenafil for pulmonary arterial hypertension: when blue turns into white. <b>2006</b> , 7, 1801-10	4
1996	Exercise training in pulmonary hypertension: implications for the evaluation of drug trials. <b>2006</b> , 114, 1448-9	13
1995	New therapeutic strategies in the management of systemic sclerosis. <b>2007</b> , 8, 607-15	37
1994	Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. <b>2007</b> , 115, 59-66	285
1993	Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. <b>2008</b> , 67, 1222-8	98

1992	Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value. <b>2007</b> , 29, 432-4	6
1991	Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. <b>2007</b> , 9, 917-21	46
1990	Effects of sildenafil on exercise capacity in hypoxic normal subjects. <b>2007</b> , 8, 155-63	59
1989	Phosphodiesterase type 5: expanding roles in cardiovascular regulation. <b>2007</b> , 101, 1084-95	164
1988	Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. <b>2007</b> , 7, 391-403	119
1987	Pulmonary hypertension in idiopathic pulmonary fibrosis. <b>2007</b> , 132, 998-1006	191
1986	Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy. <b>2007</b> , 79, 65-75	41
1985	Pulmonary arterial hypertension: current therapeutic strategies. <b>2007</b> , 4, 319-29	46
1984	Idiopathic pulmonary fibrosis. <b>2007</b> , 1, 377-89	7
1983	From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. <b>2007</b> , 27, 867-82	137
1982	The spectrum of scleroderma lung disease. <b>2007</b> , 28, 418-29	41
1981	Pulmonary manifestations of systemic lupus erythematosus. <b>2007</b> , 28, 441-50	35
1980	Chronic sildenafil in men with diabetes and erectile dysfunction. <b>2007</b> , 3, 451-64	24
1979	Emerging therapies for pulmonary arterial hypertension. <b>2007</b> , 16, 803-18	12
1978	Safety of sildenafil in the treatment of erectile dysfunction in patients with obstructive sleep apnoea. <b>2007</b> , 6, 423-30	4
1977	Eisenmenger syndrome and pulmonary arterial hypertension in adults with congenital heart disease. <b>2007</b> , 23, S19-S25	2
1976	Expert opinion on available options treating pulmonary arterial hypertension. <b>2007</b> , 8, 2247-65	30
1975	Structural insight into substrate specificity of phosphodiesterase 10. <b>2007</b> , 104, 5782-7	103



1974	Lung transplantation and pulmonary hypertension. <b>2007</b> , 11, 149-56	1
1973	PDE5 inhibitors beyond erectile dysfunction. <b>2007</b> , 19, 533-43	57
1972	Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. <b>2007</b> , 116, 1555-62	394
1971	Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. <b>2007</b> , 30, 922-7	127
1970	Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. <b>2007</b> , 115, 2331-9	118
1969	Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. <b>2007</b> , 29, 469-75	144
1968	Pathophysiology of pulmonary arterial hypertension. <b>2007</b> , 11, 104-9	8
1967	Nitric oxide in the pulmonary vasculature. <b>2007</b> , 27, 1877-85	107
1966	Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources. <b>2007</b> , 17, 72-7	11
1965	Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?. <b>2007</b> , 116, 233-5	5
1964	A USA-based registry for pulmonary arterial hypertension: 1982-2006. <b>2007</b> , 30, 1103-10	324
1963	Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. <b>2007</b> , 66, 1467-72	68
1962	Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors. <b>2007</b> , 211, 309-20	57
1961	Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate. <b>2007</b> , 46, 893-8	3
1960	Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. <b>2007</b> , 334, 466-80	14
1959	A case of long-term sildenafil therapy in a young dog with pulmonary hypertension. <b>2007</b> , 69, 1073-5	15
1958	Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. <b>2007</b> , 19, 611-8	36
1957	Bibliography. Current world literature. Clinical trial. <b>2007</b> , 22, 379-81	

1956	Antibiotic selection is crucial for optimal empiric monotherapy of ventilator-associated pneumonia. <b>2007, 35, 1992-4</b>	1
1955	Are nitrates safe in patients who use sildenafil? Maybe. <b>2007, 35, 1988-90</b>	5
1954	Electric impedance tomography, the final frontier is close: the bedside reality. <b>2007, 35, 1996-7</b>	4
1953	Higher volume isn't always better. <b>2007, 35, 1982-3</b>	
1952	The costs of prolonged mechanical ventilation: how much is too much?. <b>2007, 35, 1994</b>	1
1951	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. <b>2007, 15, 76-86</b>	52
1950	Gene and stem cell therapy in the treatment of erectile dysfunction and pulmonary hypertension; potential treatments for the common problem of endothelial dysfunction. <b>2007, 7, 131-53</b>	9
1949	Neurogenic pulmonary edema: another multiple-hit model of acute lung injury. <b>2007, 35, 1979-80</b>	11
1948	Screening and therapy of pulmonary hypertension in systemic sclerosis. <b>2007, 19, 598-603</b>	13
1947	Moving beyond assessment: without a goal, how should you know when you failed?. <b>2007, 35, 1987-8</b>	0
1946	Levosimendan: right for the right ventricle?. <b>2007, 35, 1995-6</b>	0
1945	Caveats for triple-H therapy in the management of vasospasm after aneurysmal subarachnoid hemorrhage. <b>2007, 35, 1985-6</b>	5
1944	Carbon monoxide, toxic by-product or protective gaseous monoxide?. <b>2007, 35, 1990-1</b>	1
1943	Is there an association between hemostatic abnormalities and the outcome of acute lung injury?. <b>2007, 35, 1980-2</b>	2
1942	How should we assess right ventricular function in 2008?. <b>2007, 9, H22-H28</b>	22
1941	[Pulmonary arterial hypertension--experience of Centro Hospitalar de Vila Nova de Gaia]. <b>2007, 13, 239-54</b>	3
1940	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <b>2007, 2007, 191-196</b>	
1939	The Anesthesiologist and Pulmonary Arterial Hypertension. <b>2007, 11, 93-95</b>	1

1938	Classification of acute kidney injury using RIFLE: What's the purpose?. <b>2007</b> , 35, 1983-4	31
1937	Analyzing the short-term effect of placebo therapy in pulmonary arterial hypertension: potential implications for the design of future clinical trials. <b>2007</b> , 132, 764-72	16
1936	Reproducibility of cardioventilatory measurements using a respiratory mass spectrometer. <b>2007</b> , 157, 310-5	3
1935	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. <b>2007</b> , 159, 196-201	28
1934	Diagnosis and management of pulmonary hypertension over the past 100 years. <b>2007</b> , 101, 389-98	22
1933	Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy. <b>2007</b> , 101, 2099-107	23
1932	Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse. <b>2007</b> , 43, 545-51	16
1931	A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. <b>2007</b> , 153, 1037-47	179
1930	[Pulmonary arterial hypertension in children: new therapeutic approaches]. <b>2007</b> , 26, 570-5	3
1929	Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. <b>2007</b> , 83, 68-71; discussion 71	73
1928	Evidence-based pharmacologic management of pulmonary arterial hypertension. <b>2007</b> , 29, 2134-53	67
1927	Cardiac effects of pulmonary disease. <b>2007</b> , 37, 949-62, vii	15
1926	Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. <b>2007</b> , 78, 136-40	41
1925	The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10. <b>2007</b> , 371, 302-7	48
1924	Management of pulmonary arterial hypertension with a focus on combination therapies. <b>2007</b> , 26, 437-46	59
1923	Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. <b>2007</b> , 26, 1079-83	19
1922	Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. <b>2007</b> , 118, 178-82	31
1921	Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. <b>2007</b> , 119, 400-2	5

1920	Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. <b>2007</b> , 120, 306-13	52
1919	Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. <b>2007</b> , 120, 301-5	93
1918	Sildenafil in Eisenmenger syndrome: safety first. <b>2007</b> , 120, 314-6	6
1917	Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. <b>2007</b> , 116, 238-48	420
1916	Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine. <b>2007</b> , 4, 393-412	4
1915	[The treatment of idiopathic pulmonary artery hypertension and its relation to systemic sclerosis]. <b>2007</b> , 28 Suppl 4, S273-6	
1914	Pulmonary arterial hypertension [Experience of Centro Hospitalar de Vila Nova de Gaia. <b>2007</b> , 13, 239-254	3
1913	Cardiovascular Activity. <b>2007</b> , 47-391	
1912	Pulmonary vascular disease in adults with congenital heart disease. <b>2007</b> , 115, 1039-50	292
1911	Sildenafil Citrate Therapy in 22 Dogs with Pulmonary Hypertension. <b>2007</b> , 21, 1258-1264	88
1910	Standard therapies for pulmonary arterial hypertension. <b>2007</b> , 28, 91-115, viii	19
1909	Clinical trials in systemic sclerosis: lessons learned and outcomes. <b>2007</b> , 9 Suppl 2, S7	25
1908	Pulmonary hypertension associated with left-sided heart disease. <b>2007</b> , 28, 233-41, x	158
1907	Long-term therapeutic outcomes in pulmonary arterial hypertension. <b>2007</b> , 23, S11-S18	
1906	Phosphodiesterase regulation of nitric oxide signaling. <b>2007</b> , 75, 303-14	112
1905	Pulmonary arterial hypertension [The challenge in diagnosis and treatment. <b>2007</b> , 23, S3-S9	1
1904	Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. <b>2007</b> , 8, 95-109	26
1903	Pulmonary hypertension in the critical care setting: classification, pathophysiology, diagnosis, and management. <b>2007</b> , 23, 801-34, vi-vii	17

1902	Prise en charge diagnostique et thérapeutique de l'hypertension artérielle pulmonaire. <b>2007</b> , 16, 294-301	3
1901	The nitric oxide/cGMP signaling pathway in pulmonary hypertension. <b>2007</b> , 28, 143-67, ix	66
1900	Combination therapy and new types of agents for pulmonary arterial hypertension. <b>2007</b> , 28, 169-85, ix	41
1899	Surgical therapies for pulmonary arterial hypertension. <b>2007</b> , 28, 187-202, ix	7
1898	[Oral sildenafil in neonatal medicine: "tested in adults also used in neonates"]. <b>2007</b> , 66, 167-76	7
1897	Tratamiento con sildenafil y/o bosentán en niños y jóvenes con hipertensión arterial pulmonar idiopática y síndrome de Eisenmenger. <b>2007</b> , 60, 366-372	15
1896	Psychosocial aspects of pulmonary hypertension: a review. <b>2007</b> , 48, 467-75	35
1895	Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. <b>2007</b> , 67, 57-73	30
1894	Scleroderma lung: pathogenesis, evaluation and current therapy. <b>2007</b> , 67, 985-96	11
1893	Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. <b>2007</b> , 131, 1917-28	421
1892	[Pulmonary hypertension treatment: future prospects]. <b>2007</b> , 43, 131-5	0
1891	[Clinical efficacy of sildenafil in patients with pulmonary hypertension in functional class II or III]. <b>2007</b> , 43, 272-6	2
1890	Treatment With Sildenafil, Bosentan, or Both in Children and Young People With Idiopathic Pulmonary Arterial Hypertension and Eisenmenger's Syndrome. <b>2007</b> , 60, 366-372	1
1889	Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. <b>2007</b> , 49, 1079-88	87
1888	Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. <b>2007</b> , 49, 1566-71	256
1887	Living-donor lobar lung transplantation for pulmonary arterial hypertension after failure of epoprostenol therapy. <b>2007</b> , 50, 523-7	23
1886	Type 5 phosphodiesterase inhibition in heart failure: the next step. <b>2007</b> , 50, 2145-7	14
1885	Long-term use of sildenafil in the therapeutic management of heart failure. <b>2007</b> , 50, 2136-44	256

1884	Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. <b>2007</b> , 28, 75-89, viii	38
1883	Pulmonary Hypertension. 191-217	
1882	Sildenafil: A recent advance in the treatment of pulmonary arterial hypertension. <b>2007</b> , 2, 61-68	
1881	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. <b>2007</b> , 3, 527-542	1
1880	Pulmonary arterial hypertension: evaluation and management. <b>2007</b> , 100, 393-9	9
1879	Pulmonary Hypertension. <b>2007</b> , 374-382	1
1878	Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. <b>2007</b> ,	
1877	Sildenafil may facilitate weaning in mechanically ventilated COPD patients: a report of three cases. <b>2007</b> , 35, 610-3	3
1876	Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes. <b>2007</b> , 103, 1161-5	36
1875	. <b>2007</b> ,	2
1874	Relaxation of the isolated human internal anal sphincter by sildenafil. <b>2007</b> , 94, 894-902	17
1873	Maladies Systémiques et Rhumatismes Inflammatoires (Hors PR, SpA et arthropathies métaboliques). <b>2007</b> , 74, 29-41	
1872	Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. <b>2007</b> , 6, 617-35	119
1871	Ambrisentan. <b>2007</b> , 6, 697-8	6
1870	Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. <b>2007</b> , 37, 38-48	14
1869	Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors. <b>2007</b> , 66, 1029-38	60
1868	What's new in pulmonary hypertension?. <b>2007</b> , 61, 3-4	6
1867	Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. <b>2007</b> , 61, 1756-65	12

1866	Futuro del tratamiento de la hipertensi3n pulmonar. <b>2007</b> , 43, 131-135	6
1865	Hipertensi3n pulmonar: eficacia cl3nica del sildenafil en clases funcionales II-III. <b>2007</b> , 43, 272-276	8
1864	Phosphodiesterase type 5 inhibitors: the day after. <b>2007</b> , 51, 75-88; discussion 89	73
1863	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. <b>2007</b> , 52, 990-1005	45
1862	Traitement m3dical de l' hypertension art3rielle pulmonaire. <b>2007</b> , 56, S123-S136	
1861	Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). <b>2007</b> , 46, 449-55	28
1860	Therapeutic challenges for systemic sclerosis: facts and future targets. <b>2007</b> , 1110, 448-54	8
1859	Treatment options in pulmonary arterial hypertension. <b>2007</b> , 8, 5-8	
1858	[Novel indications for phosphodiesterase type 5 inhibitors]. <b>2007</b> , 102, 617-30	4
1857	Pulmonale Hypertonie. <b>2007</b> , 4, 283-302	2
1856	Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. <b>2007</b> , 96, 211-7	29
1855	[Diagnosis and therapy of chronic pulmonary hypertension]. <b>2007</b> , 96, 301-30	22
1854	Pulmonary hypertension: current diagnosis and treatment. <b>2007</b> , 96, 527-41	53
1853	Pulmonal arterielle Hypertonie. <b>2007</b> , 2, 101-119	1
1852	Therapy of pulmonary arterial hypertension in systemic sclerosis: an update. <b>2007</b> , 9, 158-64	6
1851	Approach to patients with heart failure and pulmonary hypertension. <b>2007</b> , 9, 302-9	7
1850	Pulmonary hypertension: evaluation and management. <b>2007</b> , 33, 150-61	11
1849	Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. <b>2008</b> , 64, 43-50	120

1848	[Fast and efficient healing of scleroderma-associated acral ulcers with sildenafil]. <b>2008</b> , 59, 230-2	7
1847	[The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]. <b>2008</b> , 47, 1582-7	3
1846	Sildenafil and phosphodiesterase-5 inhibitors for heart failure. <b>2008</b> , 5, 110-4	17
1845	Pulmonary hypertension secondary to left ventricular systolic dysfunction: contemporary diagnosis and management. <b>2008</b> , 5, 226-32	11
1844	Phosphodiesterase 5 inhibition in essential hypertension. <b>2008</b> , 10, 52-7	27
1843	Bewegungstherapie bei pulmonaler Hypertonie. <b>2008</b> , 5, 98-102	
1842	Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. <b>2008</b> , 103, 421-30	29
1841	Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. <b>2008</b> , 71, 205-13	23
1840	Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. <b>2008</b> , 59, 706-13	10
1839	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. <b>2008</b> , 59, 867-75	45
1838	Anesthetic management of patients with pulmonary hypertension. <b>2008</b> , 12, 91-6	32
1837	Effects of sildenafil on the fetal growth of guinea pigs and their ability to survive induced intrapartum asphyxia. <b>2008</b> , 198, 127.e1-6	23
1836	PDE5 inhibitors and pulmonary hypertension. <b>2008</b> , 5, 171-178	
1835	Pulmonary hypertension and left heart disease: emerging concepts and treatment strategies. <b>2008</b> , 62, 29-31	4
1834	Emerging treatments for pulmonary arterial hypertension. <b>2008</b> , 2, 132-40	1
1833	Treatment options and strategies for acute severe pulmonary embolism. <b>2008</b> , 38, 657-67	11
1832	Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. <b>2008</b> , 25, 37-44	101
1831	Iptakalim inhibited endothelin-1-induced proliferation of human pulmonary arterial smooth muscle cells through the activation of K(ATP) channel. <b>2008</b> , 48, 92-9	15



1830	An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies. <b>2008</b> , 75, 1717-28	27
1829	Experiencia en el tratamiento de la hipertensi3n arterial pulmonar con imatinib. <b>2008</b> , 44, 689-691	6
1828	A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. <b>2008</b> , 136, 168-78, 178.e1-3	79
1827	Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. <b>2008</b> , 48, 610-8	85
1826	Looking to the future for erectile dysfunction therapies. <b>2008</b> , 68, 231-50	55
1825	Sildenafil: a review of its use in pulmonary arterial hypertension. <b>2008</b> , 68, 383-97	50
1824	Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. <b>2008</b> , 68, 1049-66	120
1823	[Diagnosis and treatment of pulmonary hypertension]. <b>2008</b> , 208, 142-55	6
1822	Diagn3stico y tratamiento. <b>2008</b> , 7, 218-226	
1821	[Experience with imatinib to treat pulmonary arterial hypertension]. <b>2008</b> , 44, 689-91	1
1820	Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. <b>2008</b> , 51, 161-9	162
1819	Pulmonary arterial hypertension. <b>2008</b> , 51, 1527-38	225
1818	Vascular Complications in Human Disease. <b>2008</b> ,	
1817	Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. <b>2008</b> , 47, 12760-8	66
1816	Medical therapy for pulmonary arterial hypertension. <b>2008</b> , 9, 65-81	7
1815	Pulmonary Hypertension. <b>2008</b> ,	3
1814	Cardiovascular consequences of pulmonary hypertension. <b>2008</b> , 43, 17-36; v	1
1813	Therapeutic advances in pulmonary arterial hypertension. <b>2008</b> , 2, 249-65	30

1812	Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. <b>2009</b> , 95, 312-7	203
1811	United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). <b>2008</b> , 27, 124-30	67
1810	Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?. <b>2008</b> , 27, 329-34	109
1809	Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. <b>2008</b> , 27, 780-8	30
1808	Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension. <b>2008</b> , 27, 1326-32	18
1807	Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. <b>2008</b> , 125, 416-7	23
1806	Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. <b>2008</b> , 129, 163-71	112
1805	Effects of San-Huang-Xie-Xin-Tang on U46619-induced increase in pulmonary arterial blood pressure. <b>2008</b> , 117, 457-62	32
1804	NO netting, health and stress - studying wellness from a net perspective. <b>2008</b> , 70, 85-91	1
1803	Sildenafil improves endothelial function in patients with pulmonary hypertension. <b>2008</b> , 21, 172-7	18
1802	Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. <b>2008</b> , 21, 516-21	7
1801	Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. <b>2008</b> , 21, 558-64	49
1800	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. <b>2008</b> , 21, 824-32	57
1799	[Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008]. <b>2008</b> , 29, 283-9	1
1798	Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. <b>2008</b> , 102, 1073-9	99
1797	Pathogenic mechanisms of pulmonary arterial hypertension. <b>2008</b> , 44, 14-30	195
1796	Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. <b>2008</b> , 1, 272-80	43
1795	Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. <b>2008</b> , 14, 189-97	92

1794	Alveolar gas diffusion abnormalities in heart failure. <b>2008</b> , 14, 695-702	79
1793	Tratamiento de la hipertensi?n arterial pulmonar. Estrategias terap?uticas. F?rmacos. Criterios de empleo. Indicaciones. Contraindicaciones. Posolog?a. Efectos secundarios. Criterios de asociaci?n y sustituci?n. <b>2008</b> , 10, 1566-1574	
1792	Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. <b>2008</b> , 371, 2093-100	683
1791	Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients. <b>2008</b> , 38, 1186-93	22
1790	Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future. <b>2008</b> , 34, 191-7; viii	6
1789	[Respiratory involvement in systemic lupus erythematosus]. <b>2008</b> , 25, 1289-303	20
1788	[Pulmonary arterial hypertension in women]. <b>2008</b> , 25, 451-60	4
1787	Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. <b>2008</b> , 8, 171-85	39
1786	Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. <b>2008</b> , 48, 926-34	86
1785	Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. <b>2008</b> , 63 Suppl 5, v1-58	427
1784	References. 124-132	
1783	The use of phosphodiesterase 5 inhibitors with concomitant medications. <b>2008</b> , 31, 799-808	49
1782	A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. <b>2009</b> , 30, 394-403	440
1781	Pulmonary arterial hypertension in congenital cardiac disease--the need for refinement of the Evian-Venice classification. <b>2008</b> , 18, 10-7	50
1780	Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. <b>2008</b> , 75, 272-80	85
1779	Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. <b>2008</b> , 32, 881-91	186
1778	PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. <b>2008</b> , 294, L24-33	112
1777	New drug targets for pulmonary hypertension: Rho GTPases in pulmonary vascular remodelling. <b>2008</b> , 84, 348-53	6

1776 Systemic sclerosis: an update for clinicians. **2008**, 69, 464-70

1775 Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. **2008**, 29, 1681-7 177

1774 Traditional and alternative designs for pulmonary arterial hypertension trials. **2008**, 5, 610-6 5

1773 Inoperable chronic thromboembolic pulmonary hypertension: treatable with medical therapy. **2008**, 134, 221-223 3

1772 Pulmonary vascular involvement in COPD. **2008**, 134, 808-814 181

1771 Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. **2008**, 48, 1451-9 59

1770 The effect of sildenafil on ocular blood flow. **2008**, 92, 469-73 43

1769 Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. **2008**, 118, 1195-201 78

1768 A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, 4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary hypertension. **2008**, 63 Suppl 2, ii1-ii41 75

1767 Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. **2008**, 63 Suppl 2, ii1-ii41 26

1766 Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. **2008**, 73, 104-10 50

1765 Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. **2008**, 326, 380-7 48

1764 Cor Pulmonale and Pulmonary Complications of Cardiac Disease. **2008**, 735-757 1

1763 Pulmonary Arterial Hypertension. **2008**, 759-771

1762 Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. **2008**, 94 Suppl 1, i1-41 45

1761 Treatment of complications associated with systemic sclerosis. **2008**, 65, 315-21 7

1760 Pulmonary Hypertension and Lung Transplantation. **2008**, 4, 17-29

1759 Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. **2008**, 10, 1158-65 41

1758	Handbook of Pediatric Cardiovascular Drugs. <b>2008</b> ,	6
1757	Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. <b>2008</b> , 67, 808-14	54
1756	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. <b>2008</b> , 32, 198-209	101
1755	Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. <b>2008</b> , 47, 1367-72	15
1754	Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. <b>2008</b> , 117, 3010-9	769
1753	New perspectives in the treatment of idiopathic pulmonary fibrosis. <b>2008</b> , 2, 75-93	21
1752	Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. <b>2008</b> , 1, 227-33	108
1751	Role of phosphodiesterases in modulation of BKCa channels in hypertensive pulmonary arterial smooth muscle. <b>2008</b> , 2, 119-27	11
1750	[Pharmacological treatment of pulmonary hypertension in patients with congenital heart disease]. <b>2008</b> , 133 Suppl 6, S209-11	2
1749	The cancer paradigm of severe pulmonary arterial hypertension. <b>2008</b> , 178, 558-64	189
1748	Therapeutic targets in neonatal pulmonary hypertension: linking pathophysiology to clinical medicine. <b>2008</b> , 2, 85-96	2
1747	Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease. <b>2008</b> , 20, 168-72	1
1746	Role of iNO in the modulation of pulmonary vascular resistance. <b>2008</b> , 28 Suppl 3, S84-92	6
1745	[Dana Point: what is new in the treatment of pulmonary hypertension?]. <b>2008</b> , 133 Suppl 6, S191-5	4
1744	Surrogate and combined end points in pulmonary arterial hypertension. <b>2008</b> , 5, 617-22	28
1743	Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. <b>2008</b> , 178, 861-9	54
1742	Patients with pulmonary arterial hypertension in clinical trials: who are they?. <b>2008</b> , 5, 603-9	9
1741	Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. <b>2008</b> , 2008, 51-53	

1740	Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. <b>2008</b> , 134, 229-236	192
1739	Editors' perspective and conclusions. <b>2008</b> , 22 Suppl 3, S63-7	
1738	Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. <b>2008</b> , 72, 1142-6	35
1737	Eisenmenger syndrome: A review of the pathophysiology and therapeutic options. <b>2008</b> , 3, 138-145	8
1736	ECG monitoring of treatment response in pulmonary arterial hypertension patients. <b>2008</b> , 134, 1250-1257	30
1735	Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. <b>2008</b> , 149, 521-30	437
1734	Appendices. 223-288	
1733	Correction: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment. <b>2008</b> , 149, 439	
1732	Dramatic functional improvement following bariatric surgery in a patient with pulmonary arterial hypertension and morbid obesity. <b>2008</b> , 133, 789-92	20
1731	Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. <b>2008</b> , 133, 183-9	68
1730	Endothelial effects of drugs designed to treat erectile dysfunction. <b>2008</b> , 14, 3768-78	24
1729	Right Ventricular Failure in the Critically Ill Patient With Pulmonary Arterial Hypertension. <b>2008</b> , 15, 161-166	
1728	Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. <b>2008</b> , 26, 501-7	19
1727	Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. <b>2008</b> , 23, 545-54	59
1726	Pulmonary arterial hypertension in children: a medical update. <b>2008</b> , 20, 288-93	21
1725	. <b>2008</b> ,	1
1724	. <b>2008</b> ,	5
1723	Hipertensi3 pulmonar idiop3ica en pediatri3: Caso cl3nico y revisi3 de la literatura. <b>2008</b> , 24,	

- 1722 Chronic Obstructive Pulmonary Disease with Severe Pulmonary Hypertension: A Case Report. **2008**, 25, 50
- 1721 [Role of nitric oxide in the control of the pulmonary circulation: physiological, pathophysiological, and therapeutic implications]. **2008**, 34, 412-9 19
- 1720 Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. **2008**, 41, 657-63 29
- 1719 Is patient cost-sharing the best way to protect the medical commons?. **2008**, 149, 435; author reply 435-6
- 1718 Monitoring Cholesterol Levels: Understanding Variance and Finding the Most Useful Data. **2008**, 149, 436
- 1717 Monitoring Cholesterol Levels: Understanding Variance and Finding the Most Useful Data. **2008**, 149, 437
- 1716 Sildenafil-induced thrombocytopenia. **2008**, 149, 437-9 6
- 1715 [Treatment of pulmonary hypertension associated with connective tissue disease]. **2008**, 31, 424-31 1
- 1714 Current pharmacological treatment of pulmonary arterial hypertension. **2008**, 3, 11-9 10
- 1713 Portopulmonary hypertension: state of the art. **2008**, 7, 321-330 51
- 1712 Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension. **2008**, 4, 1111-3 6
- 1711 Monitoring Cholesterol Levels: Understanding Variance and Finding the Most Useful Data. **2008**, 149, 436
- 1710 Integrated care and optimal management of pulmonary arterial hypertension. **2009**, 2, 67-78 5
- 1709 Primary Pulmonary Hypertension. **2009**, 89-107
- 1708 A Review of Sildenafil in the Treatment of Pediatric Pulmonary Arterial Hypertension. **2009**, 1, CMT.S1959 1
- 1707 Treatment of pediatric pulmonary hypertension. **2009**, 5, 509-24 17
- 1706 Review of inhaled iloprost for the control of pulmonary artery hypertension in children. **2009**, 5, 325-31 38
- 1705 Pulmonary Vasodilators in COPD. **2009**, 699-704

- 1704 Safety and Efficacy of Ambrisentan in the Treatment of Pulmonary Arterial Hypertension. **2009**, 1, CMT.S2675
- 1703 Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. **2009**, 50, 513-29 29
- 1702 Present and Prospective Pharmacotherapies in Pulmonary Arterial Hypertension. **2009**, 1, CMT.S2108
- 1701 Validation of a treadmill six-minute walk test protocol for the evaluation of patients with pulmonary arterial hypertension. **2009**, 35, 423-30 22
- 1700 Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. **2009**, 5, 607-19 24
- 1699 Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. **2009**, 49, 109-15 57
- 1698 Guidelines for the diagnosis and treatment of pulmonary hypertension. **2009**, 34, 1219-63 919
- 1697 The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. **2009**, 33, 1186-94 96
- 1696 Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?. **2009**, 32 Suppl 2, S420-2 7
- 1695 The effects of vasodilators in pulmonary hypertension: pulmonary vascular or peripheral vascular?. **2009**, 2, 145-50 19
- 1694 Advanced pulmonary vascular disease: the Eisenmenger syndrome. **2009**, 19 Suppl 1, 39-44 3
- 1693 Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. **2009**, 36, 1481-5 46
- 1692 Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent?. **2009**, 82, 4-6 2
- 1691 Advances in therapies for pediatric pulmonary arterial hypertension. **2009**, 3, 265-82 4
- 1690 ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. **2009**, 119, 2250-94 829
- 1689 Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. **2009**, 48 Suppl 3, iii25-31 48
- 1688 Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. **2009**, 95, 1531-6 32
- 1687 Conventional and targeted medical therapies. **2009**, 19 Suppl 1, 28-34 4



1686	Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. <b>2009</b> , 36, 657-64	26
1685	End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?. <b>2009</b> , 34, 231-42	44
1684	Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. <b>2009</b> , 82, 30-9	56
1683	PDE5 inhibitors: in vitro and in vivo pharmacological profile. <b>2009</b> , 15, 3464-75	53
1682	Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. <b>2009</b> , 135, 137-142	67
1681	Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. <b>2009</b> , 135, 1455-1461	122
1680	A 22-year-old woman with unexplained dyspnea. <b>2009</b> , 136, 867-876	1
1679	Vasoproliferation and antiproliferative treatment options in pulmonary arterial hypertension. <b>2009</b> , 4, 142-9	3
1678	Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. <b>2009</b> , 6, 349-55	25
1677	Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. <b>2009</b> , 179, 835-42	170
1676	Recent Advances in the Management of Pulmonary Arterial Hypertension. <b>2009</b> , 5, 41-48	
1675	The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. <b>2009</b> , 40, 683-91	80
1674	Medical treatment of pulmonary arterial hypertension. <b>2009</b> , 30, 484-92	6
1673	Pulmonary arterial hypertension complicating connective tissue diseases. <b>2009</b> , 30, 429-39	48
1672	The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. <b>2009</b> , 32, 911-5	9
1671	Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. <b>2009</b> , 296, L220-8	25
1670	Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. <b>2009</b> , 21, 149-57	12
1669	Trends in pulmonary arterial hypertension. <b>2009</b> , 18, 7-12	15

1668	Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. <b>2009</b> , 68, 961-5	59
1667	Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. <b>2009</b> , 33, 861-70	39
1666	Sildenafil increases endothelial progenitor cell function and improves ischemia-induced neovascularization in hypercholesterolemic apolipoprotein E-deficient mice. <b>2009</b> , 54, 1043-9	39
1665	Therapeutic targets in pulmonary arterial hypertension. <b>2009</b> , 121, 69-88	71
1664	Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. <b>2009</b> , 122, 216-38	273
1663	Non-congenital heart disease associated pediatric pulmonary arterial hypertension. <b>2009</b> , 27, 13-23	18
1662	Pulmonary hypertension in bronchopulmonary dysplasia. <b>2009</b> , 27, 43-48	35
1661	Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. <b>2009</b> , 154, 379-84, 384.e1-2	196
1660	Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. <b>2009</b> , 155, 841-847.e1	180
1659	Right but not left ventricular function recovers early after living-donor lobar lung transplantation in patients with pulmonary arterial hypertension. <b>2009</b> , 138, 222-6	19
1658	A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. <b>2009</b> , 138, 1417-24	109
1657	Phosphodiesterase inhibitors and the eye. <b>2009</b> , 37, 514-23	34
1656	Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?. <b>2009</b> , 51, 90-5	19
1655	Treating heart failure with sildenafil. <b>2009</b> , 15, 181-5	10
1654	Cardiovascular effects of phosphodiesterase type 5 inhibitors. <b>2009</b> , 6, 658-74	38
1653	2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). <b>2009</b> , 6, 1794-808; quiz 1793, 1809-10	33
1652	Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. <b>2009</b> , 14, 284-90	15
1651	[Combination therapy for pulmonary arterial hypertension]. <b>2009</b> , 45, 36-40	1

1650	[Double-lung transplantation in 15 patients with pulmonary hypertension]. <b>2009</b> , 45, 366-70	6
1649	Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta. <b>2009</b> , 615, 155-62	28
1648	Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. <b>2009</b> , 15, 15-9	82
1647	Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. <b>2009</b> , 15, 30-6	74
1646	Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. <b>2009</b> , 60, 569-77	190
1645	Clinical practice: pulmonary hypertension in children. <b>2009</b> , 168, 515-22	13
1644	Pulmonary Hypertension in Renal Failure Patients. <b>2009</b> , 18, 68-73	
1643	Milde symptomatische pulmonal-arterielle Hypertonie. <b>2009</b> , 6, 35-36	
1642	ERG evaluation of daily, high-dose sildenafil usage. <b>2009</b> , 118, 225-31	23
1641	Phosphodiesterase inhibition in heart failure. <b>2009</b> , 14, 255-63	51
1640	Pulmonary arterial hypertension in children: a medical update. <b>2009</b> , 76, 77-81	10
1639	Pulmonary arterial hypertension. <b>2009</b> , 11, 139-45	5
1638	Pulmonary arterial hypertension. <b>2009</b> , 4, 459-70	10
1637	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. <b>2009</b> , 26, 813-25	75
1636	[Therapy of pulmonary arterial hypertension]. <b>2009</b> , 50, 1101-2, 1104-9	2
1635	Cerebral hemorrhage associated with sildenafil (Revatio) in an infant. <b>2009</b> , 30, 998-9	9
1634	Sildenafil for the treatment of pulmonary hypertension in pediatric patients. <b>2009</b> , 30, 871-82	36
1633	Endothelin receptor antagonists in preclinical models of pulmonary hypertension. <b>2009</b> , 39 Suppl 2, 3-13	8

1632	The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. <b>2009</b> , 39 Suppl 2, 38-49	38
1631	Bleeding events in pulmonary arterial hypertension. <b>2009</b> , 39 Suppl 2, 68-73	12
1630	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. <b>2009</b> , 30, 1-24	45
1629	Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. <b>2010</b> , 64, 240-55	119
1628	The six-minute walk test: a useful metric for the cardiopulmonary patient. <b>2009</b> , 39, 495-501	236
1627	The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. <b>2009</b> , 156, 909-19	46
1626	Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. <b>2009</b> , 157, 1241-9	46
1625	The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III. <b>2009</b> , 12, 1100-5	11
1624	Evaluation, risk stratification, and management of pulmonary hypertension in patients with congenital heart disease. <b>2009</b> , 106-11	8
1623	[Pulmonary arterial hypertension related to systemic sclerosis in 2008]. <b>2009</b> , 34, 7-15	1
1622	EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). <b>2009</b> , 68, 620-8	440
1621	Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. <b>2009</b> , 15, 31-4	26
1620	Molecular mechanisms of pulmonary hypertension. <b>2009</b> , 403, 9-16	38
1619	Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan. <b>2009</b> , 103, 1688-92	13
1618	Refolding and kinetic characterization of the phosphodiesterase-8A catalytic domain. <b>2009</b> , 64, 82-8	11
1617	Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. <b>2009</b> , 28, 280-4	17
1616	Comparison of baseline characteristics and survival between patients with idiopathic and connective tissue disease-related pulmonary arterial hypertension. <b>2009</b> , 28, 621-7	30
1615	Cyclic GMP-hydrolyzing phosphodiesterases. <b>2009</b> , 367-408	28

1614	Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 1864-71	59.2	167
1613	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <b>2009</b> , 33, 1117-1177		2531
1612	ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. <b>2009</b> , 53, 1573-619		1257
1611	End points and clinical trial design in pulmonary arterial hypertension. <b>2009</b> , 54, S97-S107		166
1610	Diagnosis and assessment of pulmonary arterial hypertension. <b>2009</b> , 54, S55-S66		828
1609	Updated evidence-based treatment algorithm in pulmonary arterial hypertension. <b>2009</b> , 54, S78-S84		379
1608	Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. <b>2009</b> , 54, 1971-81		191
1607	Long-term outcome of the child with congenital heart disease. <b>2009</b> , 19, 37-42		6
1606	Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells. <b>2009</b> , 59, 312-8		17
1605	Combination Therapy for Pulmonary Arterial Hypertension. <b>2009</b> , 45, 36-40		
1604	Double-lung Transplantation in 15 Patients With Pulmonary Hypertension. <b>2009</b> , 45, 366-370		
1603	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <b>2009</b> , 62, 1464.e1-1464.e58		1
1602	Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. <b>2009</b> , 29, 635-46		29
1601	Effects and mechanisms of action of sildenafil citrate in human chorionic arteries. <b>2009</b> , 7, 34		26
1600	A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. <b>2009</b> , 28, 369-82		120
1599	Pulmonary Hypertension: Diagnosis and Management. <b>2009</b> , 84, 191-207		74
1598	Pulmonary Problems in Pregnancy. <b>2009</b> ,		
1597	cGMP: Generators, Effectors and Therapeutic Implications. <b>2009</b> ,		13

1596	Successful pregnancy in pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. <b>2009</b> , 3, 7255	18
1595	Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. <b>2009</b> , 9, 331-50	21
1594	Tadalafil therapy for pulmonary arterial hypertension. <b>2009</b> , 119, 2894-903	769
1593	Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. <b>2009</b> , 18, 35-41	38
1592	First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. <b>2009</b> , 33, 785-92	186
1591	Sildenafil's protective effect against cardiac hypertrophy. <b>2009</b> , 2, 323-7	2
1590	Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. <b>2009</b> , 7, 43-59	16
1589	Vardenafil: efficacy, tolerability and future directions. <b>2009</b> , 5, 553-62	3
1588	Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. <b>2009</b> , 49, 1343-52	48
1587	Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats. <b>2009</b> , 33, 1122-32	52
1586	Hipertensi3 arterial pulmonar. <b>2009</b> , 10, 2912-2918	
1585	Gu3 de pr3ctica cl3nica para el diagn3stico y tratamiento de la hipertensi3 pulmonar. <b>2009</b> , 62, 1464.e1-1464.e58	3
1584	The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. <b>2009</b> , 12, 192-206	15
1583	Approches th3rapeutiques actuelles dans l3HTAP. <b>2009</b> , 1, 186-189	
1582	Actualit3 th3rapeutiques dans l3hypertension artfielle pulmonaire. <b>2009</b> , 2009, 18-24	
1581	Therapy for pulmonary arterial hypertension associated with systemic sclerosis. <b>2009</b> , 21, 642-8	26
1580	Pulmonary hypertension and right ventricular function: interdependence in pathophysiology and management. <b>2009</b> , 47, 97-120	16
1579	Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. <b>2009</b> , 111, 235-43	40

1578	Endothelin receptor antagonists for pulmonary arterial hypertension. <b>2009</b> , CD004434	10
1577	Advanced pulmonary vascular disease: the Eisenmenger syndrome. <b>2009</b> , 19, 622-6	10
1576	Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease. <b>2009</b> , 73, 1965-8	14
1575	The current treatment of pulmonary hypertension. <b>2009</b> , 5, 20-3	2
1574	Is there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function?. <b>2009</b> , 15, 3506-20	9
1573	Phosphodiesterase type 5 inhibitors: unmet needs. <b>2009</b> , 15, 3476-85	25
1572	Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension. <b>2010</b> , 16 Suppl 1, S35-41	19
1571	Idiopathic pulmonary arterial hypertension in childhood. <b>2010</b> , 18, 64-6	3
1570	C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. <b>2010</b> , 16, 4080-8	57
1569	The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results. <b>2010</b> , 6, 356-62	8
1568	Pulmonary arterial hypertension. <b>2010</b> , 8, 412-20	3
1567	Pulmonary hypertension in Latin America: pulmonary vascular disease: the global perspective. <b>2010</b> , 137, 78S-84S	19
1566	Sclérodémie systémique. <b>2010</b> , 5, 1-14	
1565	Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. <b>2010</b> , 137, 1297-303	38
1564	Endpoints in pulmonary arterial hypertension: the role of clinical worsening. <b>2010</b> , 16 Suppl 1, S1-9	19
1563	Acute pulmonary hypertension in infants and children: cGMP-related drugs. <b>2010</b> , 11, S37-40	9
1562	Clinical worsening in trials of pulmonary arterial hypertension: results and implications. <b>2010</b> , 16 Suppl 1, S11-9	30
1561	Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. <b>2010</b> , 16 Suppl 1, S27-34	16

1560	Perspective on the optimal endpoints for pulmonary arterial hypertension trials. <b>2010</b> , 16 Suppl 1, S43-6	9
1559	Update on anaesthetic approach to pulmonary hypertension. <b>2010</b> , 27, 317-23	22
1558	Pulmonary arterial hypertension in connective tissue diseases. <b>2010</b> , 18, 85-8	12
1557	Pulmonary arterial hypertension: pathobiology, diagnosis, treatment, and emerging therapies. <b>2010</b> , 18, 58-63	19
1556	Should We Administer Sildenafil to Patients with Obstructive Pulmonary Disease and Pulmonary Hypertension? No. <b>2010</b> , 182, 1206-1207	
1555	Portopulmonary hypertension: short review. <b>2010</b> , 22, 385-90	23
1554	2. Phosphodiesterase-5 Inhibitors.. <b>2010</b> , 99, 1557-1562	
1553	Inhalational therapy for pulmonary arterial hypertension: current status and future prospects. <b>2010</b> , 27, 313-70	22
1552	Pulmonary hemodynamic response to acute combination and monotherapy with sildenafil and brain natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension. <b>2010</b> , 339, 55-9	7
1551	Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation. <b>2011</b> , 1, 123-39	3
1550	Avanafil: a new phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. <b>2010</b> , 6, 599-605	
1549	Pulmonary hypertension in children: a historical overview. <b>2010</b> , 11, S4-9	22
1548	Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. <b>2010</b> , 74, 1458-64	40
1547	Identification of new prognostic factors of pulmonary hypertension. <b>2010</b> , 74, 1965-71	37
1546	A case of isolated peripheral pulmonary artery branch stenosis associated with multiple pulmonary artery aneurysms. <b>2010</b> , 49, 1895-9	7
1545	EULAR-Empfehlungen zur Behandlung der systemischen Sklerose. <b>2010</b> , 69, 87-92	0
1544	Pulmonary arterial hypertension: today's choice of treatment. <b>2010</b> , 21, 40-46	1
1543	Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. <b>2010</b> , 36, 758-64	34



- 1542 Should we administer sildenafil to patients with acute respiratory distress syndrome? No. **2010**, 36, 1102-3; author reply 1104-5
- 1541 There is no place (yet) for routine administration of sildenafil to patients with ARDS. **2010**, 36, 1104-1105 0
- 1540 Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. **2010**, 188, 115-23 59
- 1539 Aktuelle Therapie der pulmonal-arteriellen Hypertonie. **2010**, 7, 192-199
- 1538 Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease. **2010**, 6, 13-31 15
- 1537 Diagnostik und Therapie der pulmonalen Hypertonie. **2010**, 4, 189-207 3
- 1536 Sildenafil and steroid therapy effectively improved POEMS syndrome-associated pulmonary arterial hypertension. **2010**, 92, 774-6 3
- 1535 Medical therapy for pediatric pulmonary arterial hypertension. **2010**, 157, 528-32 32
- 1534 Systemic sclerosis: clinical features and management. **2010**, 38, 109-115 2
- 1533 Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. **2010**, 126, 186-99 26
- 1532 Long-term results and consequences of single ventricle palliation. **2010**, 29, 19-23 17
- 1531 Management of pulmonary arterial hypertension in children. **2010**, 11, 240-5 7
- 1530 Functional improvement in a patient with cirrhosis and portopulmonary hypertension treated by sildenafil for 2 years. **2010**, 3, 263-266
- 1529 Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?. **2010**, 10, 9 14
- 1528 Role of combination therapy in the treatment of pulmonary arterial hypertension. **2010**, 30, 390-404 7
- 1527 Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. **2010**, 105, 1485-9 30
- 1526 [Peak oxygen uptake during the six-minute walk test in diffuse interstitial lung disease and pulmonary hypertension]. **2010**, 46, 122-8 16
- 1525 Phosphodiesterase inhibitors in the management of autoimmune disease. **2010**, 9, 511-5 24

1524	Pulmonary arterial hypertension in systemic sclerosis. <b>2010</b> , 9, 761-70	21
1523	Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. <b>2010</b> , 11, 12	58
1522	[PDE5 inhibitors in the treatment of pulmonary hypertension]. <b>2010</b> , 39, 391-6	1
1521	Sickle-cell anemia and pulmonary hypertension. <b>2010</b> , 22, 198-204	
1520	Pulmonary arterial hypertension in adults with congenital heart disease. <b>2010</b> , 64, 13-24	8
1519	Targeting non-malignant disorders with tyrosine kinase inhibitors. <b>2010</b> , 9, 956-70	102
1518	The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. <b>2010</b> , 15, 1226-32	29
1517	Dramatic response of a patient with pregnancy induced idiopathic pulmonary arterial hypertension to sildenafil treatment. <b>2010</b> , 36, 414-7	7
1516	Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscles cells. <b>2010</b> , 37, 362-7	16
1515	Phosphodiesterase Families. <b>2010</b> , 1409-1414	1
1514	Initial Experience with Sildenafil, Bosentan, and Nitric Oxide for Pediatric Cardiomyopathy Patients with Elevated Pulmonary Vascular Resistance before and after Orthotopic Heart Transplantation. <b>2010</b> , 2010, 656984	23
1513	Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension. <b>2010</b> , 40, 659-64	9
1512	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. <b>2010</b> , 6, 273-80	21
1511	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. <b>2010</b> , 2, 151-61	18
1510	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. <b>2010</b> , 4, 61-70	28
1509	Inhaled treprostinil and pulmonary arterial hypertension. <b>2010</b> , 6, 1115-24	6
1508	Recent Updates in Both the Diagnosis and Treatment Options that Impact the Clinical Treatment of Pulmonary Arterial Hypertension. <b>2010</b> , 2, CMT.S4192	
1507	Diagnosis and treatment of pulmonary hypertension: an update. <b>2010</b> , 36, 795-811	18

1506	Ventrículo derecho: Relación con patología respiratoria y patología del ventrículo izquierdo. <b>2010</b> , 26,	
1505	Pulmonary Circulation. <b>2010</b> , 117-141	3
1504	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. <b>2010</b> , 49, 490-500	74
1503	Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. <b>2010</b> , 31, 1124-31	137
1502	Patient subgroups and potential risk factors in systemic sclerosis: is there a possibility of an early diagnosis?. <b>2010</b> , 5, 555-564	1
1501	Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. <b>2010</b> , 121, 2045-66	367
1500	Treatment options for paediatric pulmonary arterial hypertension. <b>2010</b> , 19, 321-30	10
1499	Management of severe pulmonary arterial hypertension. <b>2010</b> , 19, 279-87	13
1498	PPHN: is sildenafil the new nitric? A review of the literature. <b>2010</b> , 10, 69-74	9
1497	Management of dyspnea in advanced pulmonary arterial hypertension. <b>2010</b> , 4, 76-84	11
1496	Therapeutic approaches in adults with congenital heart disease-associated pulmonary arterial hypertension. <b>2010</b> , 19, 300-7	6
1495	Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects. <b>2010</b> , 2010, 708067	4
1494	Molecular Basis of Pulmonary Disease. <b>2010</b> ,	3
1493	Tadalafil for the treatment of pulmonary arterial hypertension. <b>2010</b> , 11, 127-32	27
1492	Clinical use of sildenafil in pulmonary artery hypertension. <b>2010</b> , 4, 13-9	11
1491	Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. <b>2010</b> , 122, 88-95	78
1490	Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. <b>2010</b> , 182, 1171-7	276
1489	Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain. <b>2010</b> , 285, 38149-56	27

1488	Targeted therapy for systemic sclerosis: how close are we?. <b>2010</b> , 6, 269-78	18
1487	Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. <b>2010</b> , 96, 2005-9	28
1486	[Pulmonary arterial hypertension related to connective tissue diseases]. <b>2010</b> , 10 Suppl 1, 57-62	
1485	Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. <b>2010</b> , 19, 272-8	32
1484	Pulmonary arterial hypertension in adults with congenital heart disease: The Eisenmenger syndrome. <b>2010</b> , 2, 69	
1483	[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension]. <b>2010</b> , 10 Suppl 2, 16-8	3
1482	Arzneiverordnungs-Report 2010. <b>2010</b> ,	28
1481	[Therapeutic algorithms in pulmonary hypertension in the light of current guidelines]. <b>2010</b> , 10 Suppl 2, 19-26	1
1480	Is Right Ventricular Failure Common in the Intensive Care Unit? How Should It Be Managed?. <b>2010</b> , 335-343	
1479	Pulmonary hypertension in women. <b>2010</b> , 8, 1549-58	31
1478	Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. <b>2010</b> , 31, 2080-6	129
1477	Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. <b>2010</b> , 137, 85S-94S	19
1476	Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. <b>2010</b> , 137, 376-87	798
1475	[Diagnosis and treatment of pulmonary hypertension: European guidelines 2009]. <b>2010</b> , 64, 401-14	15
1474	Pulmonary arterial hypertension and lung transplantation. <b>2010</b> , 31, 147-60	12
1473	Pulmonary Palacos embolism: a case report. <b>2010</b> , 58, 437-9	13
1472	Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009. <b>2010</b> , 135, e2-e15	0
1471	[Treatment of pulmonary arterial hypertension (PAH): recommendations of the Cologne Consensus Conference 2010]. <b>2010</b> , 135 Suppl 3, S87-101	9

1470	Guidelines for the management of pulmonary hypertension patients. <b>2010</b> , 16 Suppl 4, S7-S85	1
1469	Should we administer sildenafil to patients with obstructive pulmonary disease and pulmonary hypertension? No. <b>2010</b> , 182, 1206; author reply 1206-7	1
1468	Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. <b>2010</b> , 6, 285-96	33
1467	Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. <b>2010</b> , 181, 270-8	210
1466	Genomics of pulmonary arterial hypertension: implications for therapy. <b>2010</b> , 6, 101-14	9
1465	[Guidelines for the diagnosis and treatment of pulmonary hypertension]. <b>2010</b> , 27, 141-50	5
1464	Respiratory involvement in systemic lupus erythematosus. <b>2010</b> , 27, e66-78	27
1463	Regulation of cAMP by phosphodiesterases in erythrocytes. <b>2010</b> , 62, 475-82	30
1462	[Pulmonary arterial hypertension in the elderly subject]. <b>2010</b> , 27, 30-6	3
1461	Maladies vasculaires pulmonaires. <b>2010</b> , 2, 134-144	
1460	The BK potassium channel in the vascular smooth muscle and kidney: $\beta$ and $\beta$ subunits. <b>2010</b> , 78, 963-74	66
1459	Animal models of pulmonary hypertension: role in translational research. <b>2010</b> , 7, 89-97	8
1458	Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. <b>2010</b> , 55, 1456-62	25
1457	Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. <b>2010</b> , 55, 1915-22	381
1456	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. <b>2010</b> , 11, 146	17
1455	Amelioration of penile fibrosis: myth or reality. <b>2010</b> , 31, 324-35	61
1454	Targeted oral therapies in the treatment of pulmonary arterial hypertension. <b>2010</b> , 30, 811-826	11
1453	Evidence-Based Management of Right Heart Failure: a Systematic Review of an Empiric Field. <b>2010</b> , 63, 451-471	2

1452	Current therapeutic approaches to pulmonary arterial hypertension. <b>2010</b> , 63, 708-24	2
1451	Peak Oxygen Uptake During the Six-minute Walk Test in Diffuse Interstitial Lung Disease and Pulmonary Hypertension. <b>2010</b> , 46, 122-128	2
1450	Care of patients with scleroderma in the intensive care setting. <b>2010</b> , 25, 247-58	9
1449	Treating pulmonary arterial hypertension: is it worth it?. <b>2010</b> , 96, 1607-8	2
1448	Pulmonary hypertension with left-sided heart disease. <b>2010</b> , 7, 648-59	101
1447	Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. <b>2010</b> , 29, 137-49	141
1446	Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. <b>2010</b> , 29, S1-39	704
1445	Pulmonary arterial hypertension in patients with prior atrial switch procedure for d-transposition of great arteries (dTGA). <b>2010</b> , 143, 271-5	15
1444	Ocular findings of oral sildenafil use in term and near-term neonates. <b>2010</b> , 14, 159-62	22
1443	Pulmonary hypertension in dogs: diagnosis and therapy. <b>2010</b> , 40, 623-41	92
1442	Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. <b>2010</b> , 23, 456-64	25
1441	Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. <b>2010</b> , 104, 731-40	59
1440	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. <b>2010</b> , 104 Suppl 1, S74-80	9
1439	Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. <b>2010</b> , 159, 245-57	85
1438	Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. <b>2010</b> , 11, 1109-22	63
1437	Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs. <b>2010</b> , 24, 850-4	56
1436	Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. <b>2010</b> , 28, 350-5	16
1435	Management of Systemic Sclerosis and Raynaud's Phenomenon. <b>2010</b> , 157-165	

1434	Esclerodermia sistémica. <b>2010</b> , 44, 1-15	
1433	Depressive Symptoms in Pulmonary Arterial Hypertension: Prevalence and Association With Functional Status. <b>2010</b> , 51, 339-339.e8	65
1432	Tratamiento basado en la evidencia de la insuficiencia cardiaca derecha: una revisi3n sistemática de un campo empírico. <b>2010</b> , 63, 451-471	25
1431	Estrategias terapéuticas actuales en la hipertensi3n arterial pulmonar. <b>2010</b> , 63, 708-724	15
1430	Hipertensi3n pulmonar. <b>2010</b> , 10, 4505-4512	
1429	[Treatment of pulmonary arterial hypertension]. <b>2010</b> , 39 Suppl 1, 1S22-32	4
1428	Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions. <b>2010</b> , 26, e98-117	79
1427	Pulmonary hypertension: Classification and treatment. <b>2010</b> , 26, 5B-11B	1
1426	Outcomes in pulmonary hypertension: Beyond 40 metres. <b>2010</b> , 26, 12B-16B	1
1425	A substrate selectivity and inhibitor design lesson from the PDE10-cAMP crystal structure: a computational study. <b>2010</b> , 114, 5154-60	5
1424	Principles of Pulmonary Protection in Heart Surgery. <b>2010</b> ,	1
1423	Pulmonary arterial hypertension in women. <b>2010</b> , 27, e79-87	17
1422	Riociguat for pulmonary hypertension. <b>2010</b> , 6, 155-66	24
1421	Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. <b>2010</b> , 6, 19-35	17
1420	Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. <b>2010</b> , 8, 69-71; author reply 71-3	0
1419	Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. <b>2010</b> , 95, F109-14	46
1418	Emerging drugs for pulmonary hypertension. <b>2010</b> , 15, 71-85	11
1417	Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. <b>2011</b> , 11, 287-94	64

1416	Viruses in pharmaceutical research: pulmonary vascular disease. <b>2011</b> , 8, 56-64	2
1415	Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. <b>2011</b> , 97, 1876-81	56
1414	Maladies vasculaires pulmonaires. <b>2011</b> , 3, 128-139	
1413	Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial. <b>2011</b> , 74, 556-62	11
1412	Comparison of virtual high-throughput screening methods for the identification of phosphodiesterase-5 inhibitors. <b>2011</b> , 51, 1353-63	23
1411	Pulmonary arterial hypertension: a comparison between children and adults. <b>2011</b> , 37, 665-77	140
1410	Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial. <b>2011</b> , 12, 207-14	27
1409	Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?. <b>2011</b> , 8, 53-82	112
1408	Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. <b>2011</b> , 63, 811-59	213
1407	Comprehensive Cardiovascular Medicine in the Primary Care Setting. <b>2011</b> ,	
1406	Clinical and molecular genetic features of hereditary pulmonary arterial hypertension. <b>2011</b> , 1, 1721-8	4
1405	Alternatives to lung transplantation: treatment of pulmonary arterial hypertension. <b>2011</b> , 32, 399-410	8
1404	Pulmonary arterial hypertension. <b>2011</b> , 23, 645-59	1
1403	Phosphodiesterases as Drug Targets. <b>2011</b> ,	20
1402	Riociguat for the treatment of pulmonary hypertension. <b>2011</b> , 20, 567-76	69
1401	[Pulmonary hypertension in pediatric and neonatal intensive care unit. Part II: diagnosis and treatment]. <b>2011</b> , 18, 195-203	
1400	Current therapeutics and practical management strategies for pulmonary arterial hypertension. <b>2011</b> , 162, 201-13	37
1399	Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. <b>2011</b> , 415-46	26



1398	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. <b>2011</b> , 30, 632-43	79
1397	Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. <b>2011</b> , 30, 982-9	61
1396	Sildenafil and bosentan improve arterial oxygenation during acute hypoxic exercise: a controlled laboratory trial. <b>2011</b> , 22, 211-21	16
1395	Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. <b>2011</b> , 24, 169-73	7
1394	Role of phosphodiesterases in adult-onset pulmonary arterial hypertension. <b>2011</b> , 279-305	6
1393	Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension. <b>2011</b> , 251-77	28
1392	Tadalafil for the treatment of pulmonary arterial hypertension. <b>2011</b> , 5, 315-28	7
1391	Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. <b>2011</b> , 57, 1053-61	48
1390	Looking to the future: a new decade of pulmonary arterial hypertension therapy. <b>2011</b> , 20, 262-9	50
1389	Pulmonary hypertension and right ventricular dysfunction: physiology and perioperative management. <b>2011</b> , 25, 687-704	49
1388	Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. <b>2011</b> , 154 Suppl 1, S20-33	38
1387	Non-parenteral Therapy for Pulmonary Arterial Hypertension: A Review of Efficacy, Tolerability and Factors Related to Patient Adherence. <b>2011</b> , 3, CMT.S2689	
1386	Heart Failure, Exercise Intolerance, and Physical Training. <b>2011</b> , 44-51	1
1385	THE SYSTEMIC SCLERODERMAS AND RELATED DISORDERS. <b>2011</b> , 414-437	
1384	Treatment of schistosomiasis-associated pulmonary hypertension. <b>2011</b> , 37, 272-6	14
1383	Central Retinal Vein Occlusion Associated With Sildenafil (Viagra). <b>2011</b> , 16,	
1382	Endothelial Dysfunction and Therapeutic Intervention in Type 2 Diabetes. <b>2011</b> ,	
1381	Cambios en el pronóstico a largo plazo de la hipertensión arterial pulmonar. <b>2011</b> , 139, 327-333	2

1380 Dyspnea in Pulmonary Arterial Hypertension. **2011,**

1379 Pharmacotherapy for pulmonary arterial hypertension. **2011,** 54, 1299

1

1378 Diagnosis and management of pulmonary arterial hypertension. **2011,** 2011, 845864

23

1377 Therapeutic strategies in pulmonary hypertension. **2011,** 2, 21

10

1376 Prostacyclin: an inflammatory paradox. **2011,** 2, 24

69

1375 Diseases of Pulmonary Circulation. **2011,** 632-656

1374 Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. **2011,** 6, e18136

30

1373 Pulmonary vasodilators. 767-782

1372 The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography. **2011,** 31, 332-5

118

1371 Clinical trials using vasodilators in pulmonary arterial hypertension: where do we go from here?. **2011,** 6, 228-34

5

1370 Pulmonary hypertension: role of combination therapy. **2011,** 9, 457-64

2

1369 Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. **2011,** 140, 19-26

167

1368 Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. **2011,** 118, 855-64

179

1367 Pulmonary arterial hypertension associated with connective tissue diseases. **2011,** 223-235

1366 Recent progress in the management of pulmonary hypertension. **2011,** 75, 1801-10

65

1365 Addressing missing data in clinical trials. **2011,** 154, 113-7

79

1364 A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension. **2011,** 75, 677-82

17

1363 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease. **2011,** 60, 419-24

17

1362	Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. <b>2011</b> , 41, 235-44	21
1361	The initial 18 months of the first multi-disciplinary regional Pulmonary Arterial Hypertension Clinic in Australia. <b>2011</b> , 19, 89-94	3
1360	Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. <b>2011</b> , 71, 289-92	50
1359	Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. <b>2011</b> , 162, 1389-400	46
1358	New perspectives for the treatment of pulmonary hypertension. <b>2011</b> , 163, 125-40	47
1357	Current management approaches to portopulmonary hypertension. <b>2011</b> , 65, 11-8	14
1356	Effects of sildenafil citrate on five dogs with Eisenmenger's syndrome. <b>2011</b> , 52, 595-8	20
1355	Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. <b>2011</b> , 8, 2894-903	55
1354	Effects of pulmonary vasodilator therapy on ventilatory efficiency during exercise in adults with Eisenmenger syndrome. <b>2011</b> , 6, 139-46	7
1353	Pulmonary hypertension in systemic sclerosis. <b>2011</b> , 41, 19-37	31
1352	Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. <b>2011</b> , 33, 993-1004	27
1351	Pulmonary arterial hypertension. <b>2011</b> , 36, 461-517	40
1350	Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. <b>2011</b> , 660, 298-304	30
1349	Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. <b>2011</b> , 108, 302-7	35
1348	Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. <b>2011</b> , 108, 1177-82	52
1347	The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. <b>2011</b> , 34, 513-8	27
1346	Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. <b>2011</b> , 5, 191-205	5
1345	Pulmonary arterial hypertension: an update. <b>2011</b> , 19, 514-22	16

1344	Pulmonary arterial hypertension and lung transplantation. <b>2011</b> , 5, 441-54	22
1343	Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. <b>2011</b> , 14, 17-27	46
1342	Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. <b>2011</b> , 37, 502-9	63
1341	Emerging role of sildenafil in neonatology. <b>2011</b> , 48, 11-3	6
1340	Treatment for pulmonary hypertension including lung transplantation. <b>2011</b> , 59, 538-46	2
1339	Pulmonale Hypertension. <b>2011</b> , 6, 78-93	
1338	Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension. <b>2011</b> , 12, 58	4
1337	Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. <b>2011</b> , 183, 1723-9	125
1336	Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. <b>2011</b> , 12, 1845-64	3
1335	Gene therapy for pulmonary hypertension: prospects and challenges. <b>2011</b> , 11, 133-43	17
1334	Advances in the management of pediatric pulmonary hypertension. <b>2011</b> , 56, 1314-39; discussion 1339-40	32
1333	Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. <b>2011</b> , 89, 542-52	73
1332	Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. <b>2011</b> , 11, 253-63	5
1331	Combination therapy in pulmonary arterial hypertension: a meta-analysis. <b>2011</b> , 120, 157-65	51
1330	Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds. <b>2011</b> , 5, 163-71	15
1329	Treatment of pulmonary arterial hypertension with targeted therapies. <b>2011</b> , 8, 526-38	102
1328	Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. <b>2011</b> , 20, 277-86	68
1327	Future of clinical trials for pulmonary hypertension. <b>2011</b> , 123, 2919-21	5

1326	Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. <b>2011</b> , 124, 164-74	399
1325	Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension. <b>2011</b> , 1, 244-9	10
1324	Prognosis in pulmonary arterial hypertension. <b>2011</b> , 37, 971-2; author reply 972-3	2
1323	Res-erection of Viagra as a heart drug. <b>2011</b> , 4, 2-4	6
1322	PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials. <b>2011</b> , 2011, 392542	3
1321	Recent trends in pulmonary arterial hypertension. <b>2011</b> , 28, 39-48	6
1320	Diagnostic and therapeutic algorithm for pulmonary arterial hypertension. <b>2011</b> , 1, 122-4	9
1319	Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. <b>2011</b> , 37, 1104-18	75
1318	Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. <b>2011</b> , 82, 294-304	52
1317	HIV infection and pulmonary arterial hypertension. <b>2011</b> , 5, 257-66	11
1316	Living with pulmonary hypertension: quality not just quantity. <b>2011</b> , 38, 512-3	3
1315	Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. <b>2011</b> , 21, 631-8	10
1314	Does the outcome justify an oral-first treatment strategy for management of pulmonary arterial hypertension?. <b>2011</b> , 140, 697-705	4
1313	Impact of oral chronic administration of sildenafil in children and young adults after the Fontan operation. <b>2011</b> , 7, 609-12	9
1312	Disturbed spermatogenesis associated with thickened lamina propria of seminiferous tubules is not caused by dedifferentiation of myofibroblasts. <b>2011</b> , 26, 1450-61	25
1311	Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity. <b>2011</b> , 90, 353-63	27
1310	Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. <b>2011</b> , 140, 1274-1283	187
1309	Distinct allosterity induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions. <b>2011</b> , 286, 8545-8554	18

1308	Treating pulmonary arterial hypertension: current treatments and future prospects. <b>2011</b> , 2, 359-70	15
1307	From the authors. <b>2011</b> , 37, 972-973	
1306	Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. <b>2011</b> , 5, 153-61	5
1305	Pharmacokinetic evaluation of ambrisentan. <b>2011</b> , 7, 371-80	14
1304	Pulmonary arterial hypertension associated with systemic sclerosis. <b>2011</b> , 5, 267-79	28
1303	Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. <b>2011</b> , 38, 2172-9	64
1302	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. <b>2011</b> , 91, 651-90	443
1301	Pulmonary Vascular Disease and Bronchopulmonary Dysplasia: Evaluation and Treatment of Pulmonary Hypertension. <b>2011</b> , 12, e645-e651	8
1300	Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension. <b>2011</b> , 3, e14	5
1299	Overview of current therapeutic approaches for pulmonary hypertension. <b>2011</b> , 1, 138-59	34
1298	Lung transplantation for pulmonary hypertension. <b>2011</b> , 1, 182-91	31
1297	Combination therapy for the treatment of pulmonary arterial hypertension. <b>2011</b> , 5, 419-30	18
1296	Optimal management of severe pulmonary arterial hypertension. <b>2011</b> , 20, 254-61	15
1295	Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. <b>2011</b> , 37, 26-34	42
1294	Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. <b>2011</b> , 123, 1185-93	220
1293	Sildenafil for COPD: a randomized crossover trial. <b>2012</b> , 9, 211-2	2
1292	Targeted approaches to the treatment of pulmonary hypertension. <b>2012</b> , 6, 147-59	11
1291	Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study. <b>2012</b> , 9, 499-504	7

1290	Medical Treatment of Pulmonary Arterial Hypertension. <b>2012</b> , 237-245	
1289	Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. <b>2012</b> , 2012, 854941	50
1288	Wall shear stress is decreased in the pulmonary arteries of patients with pulmonary arterial hypertension: An image-based, computational fluid dynamics study. <b>2012</b> , 2, 470-6	84
1287	Pulmonary arterial hypertension: advances in pathophysiology and management. <b>2012</b> , 44, 4-11	11
1286	Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. <b>2012</b> , 40, 881-5	161
1285	Pulmonary hypertension: a review of pathophysiology and anesthetic management. <b>2012</b> , 19, 377-83	14
1284	Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs. <b>2012</b> , 19, 300-14	8
1283	Exercise for Pulmonary Hypertension. <b>2012</b> , 19, 295-296	
1282	Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction. <b>2012</b> , 27, 262-72	13
1281	End-of-Life Care Discussion With COPD Patients Improves Quality of Care. <b>2012</b> , 19, 296-297	
1280	Advances in pediatric pulmonary arterial hypertension. <b>2012</b> , 27, 70-81	25
1279	Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. <b>2012</b> , 19, 960-71	48
1278	Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. <b>2012</b> , 21, 223-33	74
1277	Inhaled treprostinil for the treatment of pulmonary arterial hypertension. <b>2012</b> , 6, 255-65	7
1276	The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. <b>2012</b> , 186, 428-33	167
1275	Of tangible benefits that remain unexplained: the Papworth village movement to take care of tuberculous families. <b>2012</b> , 186, 397-8	
1274	Impact of sildenafil on survival of patients with idiopathic pulmonary arterial hypertension. <b>2012</b> , 52, 1357-64	9
1273	Erythropoietin, but not asialoerythropoietin or carbamyl-erythropoietin, attenuates monocrotaline-induced pulmonary hypertension in rats. <b>2012</b> , 34, 575-81	7

1272	Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?. <b>2012</b> , 32, 64-9	65
1271	Pulmonary Hypertension in Congenital Heart Diseases. <b>2012</b> , 122-136	
1270	Portopulmonary Hypertension and Hepatopulmonary Syndrome. <b>2012</b> , 113-121	
1269	Aging and Lung Disease. <b>2012</b> ,	
1268	A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. <b>2012</b> , 125, 324-34	265
1267	Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. <b>2012</b> , 125, 289-97	284
1266	Long-term inhaled iloprost use in children with pulmonary arterial hypertension. <b>2012</b> , 22, 396-403	6
1265	Letter by Jamous regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study". <b>2012</b> , 125, e407; author reply e409-10	1
1264	Thrombospondin-1 in pulmonary arterial hypertension: what ails NOS?. <b>2012</b> , 93, 540-2	
1263	Oral tadalafil reduces intra-abdominal adhesion reformation in rats. <b>2012</b> , 27, 733-7	10
1262	Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases. <b>2012</b> , 12, 1224-36	15
1261	Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. <b>2012</b> , 344, e554	34
1260	How long can we leave patients with pulmonary arterial hypertension on oral drug monotherapy?. <b>2012</b> , 76, 1089-90	1
1259	Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. <b>2012</b> , 142, 1383-1390	242
1258	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study. <b>2012</b> , 2012, 125-127	
1257	Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension: The SUPER-2 Study. <b>2012</b> , 2012, 124-125	1
1256	Impact of first-line sildenafil monotherapy for pulmonary arterial hypertension. <b>2012</b> , 76, 1245-52	12
1255	Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. <b>2012</b> , 76, 1494-500	18



- 1254 Maternal outcome in pregnancy complicated with pulmonary arterial hypertension. **2012**, 76, 2249-54 61
- 1253 Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors. **2012**, 51, 2721-6 6
- 1252 WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. **2012**, 55, 89-103 18
- 1251 Right ventricular assist device in end-stage pulmonary arterial hypertension: insights from a computational model of the cardiovascular system. **2012**, 55, 234-243.e2 43
- 1250 Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. **2012**, 125, 2922-32 90
- 1249 Imatinib mesylate for the treatment of pulmonary arterial hypertension. **2012**, 21, 119-34 50
- 1248 Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. **2012**, 55, 8549-58 52
- 1247 Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. **2012**, 126, 349-56 163
- 1246 The pharmacological treatment of pulmonary arterial hypertension. **2012**, 64, 583-620 88
- 1245 Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. **2012**, 190, 573-8 13
- 1244 Pulmonary hypertension-"state of the art" management in 2012. **2012**, 64, 60-73 2
- 1243 Pharmacotherapy for pulmonary arterial hypertension. **2012**, 8, 385-402
- 1242 Pathways in pulmonary arterial hypertension: the future is here. **2012**, 21, 321-7 83
- 1241 Congenital heart disease and pulmonary hypertension. **2012**, 8, 427-45 11
- 1240 Nitric oxide modulation as a therapeutic strategy in heart failure. **2012**, 8, 255-72 11
- 1239 Pulmonary Hypertension. **2012**, 1, e172-e184
- 1238 Right ventricular adaptation and maladaptation in chronic pulmonary arterial hypertension. **2012**, 30, 257-69 34
- 1237 Orientaes para o diagnstico e tratamento da hipertenso pulmonar. **2012**, 31, 71-115

- 1236 Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. **2012**, 9, 268-75 68
- 1235 Endothelial dysfunction enhances the pulmonary and systemic vasodilator effects of phosphodiesterase-5 inhibition in awake swine at rest and during treadmill exercise. **2012**, 237, 201-10 9
- 1234 Les inhibiteurs de la phosphodiesterase 5 dans les maladies vasculaires systémiques. **2012**, 79, 187-190
- 1233 Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. **2012**, 106, 730-9 20
- 1232 Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. **2012**, 31, 364-72 38
- 1231 Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. **2012**, 155, 378-82 84
- 1230 Current pathophysiological concepts and management of pulmonary hypertension. **2012**, 155, 350-61 43
- 1229 Pulmonary hypertension in left heart disease: a review. **2012**, 156, 253-8 7
- 1228 Hemodynamic and clinical benefits associated with chronic sildenafil therapy in advanced heart failure: experience of the Montréal Heart Institute. **2012**, 28, 69-73 13
- 1227 An update view on the substrate recognition mechanism of phosphodiesterases: a computational study of PDE10 and PDE4 bound with cyclic nucleotides. **2012**, 97, 910-22 2
- 1226 Practical considerations for the pharmacotherapy of pulmonary arterial hypertension. **2012**, 32, 838-55 11
- 1225 Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. **2012**, 14, R213 66
- 1224 Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan. **2012**, 42, 1351-4 13
- 1223 Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension. **2012**, 74, 990-8 4
- 1222 Pulmonary arterial hypertension in connective tissue diseases. **2012**, 8, 413-25 47
- 1221 Treatment of pulmonary arterial hypertension in connective tissue disease. **2012**, 72, 1039-56 2
- 1220 Systemic Vascular Disease. **2012**, 347-359
- 1219 Complex Challenges of Pulmonary Hypertension. **2012**, 447-460 1

1218	Treatment of Pulmonary Hypertension. <b>2012</b> , 437-445	
1217	Cardiovascular abnormalities in sickle cell disease. <b>2012</b> , 59, 1123-33	157
1216	Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. <b>2012</b> , 60, 1192-201	178
1215	Prognostic factors and outcomes of patients with pulmonary hypertension admitted to the intensive care unit. <b>2012</b> , 27, 739.e7-13	35
1214	Paxillin regulates pulmonary arterial smooth muscle cell function in pulmonary hypertension. <b>2012</b> , 181, 1621-33	23
1213	Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. <b>2012</b> , 41, 512-7	12
1212	World Health Organization Group III pulmonary hypertension. <b>2012</b> , 55, 119-27	21
1211	Pulmonary hypertension associated with left-sided heart disease. <b>2012</b> , 8, 447-59	24
1210	A Randomized, Open-Label, 3-Way Crossover Study to Demonstrate Bioequivalence of Sildenafil Powder for Oral Suspension With Tablets Used Commercially and in Clinical Studies for the Treatment of Pulmonary Arterial Hypertension. <b>2012</b> , 1, 152-7	1
1209	Sclérodémie systémique. <b>2012</b> , 7, 1-14	
1208	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. <b>2012</b> , 9, 192-9	26
1207	Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. <b>2012</b> , 60, 344-9	21
1206	Modulation of pulmonary vascular resistance as a target for therapeutic interventions in Fontan patients: focus on phosphodiesterase inhibitors. <b>2012</b> , 8, 271-84	23
1205	Tadalafil for the treatment of pulmonary arterial hypertension. <b>2012</b> , 13, 747-55	13
1204	The 6-minute walk test in pulmonary arterial hypertension: how far is enough?. <b>2012</b> , 186, 396-7	21
1203	Hydroxysafflor yellow A (HSYA) from flowers of <i>Carthamus tinctorius</i> L. and its vasodilatation effects on pulmonary artery. <b>2012</b> , 17, 14918-27	32
1202	Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study. <b>2012</b> , 52, 425-31	6
1201	Pediatric Pulmonary Hypertension. <b>2012</b> , 730-752	

1200	Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. <b>2012</b> , 12, 75	19
1199	Assessment of measurement properties of peak VO <sub>2</sub> in children with pulmonary arterial hypertension. <b>2012</b> , 12, 54	5
1198	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. <b>2012</b> , 7, e43433	89
1197	Treatment of pulmonary hypertension. <b>2012</b> , 18, RA31-9	10
1196	Management of the Infant with Severe Bronchopulmonary Dysplasia. <b>2012</b> , 407-425	3
1195	Pulmonary Manifestations of Systemic Lupus Erythematosus. <b>2012</b> ,	
1194	Childhood Pulmonary Arterial Hypertension. <b>2012</b> , 1003-1018	
1193	Inhaled treprostinil: a therapeutic review. <b>2012</b> , 6, 19-28	32
1192	Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders. <b>2012</b> , 94-104	
1191	Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension. <b>2012</b> , 99, 876-85	6
1190	The Role of PDE5 Inhibitors in the Treatment of Testicular Dysfunction. <b>2012</b> ,	1
1189	Inhaled low-dose iloprost for pulmonary hypertension: a prospective, multicenter, open-label study. <b>2012</b> , 35, 365-70	5
1188	Treatment for pulmonary hypertension of left heart disease. <b>2012</b> , 14, 319-27	12
1187	Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report. <b>2012</b> , 12, 180-3	11
1186	Initial experience with tadalafil in pediatric pulmonary arterial hypertension. <b>2012</b> , 33, 683-8	85
1185	Effects of inhaled iloprost on congenital heart disease with Eisenmenger syndrome. <b>2012</b> , 33, 744-8	14
1184	Pulmonary hypertension and pregnancy--a review of 12 pregnancies in nine women. <b>2012</b> , 119, 752-61	41
1183	The effects of sildenafil on rectal sensitivity and tone in patients with the irritable bowel syndrome. <b>2012</b> , 35, 577-86	10

1182	Reactive oxygen and nitrogen species in pulmonary hypertension. <b>2012</b> , 52, 1970-86		138
1181	Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization. <b>2012</b> , 422, 398-408		53
1180	Phosphodiesterase 5 inhibitors in vascular systemic disorders. <b>2012</b> , 79, 338-40		2
1179	Can "inoperable" congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality?. <b>2012</b> , 7, 3-11		42
1178	Development of a biodegradable nanoparticle platform for sildenafil: formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. <b>2012</b> , 157, 469-77		45
1177	Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery. <b>2012</b> , 158, 329-35		102
1176	Diagnosis and mortality prediction in pulmonary hypertension: the value of the electrocardiogram-derived ventricular gradient. <b>2012</b> , 45, 312-8		13
1175	Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. <b>2012</b> , 64, 303-10		27
1174	An update on the evaluation and management of pulmonary hypertension in scleroderma. <b>2012</b> , 14, 1-10		5
1173	Effects of epoprostenol and sildenafil on right ventricular function in hypoxic volunteers: a tissue Doppler imaging study. <b>2012</b> , 112, 1285-94		15
1172	Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms. <b>2013</b> , 27, 271-8		10
1171	High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. <b>2013</b> , 69, 197-207		6
1170	Riociguat for the treatment of pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 330-40	59.2	861
1169	Managing an acutely ill patient with pulmonary arterial hypertension. <b>2013</b> , 7, 77-83		2
1168	Right ventricular electrical remodeling and arrhythmogenic substrate in rat pulmonary hypertension. <b>2013</b> , 49, 426-36		26
1167	Riociguat for pulmonary hypertension--a glass half full. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 386-392		45
1166	Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. <b>2013</b> , 188, 639-46		130
1165	The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future. <b>2013</b> , 7, 43-55		12

1164	Endothelial dysfunction and cardiac allograft vasculopathy. <b>2013</b> , 6, 263-77		27
1163	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. <b>2013</b> , 9, 1193-205		19
1162	One-year experience with intravenous treprostinil for pulmonary arterial hypertension. <b>2013</b> , 32, 889-96		27
1161	Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. <b>2013</b> , 33, 1047-52		13
1160	Macitentan and morbidity and mortality in pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 809-18	59.2	878
1159	Current and future therapeutic targets for pulmonary arterial hypertension. <b>2013</b> , 14, 134-43		4
1158	Novel medical therapies for pulmonary arterial hypertension. <b>2013</b> , 34, 867-80		9
1157	Four cases with group 3 out-of-proportion pulmonary hypertension with a favorable response to vasodilators. <b>2013</b> , 9, 4-7		4
1156	Choosing the best first line oral drug agent in patients with pulmonary hypertension: evidence from a network meta-analysis. <b>2013</b> , 168, 4336-8		4
1155	Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. <b>2013</b> , 31, 274-9		10
1154	Considerations for numerical modeling of the pulmonary circulation--a review with a focus on pulmonary hypertension. <b>2013</b> , 135, 61011-15		24
1153	Buka's Emergencies in Dermatology. <b>2013</b> ,		
1152	Pharmacotherapy of Pulmonary Hypertension. <b>2013</b> ,		2
1151	Updated treatment algorithm of pulmonary arterial hypertension. <b>2013</b> , 62, D60-72		495
1150	An update on medical therapy for pulmonary arterial hypertension. <b>2013</b> , 15, 614-22		17
1149	Pulmonary arterial hypertension. <b>2013</b> , 8, 97		168
1148	Pulmonary hypertension in dialysis patients. <b>2013</b> , 35, 514-20		23
1147	Pulmonary vascular complications of liver disease. <b>2013</b> , 187, 133-43		66

1146	Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. <b>2013</b> , 127, 1128-38	368
1145	Recommendations for the management and treatment of systemic sclerosis. <b>2013</b> , 53, 258-275	1
1144	Does the Society of Thoracic Surgeons risk score accurately predict operative mortality for patients with pulmonary hypertension?. <b>2013</b> , 146, 631-7	28
1143	Combination therapy in pulmonary arterial hypertension. <b>2013</b> , 111, 16C-20C	10
1142	Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil. <b>2013</b> , 186, 61-4	6
1141	Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. <b>2013</b> , 111, 278-85	47
1140	Vascular dysfunction induced by hypochlorite is improved by the selective phosphodiesterase-5-inhibitor vardenafil. <b>2013</b> , 710, 110-9	12
1139	Recomendações sobre diagnóstico e tratamento da esclerose sistémica. <b>2013</b> , 53, 258-275	5
1138	Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients. <b>2013</b> , 43, 32-7	6
1137	Right ventricular function predicts clinical response to specific vasodilator therapy in patients with pulmonary hypertension. <b>2013</b> , 30, 17-26	20
1136	Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. <b>2013</b> , 309, 1268-77	762
1135	Pulmonary hypertension: diagnosis and management. <b>2013</b> , 346, f2028	92
1134	Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. <b>2013</b> , 58, 211-8	16
1133	Endothelin receptor antagonists for pulmonary arterial hypertension. <b>2013</b> , CD004434	28
1132	In silico drug repositioning: what we need to know. <b>2013</b> , 18, 110-5	115
1131	Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. <b>2013</b> , 9, 335-49	26
1130	Pulmonary Vascular Disease. <b>2013</b> , 603-625	1
1129	Repurposing as a strategy for orphan drug development, evidence from European approvals. <b>2013</b> , 1, 473-480	8

1128	The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study. <b>2013</b> , 91, 178-84	12
1127	Modulation of the ASK1-MKK3/6-p38/MAPK signalling pathway mediates sildenafil protection against chemical hypoxia caused by malonate. <b>2013</b> , 168, 1820-34	15
1126	Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. <b>2013</b> , 143, 1699-1708	149
1125	Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. <b>2013</b> , 34, 811-24	4
1124	Combination therapy in pulmonary arterial hypertension. <b>2013</b> , 34, 841-55	11
1123	Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. <b>2013</b> , 42, 982-92	114
1122	Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials. <b>2013</b> , 3,	14
1121	Transition from prostacyclin analogue infusion to oral therapy in patients with pulmonary arterial hypertension: a 5-year follow-up. <b>2013</b> , 3, 880-8	4
1120	Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. <b>2013</b> , 144, 952-958	224
1119	Pulmonary Hypertension and the Interdependence of Ventricular Function: Part 2: Evaluating the Medical and Surgical Management. <b>2013</b> , 4, 191-197	
1118	New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension. <b>2013</b> , 22, 495-502	6
1117	The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease. <b>2013</b> , 11, 919-31	8
1116	New horizons in pulmonary arterial hypertension therapies. <b>2013</b> , 22, 503-14	29
1115	Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications. <b>2013</b> , 37, 281-90	41
1114	Pulmonary hypertension complicating connective tissue disease. <b>2013</b> , 34, 581-99	4
1113	Anatomical considerations for the development of a new transcatheter aortopulmonary shunt device in patients with severe pulmonary arterial hypertension. <b>2013</b> , 3, 639-46	11
1112	Combination of erythropoietin and sildenafil can effectively attenuate hypoxia-induced pulmonary hypertension in mice. <b>2013</b> , 3, 898-907	4
1111	Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial. <b>2013</b> , 3, 889-97	8



1110	Evidence of synergistic/additive effects of sildenafil and erythropoietin in enhancing survival and migration of hypoxic endothelial cells. <b>2013</b> , 304, L230-9	15
1109	Updating clinical endpoint definitions. <b>2013</b> , 3, 206-16	19
1108	From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension. <b>2013</b> , 3, 507-22	5
1107	Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. <b>2013</b> , 3, 100-7	30
1106	The philosophy of evidence-based clinical practice: Is evidence enough?. <b>2013</b> , 8, 131-2	3
1105	Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. <b>2013</b> , 41, 872-8	44
1104	Pulmonary hypertension and idiopathic pulmonary fibrosis: a dastardly duo. <b>2013</b> , 346, 221-5	27
1103	Pulmonary arterial hypertension: challenges in translational research and a vision for change. <b>2013</b> , 5, 208sr5	60
1102	The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. <b>2013</b> , 2, e000536	82
1101	Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. <b>2013</b> , 7, 39-49	13
1100	Treatment of Pulmonary Hypertension. <b>2013</b> ,	
1099	Scleroderma lung disease. <b>2013</b> , 22, 6-19	158
1098	Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men. <b>2013</b> , 26, 342-50	12
1097	Pharmacologic Management of Heart Failure in the Ambulatory Setting. <b>2013</b> , 241-269	1
1096	Treatment of Pulmonary Arterial Hypertension. <b>2013</b> , 596-605	
1095	Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension. <b>2013</b> , 42, 425-34	11
1094	The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. <b>2013</b> , 99, 395-403	45
1093	Mechanics and Mechanisms of Pulmonary Hypertension [Conference Summary and Translational Perspectives. <b>2013</b> , 3, 128-136	16

1092	Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study. <b>2013</b> , 3, 89-94	62
1091	Current challenges in pediatric pulmonary hypertension. <b>2013</b> , 34, 627-44	18
1090	Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy. <b>2013</b> , 3, 20-30	57
1089	Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension. <b>2013</b> , 42, 414-24	29
1088	Geometry of the randomized evidence for treatments of pulmonary hypertension. <b>2013</b> , 31, e138-46	14
1087	Erectile dysfunction in heart failure patients: a critical reappraisal. <b>2013</b> , 1, 177-91	16
1086	Value of impedance cardiography during 6-minute walk test in pulmonary hypertension. <b>2013</b> , 6, 474-80	11
1085	Pulmonary hypertension in patients with chronic and end-stage kidney disease. <b>2013</b> , 84, 682-92	74
1084	The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload. <b>2013</b> , 98, 1274-8	9
1083	Building a pulmonary vascular service: the 12-year experience and outcomes of the Auckland pulmonary arterial hypertension clinic. <b>2013</b> , 43, 635-42	2
1082	Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?. <b>2013</b> , 22, 217-26	55
1081	The effect of sildenafil on retinopathy of prematurity in very preterm infants. <b>2013</b> , 33, 218-21	17
1080	Treatment options in systemic sclerosis. <b>2013</b> , 1, 851-865	
1079	Sildenafil increases sympathetically mediated vascular tone in humans. <b>2013</b> , 26, 762-9	12
1078	Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. <b>2013</b> , 127, 624-33	238
1077	[Enhanced Ca <sup>2+</sup> -sensing receptor function in pulmonary hypertension]. <b>2013</b> , 133, 1351-9	7
1076	Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. <b>2013</b> , 77, 2127-33	6
1075	Management of chronic thromboembolic pulmonary hypertension: current status and emerging options. <b>2013</b> , 10, 345-357	2

1074	A paradigm shift in pulmonary arterial hypertension management. <b>2013</b> , 22, 423-6	3
1073	Systemic sclerosis-associated pulmonary arterial hypertension. <b>2013</b> , 144, 1346-1356	92
1072	The influence of alternative instruction on 6-min walk test distance. <b>2013</b> , 144, 1900-1905	28
1071	The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. <b>2013</b> , 22, 487-94	30
1070	Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers. <b>2013</b> , 61, 444-51	8
1069	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. <b>2013</b> , 98, 1359-67	35
1068	Updated role of nitric oxide in disorders of erythrocyte function. <b>2013</b> , 13, 83-7	11
1067	Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach?. <b>2013</b> , 28, 141-8	10
1066	Pulmonary arterial hypertension: diagnosis and treatment. <b>2013</b> , 3, 273-279	
1065	Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance. <b>2013</b> , 20, 111-5	
1064	Pulmonary Arterial Hypertension. <b>2013</b> , 667-686	4
1063	Pulmonary Arterial Hypertension: An Overview. <b>2013</b> ,	
1062	Recent strategies in treatment of pulmonary arterial hypertension, a review. <b>2015</b> , 7, 307-22	16
1061	Pulmonary Hypertension/Pulmonary Arterial Hypertension. <b>2014</b> , 2625-2635	
1060	Efficacy of sildenafil therapy for pulmonary hypertension in dogs: a systematic review. <b>2014</b> , 46, 277-287	1
1059	Management of erectile dysfunction in hypertension: Tips and tricks. <b>2014</b> , 6, 908-15	36
1058	10.3 Rechtsherzversagen. <b>2014</b> ,	
1057	Adjunctive treatments in pediatric acute respiratory distress syndrome. <b>2014</b> , 8, 703-16	9

1056	Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects. <b>2014</b> , 78, 1035-42	18
1055	Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. <b>2014</b> , 12, 185	58
1054	Quality of life as a prognostic marker in pulmonary arterial hypertension. <b>2014</b> , 12, 130	28
1053	PKG-1 $\beta$ leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension. <b>2014</b> , 307, L537-44	14
1052	Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system. <b>2014</b> , 19, 53-64	17
1051	Sildenafil for the treatment of pulmonary hypertension in children. <b>2014</b> , 12, 1157-84	12
1050	Evaluation of drug interaction of glimepiride with phosphodiesterase inhibitors type V in diabetic nephropathy. <b>2014</b> , 122, 597-601	1
1049	Aging of platelet nitric oxide signaling: pathogenesis, clinical implications, and therapeutics. <b>2014</b> , 40, 660-8	10
1048	Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies. <b>2014</b> , 2014, 743868	8
1047	State of the art: pulmonary hypertension. <b>2014</b> , 10, 188-197	1
1046	Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. <b>2014</b> , 145, 1055-1063	32
1045	Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <b>2014</b> , 146, 449-475	200
1044	Pulmonary Hypertension. <b>2014</b> , 426-432	
1043	[Imatinib for pulmonary arterial hypertension]. <b>2014</b> , 139 Suppl 4, S151-4	1
1042	Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controls. <b>2014</b> , 2, e12038	7
1041	Sex and haemodynamics in pulmonary arterial hypertension. <b>2014</b> , 43, 523-30	58
1040	Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. <b>2014</b> , 19, 700-6	27
1039	Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. <b>2014</b> , 76, 541-9	61

1038	Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials. <b>2014</b> , 68, 568-77	6
1037	The use of oral sildenafil for management of right ventricular dysfunction after pediatric heart transplantation. <b>2014</b> , 14, 453-8	10
1036	Advances in therapeutic interventions for patients with pulmonary arterial hypertension. <b>2014</b> , 130, 2189-208	209
1035	Riociguat for pulmonary hypertension. <b>2014</b> , 7, 259-70	6
1034	Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload. <b>2014</b> , 307, H361-9	24
1033	Existing drugs and agents under investigation for pulmonary arterial hypertension. <b>2014</b> , 22, 297-305	10
1032	Swelling-activated Cl <sup>-</sup> currents and intracellular CLC-3 are involved in proliferation of human pulmonary artery smooth muscle cells. <b>2014</b> , 32, 318-30	17
1031	Safety of sildenafil in infants*. <b>2014</b> , 15, 362-8	29
1030	Goal-oriented treatment of pulmonary arterial hypertension. <b>2014</b> , 20, 409-13	3
1029	Severe pulmonary arterial hypertension: treatment options and the bridge to transplantation. <b>2014</b> , 23, 488-97	18
1028	Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet?. <b>2014</b> , 23, 458-68	9
1027	Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. <b>2014</b> , 7, 107-14	111
1026	Macitentan for the treatment of pulmonary arterial hypertension. <b>2014</b> , 15, 2733-9	2
1025	Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension. <b>2014</b> , 4, 45-52	3
1024	Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. <b>2014</b> , 44, 425-34	48
1023	Reducing TRPC1 Expression through Liposome-Mediated siRNA Delivery Markedly Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension in a Murine Model. <b>2014</b> , 2014, 316214	16
1022	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension. <b>2014</b> , 9, S79-91	4
1021	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension. <b>2014</b> , 9, S92-7	29

1020	Riociguat: PATENT-1 Study. <b>2014</b> , 2014, 31-5	4
1019	The role of endothelin-1 in pulmonary arterial hypertension. <b>2014</b> , 2014, 62-78	66
1018	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <b>2014</b> , 2014, 257-90	10
1017	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseases. <b>2014</b> , 9, S26-37	3
1016	The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases. <b>2014</b> , 2014, 501612	23
1015	Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. <b>2014</b> , 4, 669-78	14
1014	Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up. <b>2014</b> , 99, e17-8	10
1013	Evidence based computational drug repositioning candidate screening pipeline design: Case Study. <b>2014</b> ,	
1012	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. <b>2014</b> , 33, 689-97	14
1011	CCTTT pentanucleotide repeats in inducible nitric oxide synthase gene expression in patients with pulmonary arterial hypertension. <b>2014</b> , 50, 141-5	7
1010	Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. <b>2014</b> , 89, 86-98	21
1009	The contribution of sildenafil (Viagra) to ovarian stimulation with gonadotropins in a woman with poor ovarian response. <b>2014</b> , 30, 478-80	5
1008	Topiramate use does not reduce flares of inflammatory bowel disease. <b>2014</b> , 59, 1535-43	20
1007	Drug treatment of pulmonary hypertension in children. <b>2014</b> , 16, 43-65	32
1006	Advances in targeting cyclic nucleotide phosphodiesterases. <b>2014</b> , 13, 290-314	488
1005	Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. <b>2014</b> , 108, 531-7	29
1004	Preparation of sildenafil citrate microcapsules and in vitro/in vivo evaluation of taste masking efficiency. <b>2014</b> , 466, 286-95	33
1003	Pulmonary hypertension related to congenital heart disease: a call for action. <b>2014</b> , 35, 691-700	107

1002	STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. <b>2014</b> , 129, 1914-23	129
1001	Pulmonary hypertension and breathlessness: is it a combination we can ignore?. <b>2014</b> , 44, 114-23	4
1000	Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases. <b>2014</b> , 28, 593-607	18
999	Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. <b>2014</b> , 19, 550-7	10
998	CCTTT Pentanucleotide Repeats in Inducible Nitric Oxide Synthase Gene Expression in Patients With Pulmonary Arterial Hypertension. <b>2014</b> , 50, 141-145	2
997	Pulmonary Manifestations of Rheumatic Disease. <b>2014</b> ,	2
996	Update on perioperative right heart assessment using transesophageal echocardiography. <b>2014</b> , 18, 341-51	15
995	Endpoints in PAH clinical trials in the era of combination therapy: how do we decide whether something is working without going bankrupt?. <b>2014</b> , 19, 1236-40	5
994	Pulmonary arterial hypertension related to connective tissue disease: a review. <b>2014</b> , 40, 103-24	26
993	Targeted therapies in pulmonary arterial hypertension. <b>2014</b> , 141, 172-91	128
992	Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. <b>2014</b> , 63, 5-11	28
991	New pharmacotherapies for pulmonary hypertension: where do they fit in?. <b>2014</b> , 16, 496	3
990	Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy. <b>2014</b> , 76, 550-7	36
989	Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. <b>2014</b> , 13, 391-405	51
988	[Pulmonary hypertension--diagnostic and current concepts]. <b>2014</b> , 156, 49-52; quiz 53	
987	Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials. <b>2014</b> , 29, 241-9	13
986	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. <b>2014</b> , 20, 1289-300	183
985	Treatment of idiopathic/hereditary pulmonary arterial hypertension. <b>2014</b> , 64, 243-9	25

984	Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction. <b>2014</b> , 11, 1101-15	28
983	Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension. <b>2014</b> , 130, 496-507	42
982	Pulmonary arterial hypertension: yesterday, today, tomorrow. <b>2014</b> , 115, 109-14	24
981	Current and advancing treatments for pulmonary arterial hypertension in childhood. <b>2014</b> , 8, 615-28	2
980	Dual specificity and novel structural folding of yeast phosphodiesterase-1 for hydrolysis of second messengers cyclic adenosine and guanosine 3',5'-monophosphate. <b>2014</b> , 53, 4938-45	12
979	Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa. <b>2014</b> , 128, 43-56	23
978	[Pulmonary arterial hypertension associated with connective tissue diseases]. <b>2014</b> , 43, 957-69	3
977	Are hemodynamics surrogate end points in pulmonary arterial hypertension?. <b>2014</b> , 130, 768-75	32
976	[Treatment of pulmonary arterial hypertension]. <b>2014</b> , 43, 981-93	0
975	Current therapeutic approach in heart failure with preserved ejection fraction. <b>2014</b> , 10, 525-38	11
974	Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation. <b>2014</b> , 43, 156-65	62
973	Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases. <b>2014</b> ,	16
972	Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension. <b>2014</b> , 48, 223-33	15
971	Update in systemic sclerosis-associated pulmonary arterial hypertension. <b>2014</b> , 43, e293-304	20
970	Predictors of sildenafil effects on exercise capacity in adolescents and adults with Fontan circulation. <b>2014</b> , 103, 641-6	12
969	Pharmacological Treatment of Pulmonary Hypertension. <b>2014</b> , 375-431	
968	Sex differences in the pulmonary circulation: implications for pulmonary hypertension. <b>2014</b> , 306, H1253-64	24
967	Pulmonary hypertension in adult congenital heart disease. <b>2014</b> , 16, 328	2



966	A new START for Sildenafil in pediatric pulmonary hypertension: reframing the dose-survival relationship in the STARTS-2 trial. <b>2014</b> , 129, 1905-8	8
965	Pulmonary arterial hypertension: the clinical syndrome. <b>2014</b> , 115, 115-30	221
964	Ion channels and transporters as therapeutic targets in the pulmonary circulation. <b>2014</b> , 144, 349-68	18
963	Management of acute right ventricular failure in the intensive care unit. <b>2014</b> , 11, 811-22	127
962	Pulmonary Hypertension. <b>2014</b> , 263-281	
961	Systemic sclerosis: clinical features and management. <b>2014</b> , 42, 167-173	
960	Oral l-citrulline malate in patients with idiopathic pulmonary arterial hypertension and Eisenmenger Syndrome: a clinical trial. <b>2014</b> , 64, 231-5	23
959	Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <b>2014</b> , 30, 1233-40	11
958	N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. <b>2014</b> , 173, 154-62	28
957	Improvement of exercise performance and ventilatory efficiency in patients with chronic heart failure after sildenafil use for 8weeks. <b>2014</b> , 63, 477-481	
956	Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. <b>2014</b> , 13, 295-305	15
955	Clinical and molecular genetics of the phosphodiesterases (PDEs). <b>2014</b> , 35, 195-233	157
954	Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. <b>2014</b> , 16, 89-107	25
953	Severe pulmonary hypertension in adult pulmonary Langerhans cell histiocytosis: the effect of sildenafil as a bridge to lung transplantation. <b>2014</b> , 53, 1985-90	6
952	Incremental shuttle walk test as a valuable assessment of exercise performance in patients with pulmonary arterial hypertension. <b>2014</b> , 78, 215-21	16
951	Acute onset of bilateral visual loss during sildenafil therapy in a young infant with congenital heart disease. <b>2014</b> , 2014,	10
950	0731. Effects of sildenafil in a porcine model of endotoxemia. <b>2014</b> , 2,	78
949	[Pharmacological treatment of pulmonary hypertension at a turning point]. <b>2014</b> , 143, 165-72	1

948	Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease. <b>2014</b> , 78, 4-11	39
947	Inhaled treprostinil sodium for pulmonary hypertension. <b>2014</b> , 2, 283-291	
946	Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. <b>2014</b> , 146, 1263-1273	54
945	Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review. <b>2014</b> , 146, 686-708	37
944	Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension. <b>2015</b> , 148, 655-666	22
943	Sex differences in response to tadalafil in pulmonary arterial hypertension. <b>2015</b> , 147, 188-197	42
942	Pulmonary hypertension trials: how can we do better?. <b>2015</b> , 9, 551-8	0
941	Effects of the Rho-kinase inhibitor, fasudil, on pulmonary hypertension. <b>2015</b> , 79, 1213-4	6
940	Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. <b>2015</b> , 5, 547-56	44
939	Progress in the understanding and management of pulmonary arterial hypertension. <b>2015</b> , 2015, 13	3
938	Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension. <b>2015</b> , 2, 14065	4
937	Current Treatment Strategies in Pulmonary Hypertension Associated with Left Heart Disease. <b>2015</b> , 2, 345-354	1
936	The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review. <b>2015</b> , 12, 54	23
935	Pulmonale Hypertension. <b>2015</b> , 10, 73-90	1
934	Endothelial cell regulation of pulmonary vascular tone, inflammation, and coagulation. <b>2015</b> , 5, 531-59	27
933	Primary intestinal lymphangiectasia treated with rapamycin in a child with tuberous sclerosis complex (TSC). <b>2015</b> , 167A, 2209-12	13
932	Pulmonary hypertension in potential heart transplant recipients: current treatment strategies. <b>2015</b> , 20, 570-6	6
931	Novel biomarkers for risk stratification in pulmonary arterial hypertension. <b>2015</b> , 1,	14

930	Central Nervous System and Pulmonary Complications of End-Stage Liver Disease. <b>2015</b> , 2107-2128	
929	Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications. <b>2015</b> , 122, 932-46	154
928	Development of a Human Model for the Study of Effects of Hypoxia, Exercise, and Sildenafil on Cardiac and Vascular Function in Chronic Heart Failure. <b>2015</b> , 66, 229-38	4
927	Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <b>2015</b> , 67, 2457-65	9
926	The changing paradigm in pulmonary hypertension trials: longer duration, new endpoints. <b>2015</b> , 21, 438-45	5
925	Characterization of lung-delivered in-situ forming controlled release formulations. <b>2015</b> , 67, 1349-54	6
924	Effect of non-antihypertensive drugs on endothelial function in hypertensive subjects evaluated by flow-mediated vasodilation. <b>2015</b> , 13, 121-7	4
923	The limits of oral therapy in pulmonary arterial hypertension management. <b>2015</b> , 11, 1731-41	7
922	Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension. <b>2015</b> , 83, 659-70	1
921	Sildenafil Protects against Myocardial Ischemia-Reperfusion Injury Following Cardiac Arrest in a Porcine Model: Possible Role of the Renin-Angiotensin System. <b>2015</b> , 16, 27015-31	14
920	Reported sildenafil side effects in pediatric pulmonary hypertension patients. <b>2015</b> , 3, 12	16
919	Comparison between the Acute Pulmonary Vascular Effects of Oxygen with Nitric Oxide and Sildenafil. <b>2015</b> , 3, 16	1
918	Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. <b>2015</b> , 7, 175-83	5
917	Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension. <b>2015</b> , 56, 86-93	10
916	Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension. <b>2015</b> , 2015, 762349	17
915	Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. <b>2015</b> , 2015, 929170	4
914	Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension. <b>2015</b> , 22, 42-6	17
913	Efficacy of pulmonary vasodilator therapy in patients with functionally single ventricle. <b>2015</b> , 56 Suppl, S26-30	9

912	The Therapeutic Effects of Human Mesenchymal Stem Cells Primed with Sphingosine-1 Phosphate on Pulmonary Artery Hypertension. <b>2015</b> , 24, 1658-71	37
911	[Medical treatment of pulmonary hypertension: what's new?]. <b>2015</b> , 56, 573-82	
910	The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension. <b>2015</b> , 13, 467-76	1
909	Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. <b>2015</b> , 15, 62	3
908	Treatment of Chronic Right Heart Failure. <b>2015</b> , 401-418	
907	Diagnosis and Management of Pulmonary Hypertension. <b>2015</b> ,	
906	Pulmonary Arterial Hypertension. <b>2015</b> , 313-332	1
905	Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. <b>2015</b> , 132, 2037-99	624
904	Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension. <b>2015</b> , 132, 2152-61	10
903	Developments in pulmonary arterial hypertension-targeted therapy for chronic thromboembolic pulmonary hypertension. <b>2015</b> , 9, 559-69	3
902	Medikamentöse Therapie der pulmonal arteriellen Hypertonie. <b>2015</b> , 12, 390-400	
901	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <b>2015</b> , 34, 1366-75	72
900	Treatment of pulmonary arterial hypertension. <b>2015</b> , 144, 566-570	
899	The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?. <b>2015</b> , 109, 557-64	24
898	The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. <b>2015</b> , 47, 144-50	29
897	Treating pulmonary hypertension in pediatrics. <b>2015</b> , 16, 711-26	13
896	Interdependence of right ventricular systolic function and left ventricular filling and its association with outcome for patients with pulmonary hypertension. <b>2015</b> , 31, 691-8	23
895	Treatment-related biomarkers in pulmonary hypertension. <b>2015</b> , 52, 663-73	20

894	Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension. <b>2015</b> , 20, 395-400	2
893	Management of Scleroderma-Associated Pulmonary Involvement. <b>2015</b> , 1, 51-67	
892	Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. <b>2015</b> , 14, 228-36	29
891	Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. <b>2015</b> , 5, 305-12	13
890	Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. <b>2015</b> , 1001, 35-40	12
889	Current Concepts in Management of Pulmonary Hypertension: Fighting the Old Demon with Modern Weapons. <b>2015</b> , 82, 1128-34	1
888	Six-minute walk test in pulmonary arterial hypertension. <b>2015</b> , 15, 249-54	34
887	Update on systemic sclerosis. <b>2015</b> , 15, 25	8
886	Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD. <b>2015</b> , 32, 24-8	2
885	Taking aim at pulmonary hypertension in heart failure with preserved ejection fraction. <b>2015</b> , 36, 2574-5	1
884	Use of outcome measures in pulmonary hypertension clinical trials. <b>2015</b> , 170, 419-29.e3	12
883	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. <b>2015</b> , 46, 405-13	136
882	An Update on Pulmonary Arterial Hypertension. <b>2015</b> , 11, 551-559	5
881	Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis. <b>2015</b> , 170, 96-103, 103.e1-14	14
880	Echocardiography in pediatric pulmonary arterial hypertension: early study on assessing disease severity and predicting outcome. <b>2015</b> , 8,	40
879	Sildenafil as a therapeutic option for digital ischemic ulceration: case report. <b>2015</b> , 40, 890-3	2
878	Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety. <b>2015</b> , 174, 1109-15	36
877	Clinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentan. <b>2015</b> , 54, 457-71	29

876	Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. <b>2015</b> , 193, 105-12	18
875	Management of pulmonary arterial hypertension. <b>2015</b> , 65, 1976-97	229
874	Pulmonary arterial hypertension: a review in pharmacotherapy. <b>2015</b> , 23, 33-51	11
873	Arterial Disorders. <b>2015</b> ,	1
872	Building the case for novel clinical trials in pulmonary arterial hypertension. <b>2015</b> , 8, 114-23	14
871	Sildenafil improves renal function in patients with pulmonary arterial hypertension. <b>2015</b> , 80, 235-41	13
870	Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension. <b>2015</b> , 57, 473-9	7
869	[Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension]. <b>2015</b> , 69, 135-43	1
868	Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. <b>2015</b> , 24, 272-82	37
867	Sildenafil in Term and Premature Infants: A Systematic Review. <b>2015</b> , 37, 2598-2607.e1	30
866	Encyclopedia of Trauma Care. <b>2015</b> , 1355-1356	
865	Management of patients with pulmonary arterial hypertension due to congenital heart disease: recent advances and future directions. <b>2015</b> , 13, 1377-92	3
864	Encyclopedia of Trauma Care. <b>2015</b> , 1166-1175	
863	Current Treatment Strategies, Guidelines and New Therapies. <b>2015</b> , 81-145	
862	New pharmacotherapy options for pulmonary arterial hypertension. <b>2015</b> , 16, 2113-31	17
861	Treatment of Pulmonary Hypertension. <b>2015</b> ,	1
860	Pulmonary Hypertension. <b>2015</b> , 179-197	
859	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. <b>2015</b> , 169, 887-98	16

858	Sildenafil attenuates the fibrotic phenotype of skin fibroblasts in patients with systemic sclerosis. <b>2015</b> , 161, 333-8	9
857	A randomized, open-label 3-way crossover study to investigate the relative bioavailability and bioequivalence of crushed sildenafil 20 mg tablets mixed with apple sauce, extemporaneously prepared suspension (EP), and intact sildenafil 20 mg tablets in healthy volunteers under fasting conditions. <b>2015</b> , 4, 74-80	6
856	[Therapy of Pulmonary Arterial Hypertension]. <b>2015</b> , 69, 483-93; quiz 494-5	
855	Management of Right Heart Failure in the Intensive Care Unit. <b>2015</b> , 36, 511-20	18
854	Riociguat for pulmonary hypertension in congenital heart disease: opportunities and challenges. <b>2015</b> , 101, 1771-2	0
853	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPCC), International Society for Heart and Lung Transplantation (ISHLT). <b>2015</b> , 101, 1659-1754	1672
852	Voltage-dependent BK and Hv1 channels expressed in non-excitabile tissues: New therapeutics opportunities as targets in human diseases. <b>2015</b> , 101, 56-64	11
851	Systemic lupus erythematosus-associated pulmonary hypertension: clinical variables and survival outcome. <b>2015</b> , 10, 149-160	1
850	Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. <b>2015</b> , 192, 1111-7	46
849	Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <b>2015</b> , 192, 1102-10	97
848	Encyclopedia of Trauma Care. <b>2015</b> , 1181-1192	
847	Management of Heart Failure. <b>2015</b> ,	1
846	Encyclopedia of Trauma Care. <b>2015</b> , 1304-1308	
845	Preclinical safety evaluation of submicronized sildenafil citrate nebulization solution in small experimental animals. <b>2015</b> , 41, 450-8	1
844	Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. <b>2015</b> , 87, 12112-20	18
843	Riociguat for the treatment of pulmonary hypertension. <b>2015</b> , 9, 679-95	10
842	Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. <b>2015</b> , 70, 56-70	64
841	Current treatment approaches to pulmonary arterial hypertension. <b>2015</b> , 31, 460-77	24

840	Novel use of sildenafil in the management of pulmonary hypertension due to post-catheter ablation 'stiff left atrial syndrome'. <b>2015</b> , 181, 55-6	7
839	Effect of macitentan on hospitalizations: results from the SERAPHIN trial. <b>2015</b> , 3, 1-8	42
838	Vasculopathy and pulmonary hypertension in sickle cell disease. <b>2015</b> , 308, L314-24	90
837	Candidacy for lung transplant and lung allocation. <b>2015</b> , 25, 1-15	6
836	Diagnosis and treatment of pulmonary hypertension. <b>2015</b> , 101, 311-9	9
835	Preparation of transfersomes encapsulating sildenafil aimed for transdermal drug delivery: Plackett-Burman design and characterization. <b>2015</b> , 25, 1-10	66
834	The Right Ventricle in Health and Disease. <b>2015</b> ,	4
833	[Treatment of pulmonary arterial hypertension]. <b>2015</b> , 144, 566-70	3
832	Pharmacotherapy of pulmonary hypertension (according to the 2015 ESC/EAS Guidelines for the diagnosis and treatment of pulmonary hypertension). <b>2016</b> , 12, 79-86	1
831	Pulmonary Hypertension - New Trends of Diagnostic and Therapy. <b>2016</b> , 70, 303-307	8
830	Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension. <b>2016</b> , 10, 1675-82	9
829	A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy. <b>2016</b> , 5,	12
828	Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension. <b>2016</b> , 57, 466-72	16
827	Patent ductus arteriosus with persistent pulmonary artery hypertension after transcatheter closure. <b>2016</b> , 12, 1609-1613	5
826	Update on pharmacotherapy for pulmonary hypertension. <b>2016</b> , 205, 271-6	9
825	Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension. <b>2016</b> , 17, S89-100	11
824	A 'green' diet-based approach to cardiovascular health? Is inorganic nitrate the answer?. <b>2016</b> , 60, 185-202	21
823	Diaphragm degeneration and cardiac structure in mdx mouse: potential clinical implications for Duchenne muscular dystrophy. <b>2016</b> , 228, 784-91	18



822	Reverse-phase high-performance liquid chromatography for the simultaneous determination of sildenafil and N-desmethyl sildenafil in plasma of children. <b>2016</b> , 30, 2070-2073	5
821	Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension. <b>2016</b> , 65, 215-22	6
820	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <b>2016</b> , 75, 1009-15	76
819	Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison. <b>2016</b> , 8, 74-82	11
818	Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <b>2016</b> , 102 Suppl 2, ii67-85	43
817	Plasma nitrite/nitrate levels: a new biomarker for pulmonary arterial hypertension?. <b>2016</b> , 48, 1265-1267	3
816	The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies. <b>2016</b> , 17, 2081-2096	21
815	Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial. <b>2016</b> , 128, 253-259	60
814	Initial dual oral combination therapy in pulmonary arterial hypertension. <b>2016</b> , 47, 1727-36	85
813	Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. <b>2016</b> , 109, 431-43	73
812	Calcilytics enhance sildenafil-induced antiproliferation in idiopathic pulmonary arterial hypertension. <b>2016</b> , 784, 15-21	13
811	Demographic and clinical characteristics of pulmonary hypertension cases and the awareness of the disease among chest physicians in Abassia Chest Hospital. <b>2016</b> , 65, 295-301	
810	Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan. <b>2016</b> , 27, 66-70	7
809	Update on pulmonary arterial hypertension pharmacotherapy. <b>2016</b> , 128, 460-73	14
808	MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions. <b>2016</b> , 329, 43-53	34
807	Future Perspectives for the Treatment of Sickle Cell Anemia. <b>2016</b> , 399-429	4
806	Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. <b>2016</b> , 150, 353-66	32
805	MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. <b>2016</b> , 107, 381-389	30

804	Mixed connective tissue disease. <b>2016</b> , 30, 95-111	60
803	Pulmonary arterial hypertension and associated conditions. <b>2016</b> , 62, 379-402	5
802	Sickle Cell Anemia. <b>2016</b> ,	4
801	Pulmonary hypertension: diagnostic approach and optimal management. <b>2016</b> , 188, 804-812	11
800	Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). <b>2016</b> , 18, 37	98
799	Ocular toxicity assessment of chronic sildenafil therapy for pulmonary arterial hypertension. <b>2016</b> , 254, 1167-74	7
798	Contemporary diagnosis and management of pulmonary hypertension. <b>2016</b> , 102, 1680-91	3
797	Pulmonary Hypertension due to Radiofrequency Catheter Ablation (RFCA) for Atrial Fibrillation: The Lungs, the Atrium or the Ventricle?. <b>2016</b> , 25, 1177-1183	7
796	The emerging role of epigenetics in pulmonary hypertension. <b>2016</b> , 48, 903-17	23
795	A Contemporary Approach to Pulmonary Arterial Hypertension. <b>2016</b> , 18, 58	1
794	The Endothelium-Dependent Nitric Oxide-cGMP Pathway. <b>2016</b> , 77, 1-27	45
793	Non-invasive evaluation of pulmonary arterial blood flow and wall shear stress in pulmonary arterial hypertension with 3D phase contrast magnetic resonance imaging. <b>2016</b> , 5, 1071	23
792	Pulmonary Arterial Hypertension: Diagnosis and Treatment. <b>2016</b> , 34, 375-89	19
791	Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. <b>2016</b> , 9, 29-35	4
790	Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension. <b>2016</b> , 194, 723-32	14
789	[Pulmonary hypertension: definition, classification and treatments]. <b>2016</b> , 210, 53-64	6
788	Comparison of preventive effect of sildenafil and therapeutic effect of sildenafil treatment in rats with monocrotaline-induced pulmonary arterial hypertension. <b>2016</b> , 78, 1607-1610	2
787	Medical Treatment of Aortic Stenosis. <b>2016</b> , 134, 1766-1784	62

786	Detrimental Impact of Vasopressin V2 Receptor Antagonism in a SU5416/Hypoxia/Normoxia-Exposed Rat Model of Pulmonary Arterial Hypertension. <b>2016</b> , 80, 989-97	6
785	Precise definitions of some terminology for longitudinal clinical trials: subjects, patient populations, analysis sets, intention to treat, and related terms. <b>2016</b> , 15, 471-485	4
784	A randomized double blinded placebo controlled trial of sildenafil for renoprotection prior to hilar clamping in patients undergoing robotic assisted laparoscopic partial nephrectomy. <b>2016</b> , 114, 785-788	4
783	Treatment of advanced group 2 PH. <b>2016</b> , 59, 78-86	
782	A highly sensitive LC-MS/MS method for concurrent determination of sildenafil and rosiglitazone in rat plasma. <b>2016</b> , 129, 21-27	9
781	Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. <b>2016</b> , 48, 787-96	64
780	Pulmonary Hypertension in Children. <b>2016</b> , 34, 451-72	28
779	Identification of Mitotic Blockers by Phenotypic Screening of a Clinical Compound Library. <b>2016</b> , 37, 1942-1946	
778	Gender-related differences in pulmonary arterial hypertension targeted drugs administration. <b>2016</b> , 114, 103-109	25
777	[Targeted therapy of pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016]. <b>2016</b> , 141, S33-S41	12
776	Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension. <b>2016</b> , 3, 16044	7
775	New paradigm for pulmonary arterial hypertension treatment. <b>2016</b> , 22, 429-33	4
774	Management of pulmonary hypertension in pregnancy. 144-159	
773	Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis. <b>2016</b> , 3, e000399	5
772	Cumulative subgroup analysis to reduce waste in clinical research for individualised medicine. <b>2016</b> , 14, 197	9
771	Current progress in therapeutic agents for pulmonary arterial hypertension: new insights into their mechanisms of action from endothelin system. <b>2016</b> , 148, 231-238	
770	Effects of extrathoracic mechanical ventilation on pulmonary hypertension secondary to lung disease. <b>2016</b> , 30, 663-70	3
769	Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. <b>2016</b> , 39, 1238-52	31

768	Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome. <b>2016</b> , 24, 410-416	4
767	MiRNA-199a-5p influences pulmonary artery hypertension via downregulating Smad3. <b>2016</b> , 473, 859-866	24
766	Treatment and Prognosis of Pulmonary Hypertension in the Left Ventricular Assist Device Patient. <b>2016</b> , 13, 140-50	3
765	Systemic Sclerodermas. <b>2016</b> , 384-405.e9	0
764	Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. <b>2016</b> , 12, 63-8	13
763	Sildenafil Treatment of Infants With Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension. <b>2016</b> , 6, 27-33	16
762	Common long-term complications of adult congenital heart disease: avoid falling in a H.E.A.P. <b>2016</b> , 14, 445-62	24
761	Medical therapies for pulmonary arterial hypertension. <b>2016</b> , 21, 273-83	7
760	Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study. <b>2016</b> , 34, 509-20	15
759	Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability. <b>2016</b> , 7, 48-57	26
758	An Update on the Management of Pulmonary Arterial Hypertension and the Pharmacist's Role. <b>2016</b> , 29, 67-76	9
757	Pushing the Envelope on the Indications and Doses of Pulmonary Arterial Hypertension Medications: What Is Reasonable?. <b>2016</b> , 67, 319-21	1
756	Quantitative Dual-Energy Computed Tomography Supports a Vascular Etiology of Smoking-induced Inflammatory Lung Disease. <b>2016</b> , 193, 652-61	60
755	The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension. <b>2016</b> , 13, 842-9	22
754	Modafinil improves monocrotaline-induced pulmonary hypertension rat model. <b>2016</b> , 80, 119-27	9
753	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. <b>2016</b> , 69, 177.e1-177.e62	137
752	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). <b>2016</b> , 18, 10	28
751	Treatment of pulmonary hypertension. <b>2016</b> , 4, 323-36	75

750	Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?. <b>2016</b> , 24, 268-74	32
749	The metabolism of the dual endothelin receptor antagonist macitentan in rat and dog. <b>2016</b> , 46, 253-67	4
748	Sildenafil citrate (Viagra) reduces surface roughness of human erythrocytes: Atomic-force-microscopic study. <b>2016</b> , 4, 63-68	
747	Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension. <b>2016</b> , 34, 751-70	22
746	From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress. <b>2016</b> , 102, 320-30	17
745	Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension. <b>2016</b> , 34, 533-50	20
744	A Phase I proof-of-concept and safety trial of sildenafil to treat cerebral vasospasm following subarachnoid hemorrhage. <b>2016</b> , 124, 318-27	12
743	Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand. <b>2016</b> , 16, 525-36	4
742	The molecular targets of approved treatments for pulmonary arterial hypertension. <b>2016</b> , 71, 73-83	87
741	New Pharmacological Strategies to Increase cGMP. <b>2016</b> , 67, 229-43	26
740	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), 2015, 9(4)	3455
739	A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. <b>2016</b> , 75, 1457-65	9
738	Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. <b>2016</b> , 21, 190-199	92
737	Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?. <b>2016</b> , 39, 131-42	18
736	Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis. <b>2016</b> , 25, 46-52	8
735	Connective Tissue Diseases. <b>2016</b> , 1165-1187.e14	
734	Pulmonary Hypertension. <b>2016</b> , 1031-1049.e4	1
733	Formulation and process considerations for the design of sildenafil-loaded polymeric microparticles by vibrational spray-drying. <b>2017</b> , 22, 691-698	8

732	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. <b>2017</b> , 151, 468-480	57
731	Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. <b>2017</b> , 36, 166-174	57
730	Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. <b>2017</b> , 36, 399-406	8
729	COUNTERPOINT: Should Wireless Pulmonary Artery Hemodynamic Monitoring Be Used to Monitor Patients With Pulmonary Hypertension? No. <b>2017</b> , 152, 16-18	0
728	Targeting the NO-sGC-cGMP Pathway in Pulmonary Arterial Hypertension. <b>2017</b> , 139-151	1
727	Osteoprotegerin Disruption Attenuates HySu-Induced Pulmonary Hypertension Through Integrin $\alpha$ 5 $\beta$ /FAK/AKT Pathway Suppression. <b>2017</b> , 10,	22
726	Right Ventricular Function. <b>2017</b> , 217-236	1
725	Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. <b>2017</b> , 17, 44	9
724	Pulmonary hypertension in connective tissue diseases: an update. <b>2017</b> , 20, 5-24	26
723	Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). <b>2017</b> , 250, 96-106	23
722	Physical Activity in Pediatric Pulmonary Arterial Hypertension Measured by Accelerometry. A Candidate Clinical Endpoint. <b>2017</b> , 196, 220-227	24
721	The effect of PDE5 inhibitors on bone and oxidative damage in ovariectomy-induced osteoporosis. <b>2017</b> , 242, 1051-1061	17
720	Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. <b>2017</b> , 94, 26-37	15
719	Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia. <b>2017</b> , 181, 12-28.e1	170
718	Evaluation and management approaches for scleroderma lung disease. <b>2017</b> , 11, 327-340	13
717	Current management of pulmonary arterial hypertension. <b>2017</b> , 28, 27-33	1
716	Identifying "super responders" in pulmonary arterial hypertension. <b>2017</b> , 7, 300-311	7
715	Pulmonary Hypertension in Women: What Does the Cardiologist Need to Know?. <b>2017</b> , 11, 1	1

714	Epidemiology and treatment of pulmonary arterial hypertension. <b>2017</b> , 14, 603-614	182
713	Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension. <b>2017</b> , 143, 291-298	11
712	Use of $\beta$ Blockers in Pulmonary Hypertension. <b>2017</b> , 10,	41
711	Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. <b>2017</b> , 8, 47-64	19
710	Retrospective evaluation of pimobendan and sildenafil therapy for severe pulmonary hypertension due to lung disease and hypoxia in 28 dogs (2007-2013). <b>2017</b> , 3, 99-106	8
709	Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation. <b>2017</b> , 188, 42-52	15
708	Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. <b>2017</b> , 46, 767-774	28
707	Stability of sildenafil in combination with heparin and dopamine. <b>2017</b> , 74, e64-e71	
706	Diagnosis and Treatment of Pulmonary Hypertension. <b>2017</b> ,	0
705	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. <b>2017</b> , 9,	144
704	Assessment and Prognostic Impact of Right Ventricular Function in Patients with Pulmonary Arterial Hypertension Undergoing Pulmonary Artery Denervation: Central Role of Global Right Ventricular Longitudinal Peak Systolic Strain. <b>2017</b> , 1, 81-90	
703	Pulmonary Hypertension in Adult Congenital Heart Disease. <b>2017</b> ,	6
702	Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. <b>2017</b> , 145, 54-63	6
701	Pulmonary Hypertension and Thrombembolism—Long-Term Management and Chronic Oral Anticoagulation. <b>2017</b> , 2, 727-741	
700	A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS. <b>2017</b> , 17, 463-471	
699	Estrategia terapèutica en hipertensiï arterial pulmonar. <b>2017</b> , 24, 41-47	
698	Beneficial effects of bile acid receptor agonists in pulmonary disease models. <b>2017</b> , 26, 1215-1228	14
697	The Nitric Oxide Pathway in Pulmonary Vascular Disease. <b>2017</b> , 120, S71-S79	54

696	Pulmonary Hypertension Complicating Connective Tissue Disease. <b>2017</b> , 38, 619-635	4
695	Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies. <b>2017</b> , 38, 606-618	5
694	Medical Treatment of Pulmonary Arterial Hypertension. <b>2017</b> , 38, 686-700	6
693	Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease. <b>2017</b> , 60, 1351-1364	27
692	Haemodynamic profiles of children with end-stage heart failure. <b>2017</b> , 38, 2900-2909	18
691	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <b>2017</b> , 50,	74
690	Effects of Sildenafil and Tadalafil on Edema and Reactive Oxygen Species Production in an Experimental Model of Lung Ischemia-Reperfusion Injury. <b>2017</b> , 49, 1461-1466	11
689	A Mixed Treatment Comparison Meta-Analysis of Pharmacotherapeutic Monotherapy and Placebo for Pulmonary Artery Hypertension. <b>2017</b> , 24, 149-159	1
688	Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. <b>2017</b> , 13, 588-592	12
687	Inhibition of nitric oxide synthase unmasks vigorous vasoconstriction in established pulmonary arterial hypertension. <b>2017</b> , 5, e13537	8
686	Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance. <b>2017</b> , 33, 2241-2249	12
685	Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. <b>2017</b> , 60, 6622-6637	23
684	Challenges in the development of chronic pulmonary hypertension models in large animals. <b>2017</b> , 7, 156-166	11
683	Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: A nationwide cohort study. <b>2017</b> , 24, 1498-1505	6
682	The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis. <b>2017</b> , 411-419	
681	Hepatoprotective role of vardenafil against experimentally induced hepatitis in mice. <b>2017</b> , 31, N/A	1
680	A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio ) in cardiac surgery: the REVAKI-1 study. <b>2017</b> , 83, 709-720	9
679	Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. <b>2017</b> , 22, 372-377	12



678	Molecular Determinants of BK Channel Functional Diversity and Functioning. <b>2017</b> , 97, 39-87	130
677	Perioperative Management of Pulmonary Hypertension. <b>2017</b> , 197-215	
676	A review of therapeutic agents for the management of pulmonary arterial hypertension. <b>2017</b> , 11, 46-63	8
675	Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. <b>2017</b> , 13, 183-192	19
674	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. <b>2017</b> , 19, 116-125	38
673	Sildenafil, unbridled optimism, and heart failure with preserved ejection fraction. <b>2017</b> , 19, 126-128	1
672	The evolving landscape of combination therapy for pulmonary arterial hypertension. <b>2017</b> , 11, 91-95	1
671	Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis. <b>2017</b> , 151, 90-105	31
670	Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review. <b>2017</b> , 7, 16218	11
669	Hipertensiñ pulmonar (I). Hipertensiñ arterial pulmonar. <b>2017</b> , 12, 2655-2673	
668	The Pulmonary Circulation. <b>2017</b> , 89-107.e2	
667	Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy. <b>2017</b> , 8, 614	19
666	Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension. <b>2017</b> , 23, S3-S4	1
665	The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease. <b>2017</b> , 6,	9
664	A Novel Therapeutic Approach in the Treatment of Pulmonary Arterial Hypertension: Allium ursinum Liophylisate Alleviates Symptoms Comparably to Sildenafil. <b>2017</b> , 18,	11
663	Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. <b>2017</b> , 11, 871-885	12
662	Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. <b>2017</b> , 11, 1195-1207	20
661	Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. <b>2017</b> , 17, 239	19

660	Drug repurposing for the treatment of glioblastoma multiforme. <b>2017</b> , 36, 169	40
659	Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. <b>2017</b> , 8, 220	39
658	Changing face of pulmonary arterial hypertension in Canada. <b>2017</b> , 1, 242-252	5
657	Reynolds Syndrome: a rare rheumatologic disease that internists should have in mind. Case report. <b>2017</b> , 3,	
656	Long-term outcomes of surgery for chronic thromboembolic pulmonary hypertension compared with medical therapy at a single Korean center. <b>2017</b> , 32, 855-864	5
655	Osthole attenuates pulmonary arterial hypertension in monocrotaline-treated rats. <b>2017</b> , 16, 2823-2829	19
654	Clinical and histopathological relationship of sildenafil and bosentan treatments in rats with monocrotaline induced pulmonary hypertension. <b>2017</b> , 118, 544-551	3
653	A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States. <b>2017</b> , 23, 92-104	10
652	Sex differences in pulmonary vascular control: focus on the nitric oxide pathway. <b>2017</b> , 5, e13200	3
651	Nitric oxide and pulmonary arterial hypertension. <b>2017</b> , 2017, 14	21
650	Pulmonary hypertension: diagnosis, imaging techniques, and novel therapies. <b>2017</b> , 7, 405-417	15
649	An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. <b>2018</b> , 20, 10	15
648	Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment. <b>2018</b> , 137, 191-200	11
647	The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. <b>2018</b> , 119, 234-243	4
646	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. <b>2018</b> , 45, 633-691	16
645	PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. <b>2018</b> , 175, 2554-2565	170
644	MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A. <b>2018</b> , 36, 1847-1857	21
643	Novel Insights and Treatment Strategies for Right Heart Failure. <b>2018</b> , 15, 141-155	6

642	Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial. <b>2018</b> , 201, 1-8	14
641	Nitric oxide pathology and therapeutics in sickle cell disease. <b>2018</b> , 68, 223-237	19
640	Effects of sildenafil treatment on thermogenesis and glucose homeostasis in diet-induced obese mice. <b>2018</b> , 8, 9	9
639	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. <b>2018</b> , 137, e578-e622	264
638	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. <b>2018</b> , 39, 1255-1264	105
637	The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. <b>2018</b> , 107, 460-470	18
636	Nitric oxide signalling in cardiovascular health and disease. <b>2018</b> , 15, 292-316	259
635	Antenatal Medical Therapies to Improve Lung Development in Congenital Diaphragmatic Hernia. <b>2018</b> , 35, 823-836	4
634	Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease. <b>2018</b> , 58, 636-647	16
633	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. <b>2018</b> , 154, 136-147	13
632	Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects. <b>2018</b> , 48, e12876	17
631	The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. <b>2018</b> , 8, 2045893217748307	21
630	The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review. <b>2018</b> , 38, 189-203	9
629	Pulmonary arterial hypertension: pathogenesis and clinical management. <b>2018</b> , 360, j5492	312
628	Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year Trial. <b>2018</b> , 240, 45-54	12
627	Pulmonary hypertension in patients with interstitial lung disease. <b>2018</b> , 50, 38-46	13
626	No, we are not-we keep forgetting the right ventricle. <b>2018</b> , 74, 141-143	1
625	Hipertensiã arterial pulmonar. <b>2018</b> , 22, 1-11	

624	Bone Morphogenetic Protein-Based Therapeutic Approaches. <b>2018</b> , 10,	31
623	Pulmonary arterial stiffness indices assessed by intravascular ultrasound in children with early pulmonary vascular disease: prediction of advanced disease and mortality during 20-year follow-up. <b>2018</b> , 19, 216-224	13
622	Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension. <b>2018</b> , 103, 468-476	2
621	Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction. <b>2018</b> , 314, H170-H179	7
620	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. <b>2018</b> , 37, 365-375	27
619	Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants. <b>2018</b> , 28, 85-92	3
618	Pulmonary Hypertension and Related Disorders. <b>2018</b> , 163-181	
617	Ethnicity in Pulmonary Arterial Hypertension: Possibilities for Novel Phenotypes in the Age of Personalized Medicine. <b>2018</b> , 153, 310-320	12
616	Management of Adults With Congenital Heart Disease and Pulmonary Arterial Hypertension in the UK: Survey of Current Practice, Unmet Needs and Expert Commentary. <b>2018</b> , 27, 1018-1027	6
615	Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. <b>2018</b> , 28, 542-547	14
614	Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: A network meta-analysis. <b>2018</b> , 50, 1-10	5
613	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. <b>2018</b> , 43, 191-216	1
612	Echocardiographic changes with non-invasive ventilation and CPAP in obesity hypoventilation syndrome. <b>2018</b> , 73, 361-368	38
611	[Acute monocular loss of vision : Differential diagnostic considerations apart from the internistic etiological clarification]. <b>2018</b> , 115, 676-679	1
610	Atrial septal defect with pulmonary hypertension: when/how can we consider closure?. <b>2018</b> , 10, S2890-S2898 <sup>11</sup>	
609	Idiopathic Pulmonary Hypertension. <b>2018</b> , 670-677	
608	OBSOLETE: Pulmonary Hypertension. <b>2018</b> ,	
607	Sildenafil zum Nintedanib hat bei IPF keinen Vorteil. <b>2018</b> , 10, 18-20	

606 Sildenafil. **2018**,

- 605 A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. **2018**, 25, 1898-1909 10
- 604 Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension. **2017**, 82, 275-282 48
- 603 Effect of sildenafil (Revatio) on postcardiac surgery acute kidney injury: a randomised, placebo-controlled clinical trial: the REVAKI-2 trial protocol. **2018**, 5, e000838 5
- 602 Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. **2018**, 12, 824 24
- 601 Comparative single-dose pharmacokinetics of sildenafil after oral and rectal administration in healthy beagle dogs. **2018**, 14, 291 3
- 600 Effects of Oral Supplementation With Nitrate-Rich Beetroot Juice in Patients With Pulmonary Arterial Hypertension-Results From BEET-PAH, an Exploratory Randomized, Double-Blind, Placebo-Controlled, Crossover Study. **2018**, 24, 640-653 14
- 599 Crystal Structures of *Candida albicans* Phosphodiesterase 2 and Implications for Its Biological Functions. **2018**, 57, 6070-6077
- 598 Druggability of Coronary Artery Disease Risk Loci. **2018**, 11, e001977 12
- 597 Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?. **2018**, 14, 253-264 20
- 596 Pulmonary Arterial Hypertension Medical Management of the Adult Patient with Congenital Heart Disease. **2018**, 3, 1-8
- 595 Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations. **2018**, 143, 139-146 3
- 594 Drug Repurposing of Metabolic Agents in Malignant Glioma. **2018**, 19, 21
- 593 The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension. **2018**, 9, 1167 17
- 592 Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. **2018**, 272S, 37-45 33
- 591 Anti-Inflammatory Effects of Vardenafil Against Cholestatic Liver Damage in Mice: a Mechanistic Study. **2018**, 47, 523-534 12
- 590 A disease looking for innovative drugs: The case of pulmonary arterial hypertension. **2018**, 55, 47-51 3
- 589 Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. **2018**, 78, 72-80 49

588	Heart Failure: Influence of Drug Interventions on Vessels. <b>2018</b> , 575-588	
587	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. <b>2018</b> , 2018, 3293584	17
586	Pulmonary Arterial Hypertension. <b>2018</b> , 14, 255-269	40
585	Chronic Right Heart Failure: Expanding Prevalence and Challenges in Outpatient Management. <b>2018</b> , 14, 413-423	3
584	Heart Failure in Adult Congenital Heart Disease. <b>2018</b> ,	
583	Role of plasma asymmetric dimethyl-L-arginine levels in detection of pulmonary hypertension in children with CHD. <b>2018</b> , 28, 1163-1168	5
582	Pulmonary Hypertension. <b>2018</b> , 204-222	
581	Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease. <b>2018</b> , 8, 2045894018792501	7
580	Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension. <b>2018</b> , 9, 890	15
579	The mechanosensitive ion channel TRPV4 is a regulator of lung development and pulmonary vasculature stabilization. <b>2018</b> , 11, 309-320	11
578	Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children. <b>2018</b> , 5,	10
577	Pulmonary Arterial Hypertension: Pathophysiology and Treatment. <b>2018</b> , 6,	50
576	Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study. <b>2018</b> , 2018, 9836820	3
575	Hypercoagulability in Pulmonary Hypertension. <b>2018</b> , 39, 595-603	7
574	Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension. <b>2018</b> , 48, 839-853	4
573	Effect of phosphodiesterase-5 inhibition on joint and muscle damage in rats with adjuvant arthritis. <b>2018</b> , 48, 635-643	2
572	Evaluation of prophylactic and therapeutic effects of sildenafil on acute radiation proctitis in rats. <b>2018</b> , 33, 362-374	3
571	Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial. <b>2018</b> , 8, 2045894018797273	2

570	Efficacy and safety of oral targeted therapies in pulmonary arterial hypertension: a meta-analysis of randomized clinical trials. <b>2018</b> , 8, 2045894018798183	3
569	Primary and Secondary Pulmonary Hypertension. <b>2018</b> , 285-314	
568	Sildenafil Exposure in the Neonatal Intensive Care Unit. <b>2019</b> , 36, 262-267	6
567	Inflammasomes: a novel therapeutic target in pulmonary hypertension?. <b>2019</b> , 176, 1880-1896	19
566	Bronchopulmonary Dysplasia. <b>2019</b> , 367-381.e5	
565	Novel Therapeutic Approaches of Pulmonary Arterial Hypertension. <b>2019</b> , 28, 112-117	1
564	Pulmonary hypertension could be a risk for deep vein thrombosis in lower extremities after joint replacement surgery. <b>2019</b> , 65, 946-950	2
563	Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia. <b>2019</b> , 19, 573	2
562	Exercise Physiology for the Pediatric and Congenital Cardiologist. <b>2019</b> ,	3
561	Orphan drug development: the increasing role of clinical pharmacology. <b>2019</b> , 46, 395-409	8
560	Phosphodiesterase inhibitors are viable options for treating esophageal motility disorders: A case report and literature review. <b>2019</b> , 20, 495-499	2
559	Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension. <b>2019</b> , 176, 4462-4473	6
558	High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach. <b>2019</b> , 14, e0217798	13
557	The potential of drug repurposing combined with reperfusion therapy in cerebral ischemic stroke: A supplementary strategy to endovascular thrombectomy. <b>2019</b> , 236, 116889	5
556	Pharmacotherapy for pulmonary arterial hypertension. <b>2019</b> , 11, S1767-S1781	27
555	A Multi-Biochemical and In Silico Study on Anti-Enzymatic Actions of Pyroglutamic Acid against PDE-5, ACE, and Urease Using Various Analytical Techniques: Unexplored Pharmacological Properties and Cytotoxicity Evaluation. <b>2019</b> , 9,	8
554	Pulmonary Arterial Hypertension and Therapeutic Interventions. <b>2019</b> , 28, 80-92	3
553	Bony Breathlessness: Reversible Pulmonary Hypertension in Melnick-Needles Syndrome Using Noninvasive Ventilation. <b>2019</b> , 140, 880-885	1

552	Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?. <b>2019</b> , 20,	18
551	A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension. <b>2019</b> , 46, 499-509	2
550	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. <b>2019</b> , 20, 208	8
549	Advances in Management of Pulmonary Hypertension Associated with Systemic Sclerosis. <b>2019</b> ,	1
548	Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol. <b>2019</b> , 19, 99-105	5
547	Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. <b>2019</b> , 244, 120-131	16
546	Palliative Care Issues in Pulmonary Arterial Hypertension #367. <b>2019</b> , 22, 220-222	2
545	Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study. <b>2019</b> , 24, 7-19	4
544	Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial. <b>2019</b> , 41, 1499-1507	8
543	A focus on riociguat in the treatment of pulmonary arterial hypertension. <b>2019</b> , 125, 202-214	8
542	Sildenafil Prevents Marfan-Associated Emphysema and Early Pulmonary Artery Dilation in Mice. <b>2019</b> , 189, 1536-1546	3
541	Challenges in pulmonary hypertension associated with left heart disease. <b>2019</b> , 17, 461-472	1
540	Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model. <b>2019</b> , 177, 269-290	7
539	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. <b>2019</b> , 124, 1520-1535	59
538	Sildenafil Monotherapy to Treat Portopulmonary Hypertension Before Liver Transplant. <b>2019</b> , 51, 1435-1438	6
537	Highlights from the 2018 North American cystic fibrosis conference. <b>2019</b> , 54, 941-948	1
536	3D-QSAR modeling of Phosphodiesterase-5 inhibitors: evaluation and comparison of the receptor- and ligand-based alignments. <b>2019</b> , 28, 820-830	1
535	Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension. <b>2019</b> , 9, 6899	6



534	Sildenafil enhances central hemodynamic responses to exercise, but not V o, in people with diabetes mellitus. <b>2019</b> , 127, 1-10	1
533	Effects of home-based exercise training on functional outcomes and quality of life in patients with pulmonary hypertension: A randomized clinical trial. <b>2019</b> , 71, 161-165	16
532	Sildenafil: Time to Look Beyond Pulmonary Pressures. <b>2019</b> , 33, 1657-1658	0
531	Acute Hemodynamic Changes after Single Administration of Udenafil in Pulmonary Arterial Hypertension: a Phase IIa Study. <b>2019</b> , 49, 353-360	2
530	Udenafil as a Therapeutic Option for Pulmonary Arterial Hypertension. <b>2019</b> , 49, 361-362	2
529	Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model. <b>2019</b> , 33, 287-295	2
528	Effect of sildenafil and pimobendan on intracardiac heartworm infections in four dogs. <b>2019</b> , 23, 96-103	3
527	An immunochromatographic strip sensor for sildenafil and its analogues. <b>2019</b> , 7, 6383-6389	16
526	Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. <b>2019</b> , 302, 126-139	29
525	Drug repositioning in pulmonary arterial hypertension: challenges and opportunities. <b>2019</b> , 9, 2045894019832226	26
524	Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies. <b>2019</b> , 10, 55	7
523	EXPRESS: Sildenafil for bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis. <b>2019</b> , 2045894019837875	16
522	Pharmacology of the Pulmonary Circulation. <b>2019</b> , 165-179	
521	Nepriylsin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. <b>2019</b> , 176, 1251-1267	15
520	Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy. <b>2019</b> , 25,	
519	Pulmonary arterial hypertension: the case for a bioelectronic treatment. <b>2019</b> , 5, 20	7
518	Novel Drug Delivery Technologies. <b>2019</b> ,	2
517	Phosphodiesterase 5 inhibitors for pulmonary hypertension. <b>2019</b> , 1, CD012621	32

516	Sildenafil for Pulmonary Arterial Hypertension. <b>2019</b> , 26, e520-e526	19
515	Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH). <b>2019</b> , 15, 1427-1442	6
514	Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease. <b>2019</b> , 21, K37-K45	8
513	Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. <b>2019</b> , 21, 141	27
512	COUNTERPOINT: Should Initial Combination Therapy Be the Standard of Care in Pulmonary Arterial Hypertension? No. <b>2019</b> , 156, 1043-1045	0
511	Sildenafil improves exercise capacity in patients with cystic fibrosis: a proof-of-concept clinical trial. <b>2019</b> , 10, 2040622319887879	4
510	The Association of Autoantibodies in Hyperthyroid Heart Disease Combined with Pulmonary Hypertension. <b>2019</b> , 2019, 9325289	1
509	Systemic sclerosis. <b>2019</b> , 291-329	
508	The right treatment for the right ventricle. <b>2019</b> , 25, 410-417	10
507	Inflammatory Basis of Pulmonary Arterial Hypertension: Implications for Perioperative and Critical Care Medicine. <b>2019</b> , 131, 898-907	16
506	Evaluation of Macitentan in Patients With Eisenmenger Syndrome. <b>2019</b> , 139, 51-63	55
505	Phosphodiesterase expression in the normal and failing heart. <b>2019</b> , 662, 160-168	11
504	Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. <b>2019</b> , 8, e011343	31
503	Effect of prolonged treatment with phosphodiesterase-5-inhibitors on endothelial dysfunction in vascular diseases and vascular risk conditions: A systematic review analysis and meta-analysis of randomized double-blind placebo-controlled trials. <b>2019</b> , 73, e13296	4
502	A Physiology-Based Approach to the Respiratory Care of Children With Severe Bronchopulmonary Dysplasia. <b>2019</b> , 363-385	2
501	Pulmonary Hypertension. <b>2019</b> , 327-341.e9	
500	Device closure of atrial septal defect with severe pulmonary hypertension in adults: Patient selection with early and intermediate term results. <b>2019</b> , 93, 309-315	4
499	Sildenafil Use in Children with Pulmonary Hypertension. <b>2019</b> , 205, 29-34.e1	30

498	Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling. <b>2019</b> , 316, L119-L130	6
497	Advances in medical therapy for pulmonary arterial hypertension. <b>2019</b> , 34, 98-103	6
496	Risk stratification and medical therapy of pulmonary arterial hypertension. <b>2019</b> , 53,	316
495	Clinical trial design and new therapies for pulmonary arterial hypertension. <b>2019</b> , 53,	81
494	The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. <b>2019</b> , 24, 789-795	44
493	The burden of pulmonary hypertension in resource-limited settings. <b>2014</b> , 9, 297-310	13
492	Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. <b>2019</b> , 49, 98-105	2
491	Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. <b>2020</b> , 47, 89-98	7
490	Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study. <b>2020</b> , 29, 331-336	6
489	Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling. <b>2020</b> , 38, 311-320	7
488	A novel secreted-cAMP pathway inhibits pulmonary hypertension via a feed-forward mechanism. <b>2020</b> , 116, 1500-1513	10
487	Effects of inorganic nitrate in a rat model of monocrotaline-induced pulmonary arterial hypertension. <b>2020</b> , 126, 99-109	4
486	Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management. <b>2020</b> , 25, 773-794	2
485	Drug repurposing approach for the identification and designing of potential E6 inhibitors against cervical cancer: an in silico investigation. <b>2020</b> , 31, 141-153	5
484	Pulmonary Hypertension. <b>2020</b> , 617-630.e3	
483	Echocardiographic Changes with Positive Airway Pressure Therapy in Obesity Hypoventilation Syndrome. Long-Term Pickwick Randomized Controlled Clinical Trial. <b>2020</b> , 201, 586-597	20
482	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <b>2020</b> , 177, 5467-5488	34
481	Soluble guanylate cyclase stimulator praliguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. <b>2020</b> , 318, F148-F159	15

480	Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis. <b>2020</b> , 9, 7-22	4
479	Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. <b>2020</b> , 19, 93-111	77
478	The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. <b>2020</b> , 301, 183-189	22
477	The cGMP system: components and function. <b>2020</b> , 401, 447-469	18
476	Pulmonary Arterial Hypertension: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. <b>2020</b> , 59, 932-943	6
475	Pharmacologic therapy for pulmonary artery hypertension. <b>2020</b> , 35, 643-656	1
474	Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. <b>2020</b> , 10, 2045894020962960	4
473	Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials. <b>2020</b> , 30, 1882-1889	1
472	Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension. <b>2020</b> , 887, 173438	4
471	Repurposing of medications for pulmonary arterial hypertension. <b>2020</b> , 10, 2045894020941494	5
470	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. <b>2020</b> , 36, 977-992	12
469	Guidelines for the Treatment of Pulmonary Arterial Hypertension. <b>2020</b> , 198, 581-596	16
468	Vascular Metabolic Mechanisms of Pulmonary Hypertension. <b>2020</b> , 40, 444-454	2
467	Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism. <b>2020</b> , 14, 5129-5141	11
466	Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease. <b>2020</b> , 190, 111311	4
465	Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. <b>2020</b> , 10,	12
464	Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?. <b>2020</b> , 21,	22
463	Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket. <b>2020</b> , 63, 9828-9837	12

462	The effect of sildenafil on pulmonary haemodynamics in a canine model of chronic embolic pulmonary hypertension. <b>2020</b> , 133, 106-110	3
461	Pediatric Pulmonary Arterial Hypertension. <b>2020</b> , 67, 903-921	2
460	Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. <b>2020</b> , 21,	6
459	Benefits of perioperative sildenafil therapy in children with a ventricular septal defect with pulmonary artery hypertension on early surgical outcomes. <b>2020</b> , 35, 3302-3309	3
458	Phenotypes of Bronchopulmonary Dysplasia. <b>2020</b> , 21,	16
457	Topological network measures for drug repositioning. <b>2021</b> , 22,	13
456	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. <b>2020</b> , 10, 2045894020941491	1
455	Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. <b>2020</b> , 10, 2045894020973124	2
454	Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. <b>2020</b> , 63, 15153-15186	5
453	Pharmacological treatment of systemic sclerosis-associated pulmonary hypertension: A systematic literature review. <b>2020</b> , 27, 135-145	
452	Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors. <b>2020</b> , 63, 15852-15863	3
451	Oral drugs used to treat persistent pulmonary hypertension of the newborn. <b>2020</b> , 13, 1295-1308	3
450	PDE5 Inhibitors in Type 2 Diabetes Cardiovascular Complications. <b>2020</b> , 1, 90-101	2
449	Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension. <b>2020</b> , 7, 77	1
448	An update on the diagnosis and treatment of pediatric pulmonary hypertension. <b>2020</b> , 21, 1253-1268	1
447	Site-Selective Copper-Catalyzed Azidation of Benzylic C-H Bonds. <b>2020</b> , 142, 11388-11393	55
446	Advanced Diagnosis and Therapy for Pulmonary Arterial Hypertension. <b>2020</b> , 10, 2040003	2
445	Long-term survival outcome for pre-capillary pulmonary hypertension at a Japanese single center. <b>2020</b> , 98, 644-652	1

444	The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern. <b>2020</b> , 8, e00619	0
443	Effectiveness and safety of exercise training and rehabilitation in pulmonary hypertension: a systematic review and meta-analysis. <b>2020</b> , 12, 2691-2705	6
442	Complications in Idiopathic Pulmonary Fibrosis: Focus on Their Clinical and Radiological Features. <b>2020</b> , 10,	4
441	The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. <b>2020</b> , 72, 692-766	53
440	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. <b>2020</b> , 21,	8
439	Thoracic Visceral Adipose Tissue Area and Pulmonary Hypertension in Lung Transplant Candidates. The Lung Transplant Body Composition Study. <b>2020</b> , 17, 1393-1400	3
438	Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. <b>2020</b> , 209, 107511	36
437	Pediatric Pulmonary Arterial Hypertension: Evaluation and Treatment. <b>2020</b> , 6, 12-28	1
436	Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension. <b>2020</b> , 17, 439-461	11
435	Drug Treatment of Pulmonary Hypertension in Children. <b>2020</b> , 22, 123-147	7
434	Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. <b>2020</b> , 13, 15-29	13
433	Differential expression of caveolin-1 during pathogenesis of combined pulmonary fibrosis and emphysema: Effect of phosphodiesterase-5 inhibitor. <b>2020</b> , 1866, 165802	2
432	Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results. <b>2020</b> , 30, 681-685	4
431	"Treat and repair" strategy for shunt lesions: a critical review. <b>2020</b> , 10, 2045894020917885	9
430	Six-minute walk distance in healthy young adults. <b>2020</b> , 165, 105933	14
429	Current and future treatments of pulmonary arterial hypertension. <b>2021</b> , 178, 6-30	42
428	PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing Sildenafil for the treatment of hypertensive cardiac hypertrophy. <b>2021</b> , 891, 173724	2
427	Management of Pulmonary Arterial Hypertension. <b>2021</b> , 15, 2	13

426	NO-sensitive guanylyl cyclase in the lung. <b>2020</b> ,	1
425	Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. <b>2021</b> , 134, 111128	15
424	Should sildenafil be started 2 weeks before the operation in ventricular septal defect patients with high pulmonary vascular resistance?. <b>2021</b> , 36, 422-423	
423	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. <b>2021</b> , 9, 85-95	33
422	The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies. <b>2021</b> , 36, 3-8	3
421	The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). <b>2021</b> , 60, 872-880	0
420	The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis. <b>2021</b> , 31, 151-161	2
419	Novel Insights Regarding Nitric Oxide and Cardiovascular Diseases. <b>2021</b> , 72, 411-425	7
418	Treating Moderate Aortic Stenosis: Too Early or Too Late?. <b>2021</b> , 23, 1	
417	Pulmonary Manifestations of Connective Tissue Diseases. <b>2021</b> , 139-175	0
416	Roles of specific drug therapies for severe pulmonary arterial hypertension in palliative care: a case report. <b>2021</b> , 5, 7	
415	Impact of Face Masks on 6-Minute Walk Test in Healthy Volunteers. <b>2021</b> , 11, 2045894020988437	1
414	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. <b>2021</b> , 15, 493-504	2
413	Critical Care Management of the Patient with Pulmonary Hypertension. <b>2021</b> , 42, 155-165	0
412	Contemporary Pharmacotherapeutic Approach in Pulmonary Arterial Hypertension. <b>2021</b> , 42, 125-131	0
411	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. <b>2021</b> , 22,	3
410	Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. <b>2021</b> , 73, 837-847	9
409	Combining Data Sets as Well as Therapies Shows Improved Outcome in Connective Tissue Disease-Associated Pulmonary Hypertension. <b>2021</b> , 73, 725-727	1

408	Pulmonary hypertension: Spectrum of disease, clinical presentation and treatment outcomes at the main respiratory pulmonary hypertension clinic in KwaZulu-Natal Province, South Africa. <b>2021</b> , 27,	0
407	Clinical and hemodynamic effects of oral sildenafil on biventricular function on patients with left ventricular systolic dysfunction. <b>2021</b> , 75, e14171	0
406	Long-Term Survival and Causes of Death in Children with Trisomy 21 After Congenital Heart Surgery. <b>2021</b> , 231, 246-253.e3	4
405	A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!. <b>2021</b> , 204, 123-125	2
404	Lactic acid inhibits iNKT cell functions via a phosphodiesterase-5 dependent pathway. <b>2021</b> , 547, 9-14	0
403	Pulmonary Hypertension. <b>2021</b> , 174, ITC49-ITC64	7
402	Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era. <b>2021</b> , 14,	5
401	Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment. <b>2021</b> , 62, 199-203	
400	Sildenafil: From angina to SARS-CoV-2. <b>2021</b> ,	
399	iPSC modeling shows uncompensated mitochondrial mediated oxidative stress underlies early heart failure in hypoplastic left heart syndrome.	1
398	Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates. <b>2021</b> , 28, 2418-2437	2
397	Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact. <b>2021</b> , 11,	6
396	Sildenafil in ophthalmology: An update. <b>2021</b> ,	3
395	Multidrug resistance proteins preferentially regulate natriuretic peptide-driven cGMP signalling in the heart and vasculature. <b>2021</b> ,	0
394	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <b>2021</b> , 9, 573-584	22
393	Current Modulation of Guanylate Cyclase Pathway Activity-Mechanism and Clinical Implications. <b>2021</b> , 26,	3
392	Pulmonary arterial hypertension associated with systemic scleroderma. <b>2021</b> , 99, 68-74	
391	The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. <b>2021</b> , 11,	5



- 390 Theoretical Substantiation of the Use of Sildenafil in the Treatment of Chronic Prostatitis. **2021**, 58-62
- 389 2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. **2021**, 2, 63-78
- 388 Screening for Pulmonary Hypertension in Systemic Sclerosis-A Primer for Cardio-Rheumatology Clinics. **2021**, 11, 1
- 387 A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome. **2021**, 73, 633-636 1
- 386 A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects. **2021**, 15, 2947-2959 0
- 385 Chronic thromboembolic pulmonary hypertension: a review. **2021**, 62, 318-325 2
- 384 Pharmacological Alteration of Cellular Mechanical Properties in Pulmonary Arterial Smooth Muscle Cells of Idiopathic Pulmonary Arterial Hypertension. **2021**, 12, 231-237 0
- 383 Pulmonary hypertension phenotypes in patients with systemic sclerosis. **2021**, 30, 5
- 382 On the Viability of Tadalafil-Based F-Radiotracers for Phosphodiesterase 5 (PDE5) PET Imaging. **2021**, 6, 21741-21754 0
- 381 Pulmonary arterial hypertension in adults with congenital heart disease: markers of disease severity, management of advanced heart failure and transplantation. **2021**, 19, 837-855 1
- 380 PDE9A deficiency does not prevent chronic-hypoxic pulmonary hypertension in mice. **2021**, 9, e15057
- 379 Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction. **2021**, 42, 4431-4441 7
- 378 The prediction of right atrial pressure using electrocardiogram: a novel approach. **2021**, 1
- 377 Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019. **2021**, 78, 1168-1184 1
- 376 A Comprehensive Guide to Lung Transplantation for the Recipient With Pulmonary Fibrosis. **2022**, 661-675
- 375 Nitric Oxide and Nitrogen Oxides. **2022**, 426-442
- 374 Novel Approaches to Drug Discovery in Interstitial Lung Disease. **2022**, 182-188
- 373 Palliative Care in Pulmonary Arterial Hypertension. **2021**, 255-279

372	Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group. <b>2021</b> , 1-24	
371	Pulmonary Arterial Hypertension. <b>2021</b> , 223-234	
370	Biventricular function at high altitude: implications for regulation of stroke volume in chronic hypoxia. <b>2007</b> , 618, 13-24	11
369	Nursing Care of Patients with Pulmonary Arterial Hypertension. <b>2011</b> , 1531-1558	2
368	Pulmonary Hypertension Associated with Connective Tissue Disease. <b>2014</b> , 139-166	1
367	Modulation of cGMP Synthesis and Metabolism. <b>2015</b> , 355-375	1
366	Disease Progression in Systemic Sclerosis Associated Pulmonary Arterial Hypertension. <b>2009</b> , 289-303	2
365	Pathophysiology and Pharmacotherapy of Adult Congenital Heart Disease. <b>2015</b> , 1269-1291	1
364	Contemporary Pharmacotherapies Involving Nitric Oxide, Prostacyclin, and Endothelin Receptor Signaling Pathways. <b>2016</b> , 257-270	1
363	Modulating cGMP to treat lung diseases. <b>2009</b> , 469-83	8
362	Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction. <b>2013</b> , 218, 315-49	10
361	Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension. <b>2013</b> , 218, 381-408	10
360	Vasoactive peptides and the pathogenesis of pulmonary hypertension: role and potential therapeutic application. <b>2013</b> , 218, 477-511	7
359	Pulmonary hypertension: biomarkers. <b>2013</b> , 218, 77-103	4
358	Vasoactive Peptides and the Pathogenesis of Pulmonary Hypertension: Role and Potential Therapeutic Application. <b>2013</b> , 477-511	8
357	Pulmonary Hypertension: Biomarkers. <b>2013</b> , 77-103	6
356	Systemic Sclerosis. <b>2013</b> , 955-969	1
355	Anesthetic Implications of Concurrent Diseases. <b>2010</b> , 1067-1149	11

354	Pulmonary Vascular Disease. <b>2010</b> , 1147-1161	1
353	Systemic Sclerosis and the Scleroderma-Spectrum Disorders. <b>2009</b> , 1311-1351	8
352	HEPATIC CIRRHOSIS. <b>2009</b> , 505-525	2
351	Pulmonary Hypertension. <b>2010</b> , 1224-1243	1
350	Congenital Heart Disease. <b>2012</b> , 1411-1467	33
349	Pulmonary Hypertension. <b>2012</b> , 1696-1718	5
348	Bronchopulmonary Dysplasia. <b>2012</b> , 386-398	2
347	New Developments in the Pathogenesis and Management of Neonatal Pulmonary Hypertension. <b>2008</b> , 241-299	4
346	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. <b>2015</b> , 85, 215-24	6
345	Effect of sildenafil on neuroinflammation and synaptic plasticity pathways in experimental autoimmune encephalomyelitis. <b>2020</b> , 85, 106581	3
344	Pulmonary arterial hypertension specific therapy: The old and the new. <b>2020</b> , 214, 107576	16
343	Pulmonary hypertension: diagnosis and management. <b>2009</b> , 84, 191-207	33
342	Chapter 8:The Discovery of the Long-acting PDE5 Inhibitor PF-489791 for the Treatment of Pulmonary Hypertension. <b>2010</b> , 166-182	2
341	Transplant Operative Considerations in Pulmonary Hypertension With Severe Right Heart Failure. <b>2020</b> , 32, 1024-1029	2
340	Pulmonary hypertension in pregnancy: experience from 45 cases at a tertiary care center. <b>2020</b> , 1-6	4
339	Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan. <b>2006</b> , 99, 880-3	14
338	Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding. <b>2017</b> , 69, 93-100	5
337	PDGF signaling in pulmonary arterial hypertension. <b>2005</b> , 115, 2691-4	117

336	Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. <b>2011</b> , 121, 2888-97	70
335	Phosphodiesterase 5. <b>2006</b> ,	8
334	Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine. <b>2011</b> , 6, e18092	17
333	Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. <b>2011</b> , 6, e18883	33
332	The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial. <b>2015</b> , 10, e0119623	6
331	Hyperplastic Growth of Pulmonary Artery Smooth Muscle Cells from Subjects with Pulmonary Arterial Hypertension Is Activated through JNK and p38 MAPK. <b>2015</b> , 10, e0123662	29
330	Impact of Mitochondrial Ca <sup>2+</sup> -Sensitive Potassium (mBKCa) Channels in Sildenafil-Induced Cardioprotection in Rats. <b>2015</b> , 10, e0144737	34
329	PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC CONNECTIVE TISSUE DISEASES: THE CURRENT STATE OF THE PROBLEM. <b>2018</b> , 56, 474-485	3
328	Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis. <b>2019</b> , 10, 369-377	6
327	Pulmonary Arterial Hypertension in Women. <b>2017</b> , 13, 224-237	8
326	Review of the diagnosis and pharmacological management of pulmonary arterial hypertension in connective tissue disease. <b>2016</b> , 16, 14-22	1
325	Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator. <b>2018</b> , 13, 35-37	9
324	In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. <b>2020</b> , 92, e20191445	1
323	[Clinical guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (Part 2)]. <b>2016</b> , 88, 63-73	9
322	Riociguat and sildenafil for pulmonary hypertension: similarity and difference. <b>2016</b> , 26, 85-91	4
321	<Editors' Choice> Pulmonary Hypertension: Diagnosis, Management, and Treatment. <b>2019</b> , 81, 19-30	9
320	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. <b>2006</b> , 1, 403-14	36
319	Sildenafil in the treatment of pulmonary hypertension. <b>2006</b> , 2, 411-22	88

318	Challenges in Endpoint Development for Pulmonary Hypertension Trials in Children. <b>2014</b> , 13, 125-128	1
317	Oral Therapies for PAH: State-of-the-Art and Investigational Approaches. <b>2006</b> , 5, 13-17	3
316	Evaluating Operability in Adults with Congenital Heart Disease and the Role of Pretreatment with Targeted Pulmonary Arterial Hypertension Therapy. <b>2007</b> , 6, 126-135	2
315	Evidence-based Medical Management of Pulmonary Hypertension 2008: Review of Updated 2007 ACCP Guidelines. <b>2008</b> , 7, 222-227	1
314	Evaluating Recent Therapeutic Trials in Pulmonary Arterial Hypertension: Raising the Bar for Clinical Investigation. <b>2009</b> , 8, 24-31	1
313	Pulmonary Hypertension and Palliative Care: What, When, Where, and Why?. <b>2016</b> , 15, 26-31	3
312	The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets. <b>2020</b> , 27, 7168-7188	10
311	Pulmonary hypertension: types and treatments. <b>2015</b> , 11, 73-9	22
310	Repurposing of Existing Statin Drugs for Treatment of Microbial Infections: How Much Promising?. <b>2019</b> , 19, 224-237	16
309	[The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat]. <b>2020</b> , 92, 77-84	3
308	Current and emerging therapeutic approaches to pulmonary hypertension. <b>2020</b> , 21, 163-179	20
307	Diagnosis and Management of Secondary Pulmonary Hypertension. <b>2006</b> , 247-258	1
306	Pulmonary Hypertension.	12
305	Pulmonary Hypertension. <b>2017</b> , 114, 73-84	57
304	The effect of sildenafil on right ventricular remodeling in a rat model of monocrotaline-induced right ventricular failure. <b>2016</b> , 59, 262-70	10
303	Management of portopulmonary hypertension: new perspectives. <b>2013</b> , 19, 8252-7	10
302	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. <b>2020</b> , 78-122	29
301	Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension: a systematic review and meta-analysis. <b>2015</b> , 7, 309-19	20

300	Vinpocetine Suppresses -Induced Inflammation via Inhibition of ERK1 by CYLD. <b>2020</b> , 204, 933-942	5
299	Prolonged, longstanding, ultra-high-dose abuse of sildenafil. <b>2015</b> , 57, 311-2	5
298	Perioperative sildenafil therapy for children with ventricular septal defects and associated pulmonary hypertension undergoing corrective surgery: A randomised clinical trial. <b>2017</b> , 61, 798-802	2
297	Short-Term Drug-Drug Interaction between Sildenafil and Bosentan under Long-Term Use in Patients with Pulmonary Arterial Hypertension. <b>2013</b> , 04, 542-548	1
296	Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment. <b>2013</b> , 9 Suppl R, R149-54	1
295	Comparison of Tadalafil and Sildenafil in Controlling Neonatal Persistent Pulmonary Hypertension. <b>2016</b> , In Press,	3
294	Evaluation of histopathological and ultrastructural changes in the testis of tadalafil treated adult male albino rats. <b>2015</b> , 2, 18	2
293	Discovery of catalytic-site-fluorescent probes for tracing phosphodiesterase 5 in living cells.. <b>2021</b> , 11, 31967-31971	
292	Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat. <b>2021</b> , 93, 1117-1124	1
291	Evidence base for specific pulmonary vasodilators in adults with congenital heart disease. <b>2021</b> , 93, 1106-1116	1
290	Update on the Treatment of Pulmonary Arterial Hypertension. <b>2021</b> , 117, 750-764	0
289	Cardiovascular Diseases That Have Emerged From the Darkness. <b>2021</b> , 10, e021095	3
288	Viagra soothes the heart.	
287	Recent Publications on Medications and Pharmacy. <b>2006</b> , 41, 92-96	
286	Management of Idiopathic PAH in Children: Reexamining the Evolving Treatment Algorithm. <b>2006</b> , 5, 13-21	1
285	Advances in Prostanoid Therapy: New Studies, New Methods of Delivery. <b>2006</b> , 5, 23-30	1
284	Role of PDE5 in Migraine. <b>2006</b> ,	
283	Reinventing the Wheel. <b>2006</b> ,	

282 Treatment of Severe Idiopathic Pulmonary Hypertension. **2007**, 758-766

281 A case of portopulmonary hypertension successfully treated by balloon-occluded retrograde transvenous obliteration and home oxygen therapy. **2007**, 48, 322-330

280 Pulmonary hypertension in systemic sclerosis: a review of diagnostic and therapeutic options. **2007**, 2, 279-286

279 Combination therapy using inhaled iloprost and sildenafil in a patient with idiopathic pulmonary arterial hypertension. **2007**, 49, 222-224

278 Pulmonary Hypertension. **2008**, 783-796

277 Pharmacological Treatment of Pulmonary Hypertension. **2008**, 226-247

276 Antihypertonika. **2008**, 361-377

275 Drug therapy: Sildenafil for post-operative pulmonary hypertension and Eisenmenger syndrome - A brief review of literature and survey of expert opinion. **2008**, 1, 70-4

274 Phase 2 and 3 Clinical Trials in Pulmonary Arterial Hypertension. **2008**, 7, 228-234

1

273 Lungengefäßkrankungen. **2008**, 433-528

272 Pulmonary Arterial Hypertension. **2008**, 393-398

271 References. **2008**, 49-57

270 Combination therapy with epoprostenol and sildenafil in a female patient with severe pulmonary arterial hypertension. **2008**, 50, 299-303

269 Near-Term Novel Therapies for PAH. **2009**, 8, 17-20

268 Which Therapy for Which Condition?. **2009**, 388-458

267 Idiopathic Pulmonary Fibrosis and Associated Pulmonary Hypertension: Genetics, Pathobiology, Diagnosis, and Management. **2009**, 51-69

266 Effect of Sildenafil on Pulmonary Hypertension after a Case of Residual Shunt of Ventricular Septal Defect. **2009**, 38, 252-258

265 Exercise and Athletics in Adults with Congenital Heart Disease. **2009**, 248-264

264 Chronic Pulmonary Hypertension. **2009**, 483-505

263 PULMONARY ARTERIAL HYPERTENSION. **2009**, 401-415

262 Sarcoidosis. **2009**, 213-242

261 Antihypertonika. **2009**, 363-380

260 Pulmonary Arterial Hypertension in Pregnancy. **2009**, 285-312

259 Pulmonary arterial hypertension. **2009**, 51, 455-461

1

258 Pulmonary Hypertension. **2009**, 893-918

257 Pulmonary Hypertension. **2010**, 404-408

256 Heart Failure in Adults with Congenital Heart Disease. **2010**, 59-85

255 Long-Term Survival in Eisenmenger Syndrome. **2010**, 418-424

254 The Role of Pulmonary Vasodilators in Pulmonary Hypertension. **2010**, 484-488

253 The Lungs and Connective Tissue Diseases. **2010**, 1398-1426

252 Idiopathic and Familial Pulmonary Arterial Hypertension. **2010**, 39-84

251 Antihypertonika. **2010**, 389-408

250 Pulmonary Hypertension. **2010**, 405-417

249 Congenital Heart Disease. **2010**, 105-121

248 Pulmonary Arterial Hypertension. **2010**, 195-211

247 Role of sildenafil in the treatment of pulmonary hypertension. **2010**, 17, 462-464



246 The pulmonary circulation. **2010**, 99-117

1

245 Idiopathic Pulmonary Hypertension: New Challenges. **2010**, 147-157

244 Pulmonary Hypertension and Cor Pulmonale. **2011**, 353-371

243 Pulmonary Hypertension and Right Ventricular Failure. 367-382

242 Peri-operative Care of the Heart Transplant Recipient. 279-289

241 Surgical Evaluation of Congenital-Heart-Disease-Associated Pulmonary Hypertension. **2011**, 1153-1168

240 Pulmonary Arterial Hypertension Related to Scleroderma and Collagen Vascular Diseases. **2011**, 1011-1022

239 Pulmonary Hypertension Associated with Interstitial Lung Disease. **2011**, 1197-1210

238 Idiopathic Pulmonary Arterial Hypertension. **2011**, 979-995

237 Pulmonary Hypertension Secondary to Congenital Systemic-to-Pulmonary (Left-to-Right) Shunts. **2011**, 1139-1151

236 Endothelin Receptor Antagonists for the Treatment of Pulmonary Arterial Hypertension. **2011**, 1465-1475

235 Right Ventricular Dysfunction in Pulmonary Hypertension. **2011**, 1313-1331

234 Hemolytic-Anemia-Associated Pulmonary Hypertension: Sickle-Cell-Disease- and Thalassemia-Associated Pulmonary Hypertension. **2011**, 1269-1282

233 Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. **2011**, 1477-1485

232 Antihypertonika. **2011**, 401-420

231 Pharmacology of the Pulmonary Circulation. **2011**, 133-142

230 Orphan-Arzneimittel. **2011**, 119-166

229 Pulmonale Hypertonie. **2011**, 309-334

- 228 Idiopathic Pulmonary Arterial Hypertension. **2011**, 464-470
- 227 Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. **2011**, 755-789 1
- 226 Les atteintes pulmonaires de la sclérodermie. **2011**, 195, 79-92
- 225 Muskuloskelettale Erkrankungen und Autoimmunopathien. **2011**, 877-966
- 224 Postoperative Cardiovascular Management. **2011**, 1025-1045
- 223 Chronická plicní hypertenze. Doporučení diagnostické léčby a postup úsk'ardiologick' společnosti, 2010. **2011**, 53, 169-182 3
- 222 Approach to the Child With Pulmonary Hypertension and Bronchopulmonary Dysplasia. **2011**, 10, 98-103 1
- 221 Pulmonary Hypertension and Right Heart Failure. 81-93
- 220 Idiopathic pulmonary arterial hypertension in children. **2011**, 559-571
- 219 Pulmonary hypertension secondary to left heart failure. **2011**, 425-434
- 218 Pulmonary vascular remodeling and pathobiology of pulmonary hypertension. **2011**, 59-77 1
- 217 ????????????????? : ?????????????????(6.?????????,75?????????). **2011**, 19, 271-277
- 216 Pulmonary Hypertension in Older Patients. **2012**, 111-131
- 215 Introduction of Postoperative Cases in Which Diagnosis and Treatment were Difficult in ICU. **2012**, 32, 507-512
- 214 Antihypertonika. **2012**, 403-424
- 213 A Case of Adenocarcinoma of the Lung Complicated with Chronic Thromboembolic Pulmonary Hypertension That Underwent Upper Pulmonary Lobectomy. **2012**, 52, 1023-1029
- 212 Pulmonary Arterial Hypertension: Psychosocial Implications and Treatment. 88-98
- 211 Pulmonary Hypertension. **2012**, 389-397

210 Krankheiten des Herzens. **2012**, 335-393

209 Cutaneous Findings of Collagen Vascular Disease and Related Emergent Complications. **2013**, 207-234

208 Local Actions of Natriuretic Peptides and Nitric Oxide in Cardiac Remodeling: Implications for Therapy. **2013**, 141-158

1

207 Antihypertonika. **2013**, 391-412

206 A Case of Interstitial Pneumonia whose Symptoms were Exacerbated by Treatment of Pulmonary Arterial Hypertension. **2013**, 63, 159-164

205 Phosphodiesterase-5 Inhibitors in Cardioprotection. **2013**, 439-458

204 Pulmonary Hypertension. **2014**, 378-393

203 Pulmonary Hypertension in Congenital Heart Disease. **2014**, 2159-2199

202 Eisenmenger Syndrome and Other Types of Pulmonary Arterial Hypertension Related to Congenital Heart Disease. **2014**, 2481-2494

2

201 Right Heart Failure. **2014**, 311-329

200 Postoperative Pulmonary Hypertension in Children with Congenital Heart Disease. **2014**, 2201-2216

199 Heart Failure and Pulmonary Hypertension in Women. **2014**, 155-173

198 Targeted Pulmonary Arterial Hypertension Therapies and a Combined Medical-Surgical Approach for Congenital Heart Disease Patients. **2013**, 11, 183-188

197 PHARMACOTHERAPY OF PULMONARY HYPERTENSION DURING PREGNANCY AND POSTPARTUM PERIOD. **2013**, 21, 129

196 A Treatment Algorithm for Pulmonary Arterial Hypertension. **2014**, 13, 31-37

195 Diagnosis and Treatment of Pulmonary Arterial Hypertension. **2014**, 1-33

194 Nitrate: The Ideal Drug Action for Isolated Systolic Hypertension in Elderly?. **2014**, 509-518

193 Chapter 13:Treatments for Pulmonary Arterial Hypertension. **2014**, 369-397

192 Antihypertonika. **2014**, 445-468

191 New Oral Drugs for Pulmonary Arterial Hypertension: Macitentan, Riociguat, and Treprostinil. **2014**, 13, 68-75 1

190 Acute heart failure. **2014**, 271-288.e5

189 Pathogenic Mechanisms of Pulmonary Hypertension. **2014**, 1-32

188 Right Ventricular Pathobiology. **2014**, 35-44

187 Nitric Oxide Therapeutics in Pulmonary Vascular Disease. **2014**, 13, 134-137

186 Effect of sildenafil on clinical evidence and hemodynamic parameters in patients with pulmonary arterial hypertension, associated with systemic rheumatic diseases. **2014**, 11, 61-66

185 Encyclopedia of Trauma Care. **2015**, 1365-1371

184 Combination Therapy for the Treatment of Pulmonary Arterial Hypertension. **2015**, 377-396

183 Pathophysiology and Treatment of Pulmonary Arterial Hypertension. **2015**, 949-974

182 [Pulmonary hypertension associated with congenital heart disease and Eisenmenger syndrome]. **2015**, 85, 32-49 4

181 Pulmonary Hypertension in Critically Ill Patients. **2015**, 413-436

180 Diagnosis and Treatment of Pulmonary Arterial Hypertension. **2015**, 4105-4133

179 [Survival in pulmonary arterial hypertension, associated with connective tissue diseases, treated by sildenafil: results of the prospective study]. **2015**, 87, 62-67

178 Herz-Kreislauf-wirksame Medikamente in der Anästhesiologie. **2015**, 1-26

177 Scleroderma: Not an orphan disease any more. **2015**, 5, 131

176 Antihypertonika. **2015**, 451-475

175 Pathogenic Mechanisms of Pulmonary Hypertension. **2015**, 4079-4104

174 Phosphodiesterases and the Effects of Forskolin. **2015**, 1-22

173 We Obtain A Hemodynamic Near Normalization? Clues from Three Long-Term Survivors on Epoprostenol Treatment. **2015**, 2,

172 The first Russian experience of sildenafil application in patients with idiopathic pulmonary hypertension. **2015**, 12, 50-55

171 Surgery, Devices, Transplantation and Other Interventional Options for the Treatment of Advanced Pulmonary Hypertension. **2016**, 283-306

170 Patient Registries in Pulmonary Arterial Hypertension: the Role of Survival Equations and Risk Calculators. **2016**, 307-325

1

169 Antihypertonika. **2016**, 335-350

168 Phosphodiesterases and the Effects of Forskolin. **2016**, 645-663

167 Comparative Relaxant Effects of Ataciguat and Zaprinast on Sheep Sphincter of Oddi. **2016**, 33, 453-7

166 Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy. **2017**, 691-700

165 ??????????????. **2017**, 25, 67-74

164 Right Heart Failure. **2017**, 161-173

163 Pulmonary Vasodilators in Patients with Pulmonary Arterial Hypertension Related to Congenital Heart Disease. **2017**, 253-266

0

162 Antihypertonika. **2017**, 335-351

161 Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort. **2017**, 16, 14-19

160 Pulmonary Arterial Hypertension. **2017**,

159 Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs. **2017**, 14, 58-64

158 Antihypertonika. **2018**, 385-400

157 Single- and Bilateral Lung Transplantation: Indications, Contraindications, Evaluation, and Requirements for Patients to Be Considered Eligible. **2018**, 17-40

- 156 Pulmonary Arterial Hypertension. **2018**, 129-142
- 155 Isolated Patent Ductus Arteriosus in an Elderly Female, Aged 65 Years—A Case Report. **2018**, 07, 352-379
- 154 Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results. **2018**, 15, 72-76 2
- 153 Principles of pharmacological correction of pulmonary arterial hypertension. **2018**, 4, 59-76 1
- 152 Herz-Kreislauf-wirksame Medikamente in der Anästhesiologie. **2019**, 417-442
- 151 Pulmonary Vascular Disease. **2019**, 153-161
- 150 Prenatal non-surgical treatments for pulmonary hypoplasia in congenital diaphragmatic hernia. **2019**, 19, 46
- 149 Inhalation Drug Therapy: Emerging Trends in Nasal and Pulmonary Drug Delivery. **2019**, 291-333 1
- 148 The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!. **2019**, 14, 189-203
- 147 Clinical Outcomes and Treatment Options in Patients With Pulmonary Hypertension Who Received Pulmonary Hypertension-Specific Drugs - Single-Center Case Series. **2019**, 1, 389-395 0
- 146 Near syncope is not always benign. **2020**, 211-226
- 145 The prognostic significance of the alterations of pulmonary hemodynamics in patients with pulmonary arterial hypertension: a meta-regression analysis of randomized controlled trials. **2021**, 10, 284 1
- 144 Pulmonary hypertension. **2020**, 3695-3710
- 143 Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results. **2020**, 16, 1009-1016
- 142 Combination of the Phosphodiesterase Inhibitors Sildenafil and Milrinone Induces Cardioprotection With Various Conditioning Strategies. **2020**, 76, 684-691 0
- 141 Tratamiento farmacológico de la hipertensión pulmonar asociada a la esclerosis sistémica: revisión sistemática de la literatura. **2020**, 27, 135-145
- 140 Effect of sildenafil citrate on brain central fatigue after exhaustive swimming exercise in rats. **2019**, 15, 651-656 2
- 139 Chronic Pulmonary Hypertension. **2020**, 465-489

- 138 Chronic Administration of Sildenafil Citrate (Viagra) on the Frontal Cortex of Adult Male Rats: An Ultrastructural Study. **2020**, 08, 38-44 1
- 137 Management of Pulmonary Hypertension in the Hospital Setting. **2020**, 155-170
- 136 Sex and gender in pulmonary arterial hypertension. **2021**, 30, 2
- 135 Pulmonary Arterial Hypertension: What Rare Diseases Tell Us About Disparities in Disease Registries, Clinical Trials, and Treatment Algorithms. **2021**, 160, 1981-1983 0
- 134 Krankheiten des Herzens. **2008**, 311-373
- 133 Liver and lung ¶Treatment of hepatopulmonary diseases. 297-308
- 132 PDE5 Inhibitors and the cGMP Pathway in Pulmonary Arterial Hypertension. **2008**, 305-319
- 131 Connective Tissue Disease Associated Pulmonary Hypertension. **2008**, 145-171
- 130 Therapy for Pulmonary Vascular Disease: Past, Present, and Future. **2008**, 3-8
- 129 Antihypertonika. **2007**, 408-424
- 128 Chronisches Cor pulmonale. **2007**, 1331-1334
- 127 Chronische pulmonale Hypertonie. **2009**, 291-303
- 126 Phosphodiesterase-5 inhibitors. **2013**, 218, 229-55 2
- 125 Update on pediatric pulmonary arterial hypertension. **2021**, 36, 67-79 3
- 124 Pulmonary Hypertension. **2021**, 255-270
- 123 A review of pulmonary arterial hypertension: role of ambrisentan. **2007**, 3, 11-22 34
- 122 Review of bosentan in the management of pulmonary arterial hypertension. **2007**, 3, 887-900 31
- 121 Diagnosis and treatment of pulmonary arterial hypertension and atrial fibrillation in an adult chimpanzee (*Pan troglodytes*). **2008**, 47, 56-60 13

120	Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. <b>2008</b> , 2, 225-31	2
119	Hemodynamic and histologic characterization of a swine ( <i>Sus scrofa domestica</i> ) model of chronic pulmonary arterial hypertension. <b>2011</b> , 61, 258-62	6
118	A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. <b>2010</b> , 26, 206-218	1
117	Sildenafil Reduces Inflammation and Prevents Pulmonary Arterial Remodeling of the Monocrotaline - induced Disease in the Wistar Rats. <b>2012</b> , 7, 109-16	9
116	Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children. <b>2013</b> , 23, 19-26	9
115	Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis. <b>2010</b> , 1, 11-20	
114	Mechanics and mechanisms of pulmonary hypertension-Conference summary and translational perspectives. <b>2013</b> , 3, 128-36	4
113	Complete therapeutical approach in pulmonary arterial hypertension: from vasodilators to lung transplantation - case report. <b>2014</b> , 9, 198-203	1
112	Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. <b>2015</b> , 67, 169-85	5
111	2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension. <b>2014</b> , 30, 401-44	11
110	Role of Meticulous Observation: Successful Pregnancy in a 30-Year-Old Woman with Severe Pulmonary Hypertension. <b>2016</b> , 15, 187-190	0
109	Severe pulmonary arterial hypertension associated with congenital cardiac shunts: evolution under specific treatment. <b>2017</b> , 10, 131-138	1
108	The role of sildenafil in the development of transplant arteriosclerosis in rat aortic grafts. <b>2017</b> , 9, 4914-4924	
107	Effects of oral sildenafil on exercise capacity in children with pulmonary arterial hypertension: a randomised trial. <b>2019</b> , 6, e001149	1
106	The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs. <b>2020</b> , 8, e14562	2
105	Update on Medical Management of Pulmonary Arterial Hypertension. <b>2022</b> , 40, 13-27	1
104	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway. <b>2021</b> , 12, 767002	4
103	A Semi-Automated Term Harmonization Pipeline Applied to Pulmonary Arterial Hypertension Clinical Trials. <b>2021</b> ,	



102	A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. <b>2021,</b>	0
101	Analysis of Geometric and Hemodynamic Profiles in Rat Arteriovenous Fistula Following PDE5A Inhibition.. <b>2021, 9, 779043</b>	0
100	Pulmonary Hypertension. <b>2021,</b>	
99	2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. <b>2022, 26, 4683</b>	9
98	The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on one Stone.. <b>2022,</b>	0
97	Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis.. <b>2022, 13, 817119</b>	0
96	Selectivity mechanism of phosphodiesterase isoform inhibitor through in silico investigations.. <b>2021, 28, 9</b>	11
95	Pharmacological developments in antihypertensive treatment through nitric oxide cGMP modulation. <b>2022,</b>	1
94	A literature review on pulmonary arterial hypertension (PAH). <b>2022, 18,</b>	
93	Therapeutic enzymes as non-conventional targets in cardiovascular impairments:A Comprehensive Review.. <b>2021,</b>	1
92	New Therapeutic Targets in Neonatal Pulmonary Hypertension. <b>2022, 1, 158-169</b>	
91	Recent developments in cGMP research: From mechanisms to medicines and back.. <b>2022,</b>	0
90	Body Mass Index and Treatment Response in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.. <b>2022,</b>	1
89	An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients.. <b>2022, 12,</b>	4
88	Pulmonary arterial hypertension.. <b>2022,</b>	1
87	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.. <b>2022,</b>	0
86	Clinical outcomes of sildenafil application in patients of poor endometrial development. <b>2022, 2, 14-19</b>	
85	Portopulmonary hypertension: Current developments and future perspectives. <b>2022, 6, 10-20</b>	0

84	Pharmacology Management in Improving Exercise Capacity of Patients with Fontan Circulation: A Systematic Review and Meta-Analysis.. <b>2022,</b>	0
83	Uncompensated mitochondrial oxidative stress underlies heart failure in an iPSC-derived model of congenital heart disease.. <b>2022,</b>	3
82	Pulmonary Hypertension and COVID-19.. <b>2021,</b>	2
81	Organic and dietary nitrates, inorganic nitrite, nitric oxide donors, and soluble guanylate cyclase stimulation. <b>2022,</b> 807-828	
80	Therapeutic approaches to improve pulmonary arterial load and right ventricular pulmonary arterial coupling. <b>2022,</b> 935-958	
79	Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.. <b>2022,</b> 327, 1379-1391	9
78	The spectrum and systemic associations of microvascular dysfunction in the heart and other organs. <b>2022,</b> 1, 298-311	0
77	An Emerging Class of New Therapeutics Targeting TGF, Activin and BMP Ligands in Pulmonary Arterial Hypertension.. <b>2022,</b>	
76	Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.. <b>2022,</b> 22, 142	0
75	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.. <b>2022,</b> 108192	1
74	The effect of Riociguat on cardiovascular function and efficiency in healthy, juvenile pigs. <b>2020,</b> 8, e14562	3
73	Modelling Pulmonary Arterial Hypertension: Clinical Concepts, Engineering Applications and an Integrated Medico-engineering Approach. <b>2022,</b> 169-187	
72	Riociguat in the Treatment of Pulmonary Arterial Hypertension in Mexico.. <b>2022,</b>	1
71	Evaluation of balloon pulmonary angioplasty using lung perfusion SPECT in patients with chronic thromboembolic pulmonary hypertension.. <b>2022,</b> 1	0
70	Which therapy for which condition?. <b>2013,</b> 463-541	
69	Tratamento da HAP com enfoque nas doenças reumáticas. <b>2014,</b> 36-43	
68	Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial.	1
67	Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). <b>2022,</b> 6-70	

66	Portopulmonary Hypertension: A Review of the Current Literature. <b>2022,</b>	0
65	Pulmonary arterial hypertension. <b>2022,</b> 158, 622-629	0
64	Sildenafil Improves Six-minute Walk Distance in Chronic Obstructive Pulmonary Disease: A Randomised, Double-blind, Placebo-controlled Trial. <b>2022,</b> 53, 81-86	0
63	Role of NO-cGMP-PKG axis in pulmonary arterial hypertension. <b>2022,</b> 157, 221-225	
62	Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021). <b>2022,</b> 6-70	
61	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. <b>2022,</b>	1
60	Early and long-term results of ventricular septal defect repair in children with severe pulmonary hypertension and elevated pulmonary vascular resistance by the double or traditional patch technique. <b>2022,</b> 62,	0
59	Dynamics of 6-Minute Walk Distance as a Predictor of Efficiency Specific Pulmonary Vasodilators. <b>2022,</b> 18, 342-349	
58	Assessment of disease outcome measures in systemic sclerosis.	0
57	Clinician's Corner: Counseling Patients with Pulmonary Vascular Disease Traveling to High Altitude.	0
56	APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION. <b>2015,</b> 42-49	2
55	Don't Turn Off the Tap! The Importance of Discovery Science to the Australian Cardiovascular Sector and Improving Clinical Outcomes Into the Future. <b>2022,</b>	
54	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879	18
53	Functional characteristics and research trends of PDE11A in human diseases (Review). <b>2022,</b> 26,	0
52	Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis. 9,	
51	CD39 in the development and progression of pulmonary arterial hypertension.	
50	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.	58
49	Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2022,</b> 146, 597-612	0

- 48 Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension. 875512252211140 ○
- 47 The 6-min walk test as a primary end-point in interstitial lung disease. **2022**, 31, 220087 ○
- 46 Targeted therapies in patients with pulmonary arterial hypertension due to congenital heart disease. **2022**, 20,
- 45 Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. **2022**, 31, 220036 1
- 44 Comparison of the effects of Bosentan and Sildenafil in treatment of Patent ductus arteriosus and pulmonary arterial hypertension in preterm infants : A randomized clinical trial..
- 43 Advanced formulations and nanotechnology-based approaches for pulmonary delivery of sildenafil: A scoping review. **2022**, 350, 308-323 ○
- 42 A novel echocardiographic estimate of pulmonary vascular resistance employing the hydraulic analogy to Ohm's law. **2022**, 42, 101121 ○
- 41 Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension: determinants and clinical impact. **2022**, 146, 107099 1
- 40 Quinazoline-Based Human Phosphodiesterase 5 Inhibitors Exhibited a Selective Vasorelaxant Effect on Rat Isolated Pulmonary Arteries Involving NO-sGC-cGMP Pathway and Calcium Inhibitory Effects. ○
- 39 Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects. **2022**, 107111 ○
- 38 Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. 1
- 37 Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties. **2022**, 14, 1954 ○
- 36 PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?. 1
- 35 Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC. **2022**, 23, ○
- 34 Randomized Clinical and Biochemical Study Comparing the Effect of L-arginine and Sildenafil in Beta Thalassemia Major Children With High Tricuspid Regurgitant Jet Velocity. **2022**, 27, 107424842211326 ○
- 33 Recent Advances in the Treatment of Pulmonary Arterial Hypertension. **2022**, 15, 1277 3
- 32 Physiopathologie et traitement de l'hypertension artérielle pulmonaire\*. **2022**, ○
- 31 Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia: Rationale and methods of a phase II randomized trial. **2022**, 30, 101025 ○

30	Theoretical study on the origins of sildenafil tautomers' relative stability. <b>2022,</b>	o
29	Management of pregnant patients with pulmonary arterial hypertension. <b>9,</b>	o
28	Patient-specific and gene-corrected induced pluripotent stem cell-derived endothelial cells elucidate single-cell phenotype of pulmonary veno-occlusive disease. <b>2022,</b>	o
27	Model-Informed drug development of gastroretentive release systems for sildenafil citrate. <b>2023,</b> 182, 81-91	o
26	How to Treat Right Heart Failure. Tips for Clinicians in Everyday Practice. <b>2023,</b> 19, 125-135	o
25	Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension. <b>2023,</b> 19, 35-43	o
24	Sex- and Gender-Related Aspects in Pulmonary Hypertension. <b>2023,</b> 19, 11-24	o
23	Comparison of intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. <b>2022,</b> 12,	o
22	The evolving landscape of pulmonary arterial hypertension clinical trials. <b>2022,</b> 400, 1884-1898	o
21	Hipertensiã pulmonar. <b>2022,</b> 13, 3979-3989	o
20	Pulmonary Hypertension.	o
19	The Role of Bone Morphogenetic Protein Receptor Type 2 (BMP2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling. <b>2022,</b> 11, 3823	o
18	Pathophysiology and Pathogenic Mechanisms of Pulmonary Hypertension: Role of Membrane Receptors, Ion Channels and Ca <sup>2+</sup> Signaling.	1
17	Pulmonary hypertension in the primary care setting. <b>2022,</b> 33, 11-18	o
16	Polymeric hydrogel forming microneedle-mediated transdermal delivery of sildenafil citrate from direct-compressed tablet reservoir for potential improvement of pulmonary hypertension therapy. <b>2022,</b> 122549	o
15	Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials. <b>2023,</b>	o
14	Metabolomic Signatures Associated With Pulmonary Arterial Hypertension Outcomes.	o
13	Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model. <b>2023,</b> 24, 2391	o

- 12 Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis. 1-15
- 11 Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis. **2023**, 13, 486
- 10 Perioperative Decision-Making in Pulmonary Hypertension. **2023**, 32, 454-466
- 9 Histone deacetylase inhibitors synergize with sildenafil to suppress purine metabolism and proliferation in pulmonary hypertension. **2023**, 149, 107157
- 8 The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges. Volume 19, 103-126
- 7 Nitric Oxide and Cardiovascular Diseases: Cardioprotection, Complications and Therapeutics. **2023**, 41-66
- 6 Neonatology for Anesthesiologists. **2017**, 513-570.e15
- 5 A review search of sildenafil uses in human and in the veterinary medicine. **2023**,
- 4 Pathophysiology and new advances in pulmonary hypertension. **2023**, 2, e000137
- 3 Advances in the discovery of drugs that treat pulmonary arterial hypertension. **2023**, 18, 445-466
- 2 Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?.
- 1 Postoperative Pulmonary Hypertension in Children with Congenital Heart Disease. **2021**, 1-18